Genomics for Good
Illumina Corporate Social Responsibility Report CY’22

Appendix
CY’22 CSR Report
2
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Sustainability 
People
Operate Responsibly 
Message from Leadership 
3 Message from the CEO
Introduction
6 2022 CSR Highlights 
7 Recognition
8 About Illumina 
9 Business Overview 
CSR Strategy and Governance 
11 Q&A with Our CFO and CPAO 
12 CSR Strategy: Creating Unique Impact 
14 2030 Targets 
15 CSR Governance 
16 Stakeholder Engagement and Materiality
Accelerate Access to Genomics 
18 Strategic Approach and Impact 
19 Drive Innovation and Affordability 
22 Catalyze Genomic Startups 
23 Democratize Genomics
24 Enable Catalytic Philanthropy
26 Genomic Data Diversity
27 Expand Reach of Genomics
31 Impact in Action 
Empower Our Communities 
33 Strategic Approach and Impact
34 Community Investment 
35 Employee Engagement 
36 Equitable Access to STEM Education 
38 Impact in Action 
Integrate Sustainability 
40 Strategic Approach and Impact 
41 Climate Action 
43 Sustainable Facilities 
46 Sustainable Products 
48 Sustainable Value Chain 
50 Leveraging Genomics 
52 Impact in Action 
Nurture Our People 
54 Strategic Approach and Impact
55 Our People 
57 Practice Diversity, Equity, and Inclusion
60 Invest in Our People 
64 Create a Culture of Care 
66 Impact in Action 
Operate Responsibly 
68 Strategic Approach and Impact
69 Corporate Governance 
70 Compliance 
72 Ethics and Integrity 
75 Data Security and Privacy 
77 Responsible Supply Chain 
81 Public Policy 
Appendix 
83 About This Report 
86 Key Performance Indicators 
100 Indices (GRI, SASB, TCFD, SDGs) 
105 Assurance Statements 
106 Disclosures 
This Is the 
Genome 
Era 
At Illumina, we are driven 
by the power of genomics 
to positively impact the 
world and shape a more 
sustainable and equitable 
future for all.
TABLE OF CONTENTS
Our fourth annual Corporate Social 
Responsibility Report documents the 
evolution of our environmental, social, 
and governance (ESG) program from 
January 1 through December 31, 2022. 
This report reflects the progress we 
have made and looks to the future 
with our continued commitment to 
deepen our impact on human health by 
serving as a champion for patients, our 
communities, our people, and our planet.
Learn more in About this Report →
Operate Responsibly 
TM

Appendix
CY’22 CSR Report
3
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Sustainability 
People
Operate Responsibly 
Message from the CEO
2023 marks Illumina’s 25th anniversary. For more 
than two decades, we have been committed to 
improving human health by unlocking the power of 
the genome. Yet today, the need is more urgent than 
ever to help build a healthier, more sustainable world 
where all people can thrive. 
Genomics has the ability to improve global health 
care, sustainability, and equity through better 
diagnosis and treatment; better representation 
in genomic data; greater access to personalized 
medicine; and a deeper understanding of the world. 
This is the genome era, and the last few years 
have shown the promise that exists around us.
Genomics enables the world to act quickly and 
mitigate the spread of infectious diseases. 
The world’s first mRNA vaccine roll-out ignited a 
wildfire of genomic innovation and breakthroughs 
that will improve human health beyond the pandemic. 
There will always be new pathogens, but what 
matters is our ability to identify and control their 
spread. Effective global surveillance, backed by 
collaboration and adoption, can prevent the next 
pathogenic outbreak from becoming another 
global pandemic.  
Genomics is transforming personalized 
medicine and saving lives. The science is being 
applied to every step of cancer care and reducing 
the diagnostic odyssey for those suffering from rare 
genetic diseases. Revolutionary therapies are hitting 
the clinic and reinventing how we fight an expanding 
number of conditions. 
Genomic data has become the blueprint for 
everything from diagnostics to precision 
therapeutics. Each day, researchers are learning 
more about genetic variants that will help unravel 
the world’s most devastating diseases and public 
health challenges. Yet, genomic data is glaringly 
imbalanced — underrepresenting the diversity of 
global populations. Together with our partners, we 
aim to increase the diversity of genomic data and 
help every patient access groundbreaking therapies. 
Genomics is being brought to bear against the 
climate crisis. We are already using genomics to 
understand which seeds will be most productive 
or most resilient to drought and disease. CRISPR 
gene-editing technology is starting to bolster the 
natural ability of plants and soil microbes to both 
capture and store atmospheric carbon. Genomics 
will be an essential tool to fight food insecurity for 
millions of people around the world. 
Francis deSouza
Chief Executive Officer
Continues on next page →
 This is the genome era, and the last 
few years have shown the promise that 
exists around us. Yet, the need is more 
urgent than ever to help build a healthier, 
more sustainable world where all people 
can thrive.

Appendix
CY’22 CSR Report
4
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Sustainability 
People
Operate Responsibly 
Message from the CEO
Guided by our mission, we are taking bold, 
meaningful steps through our business strategy 
to accelerate access to genomics, empower our 
communities, integrate environmental sustainability, 
nurture our people, and operate responsibly. 
Accelerate Access to Genomics
We are delivering breakthrough innovations that 
redefine the possibilities in genomics and accelerate 
impactful health advances globally. We reduced the 
cost of next-generation sequencing (NGS) by more 
than 99%, further democratizing the technology and 
helping patients, communities, and whole populations 
access the benefits of genomics. We introduced 
several new innovations, including the NovaSeqTM 
X – our most powerful and sustainable sequencing 
system yet. We extended our philanthropic iHope 
model, partnering with the March of Dimes Birth 
Defects Foundation of China. We continued our 
philanthropic support for the Pathogen Genomics 
Initiative (PGI), providing critical public health 
capabilities in Africa and Southeast Asia. And we 
partnered on population genomics projects including 
Precision Health Research to launch the SG100K 
Project, aiming to map the DNA of 100,000 people 
in Singapore. 
Empower Our Communities
The future of genomics depends on the curiosity, 
ingenuity, and passion of today’s STEM students. 
This year, Illumina joined the STEMM Opportunity 
Alliance (SOA) in collaboration with the White House 
Office of Science and Technology Policy to drive 
transformative change across the American science, 
technology, engineering, math, and medicine 
(STEMM) ecosystem, with the aim of removing 
systemic barriers and elevating STEMM equity. 
I personally signed an open letter pressing 
state governments and education leaders to 
make computer science a foundational part of 
K-12 curriculum. 
Integrate Sustainability
We know improving human health is directly tied 
to creating a healthier planet, both through our own 
operations and the impactful work of our partners. 
We are one of the first companies in the world and 
the first genomics company to receive verification 
of our 2050 net-zero emissions targets by the 
Science Based Targets initiative Corporate Net-Zero 
Standard. We integrated environmental design into 
our newest sequencing platform, the NovaSeqTM X, 
resulting in 90% less packaging, 50% less plastic, 
and a 61% reduction in climate change impact. 
We also awarded our annual Agricultural Greater 
Good Initiative Grant to Brazil's SENAI Innovation 
Institute for Biosynthetics, where they are exploring 
the genetic potential for carbon sequestration, 
environmental services, and food security.
Nurture Our People 
An extraordinary mission requires extraordinary 
people and leaders at every level. Illumina employees 
are the engine of innovation and key to powering 
genomics for good. To foster an inclusive culture 
where innovation and creativity thrive, we practice 
diversity and equity in all that we do. For the 
fourth consecutive year, we achieved a zero net 
pay gap. We have increased the percentage of 
female executives for the third consecutive year, 
and our US workforce includes 52 percent minority 
representation. We filed a record 193 new patents 
and we continue to have two times the number 
of female inventors compared to the US national 
rate. We launched a new employee resource 
group supporting employees affected by visible or 
invisible disability and neurodiversity. And I signed 
the Disability:IN CEO Letter on Disability Inclusion 
urging my peers to advance equality and inclusion.
The Future of Genomics Starts Now
For 25 years, we have shown the world the 
promise of genomics and the power of collaboration. 
Working with our customers, partners, and genomics 
advocates around the globe, we know what is 
possible. Now is the time to push the boundaries 
and extend the benefits of genomics to all. That 
means ensuring genomics data reflects the diversity 
of a global population. It means bringing genomics 
into the clinic and extending its applications. 
As we look to the future, it means reaffirming our 
commitment to be the best employer, the best 
environmental steward, and the best corporate 
citizen we can possibly be. 
Many thanks to our customers, partners, and 
employees around the world for helping advance 
our lifesaving work, giving back to our communities, 
supporting one another, and bringing our mission 
to life. 

Francis deSouza
Chief Executive Officer
 Guided by our mission, we are taking 
bold, meaningful steps through our business 
strategy to accelerate access to genomics, 
empower our communities, integrate 
environmental sustainability, nurture our 
people, and operate responsibly.  
Operating Responsibly
Our role as a genomics pioneer brings with it the 
responsibility to enable innovation for good, ensuring 
the technology we create and the data we collect 
are used safely, ethically, and responsibly. We have 
expanded the remit of the Nominating/Corporate 
Governance Committee to assist the Board in 
overseeing the company’s material ESG matters, 
except as specifically delegated to another Board 
committee. We also achieved ISO 27701 certification 
for Illumina’s six cloud based products for privacy 
information management. 
*Compared to Nova Seq 6000 and based on US list price, assuming 120 Gb/genome.

Appendix
CY’22 CSR Report
5
Message from the CEO
Introduction
Access
Community
People
Operate Responsibly 
People
Operate Responsibly 
CSR Strategy & Governance 
Sustainability 
2022 CSR Highlights           Recognition           About Us           Business Overview
Introduction

Appendix
CY’22 CSR Report
6
Message from the CEO
Introduction
Access
Community
People
Operate Responsibly 
People
Operate Responsibly 
CSR Strategy & Governance 
Sustainability 
2022 CSR Highlights           Recognition           About Us           Business Overview
2022 CSR Highlights 
1.2 billion lives covered 
$11 million in-kind donations 
to support Pathogen Genomics 
Initiative 
30,000+ medical education 
learners reached 
74 new genomic startups funded 
since inception
$200 genome introduced with 
NovaSeqTM X launch
Launched iHope China
$1 billion and 22% revenue 
R&D investment 
Accelerate Access to Genomics
$17.7 million total donations 
50% employee participation in 
giving and volunteer programs 
> 1.2 million STEM learners 
reached since 2019
20,662 volunteer hours donated
1,747 causes supported 
Community investment in 
46 countries
Empower Our Communities
Maintained a zero net pay gap 
52% minority representation 
in the US workforce 
45% global female workforce 
5% increase in female executive 
leadership representation in the last 
three years 
86% employee engagement index
New disability ERGs launched
62 hours average training per 
employee
Nurture Our People
First genomics company to have 
net zero targets verified by SBTi 
100% of global electricity 
consumption came from 
renewable sources 
100% of our strategic suppliers 
committed to minimize their 
environmental footprint 
61% climate impact reduction 
with NovaSeqTM X compared to 
NovaSeqTM 6000 
Integrate Sustainability
100% Illumina core facilities 
participated in third-party audit 
programs 
18% diverse supplier spend
Achieved Privacy Information 
Management ISO 27701 
certification 
Expanded remit of the 
Nominating/Corporate 
Governance Committee 
to assist the Board in 
overseeing ESG matters
Operate Responsibly

Appendix
CY’22 CSR Report
7
Message from the CEO
Introduction
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
People
Operate Responsibly 
Sustainability 
2022 CSR Highlights           Recognition           About Us           Business Overview
Recognition 2022
Workplace
•	Glassdoor Best Place to Work
•	BioSpace Best Place to Work
•	Refinitiv Top 100 Global D&I Index
•	Just Capital Top 100 US Companies 
Supporting Healthy Communities & Families
•	Just Capital Workforce Equity & Mobility
•	Wall Street Journal Top 250
Regional
•	SANDAG Green Commute Award San Diego
•	AmCham Cares CSR Singapore 
•	MIT Tech Review 50 Smartest Companies in China 
•	Water Efficiency Building (WEB) Singapore
•	Best Employer Straits Times Singapore
•	Workplace Safety Award Singapore
Leadership
•	Most Responsible CEO | Francis deSouza
•	Top Chief Human Resources Officer | Aimee Hoyt
•	Savoy Most Influential Black Exec | Kathryne Reeves
•	Forbes 50 over 50 | Susan Tousi
1  |  1  |  3

Appendix
CY’22 CSR Report
8
Message from the CEO
Introduction
Access
Community
People
Operate Responsibly 
People
Operate Responsibly 
CSR Strategy & Governance 
Sustainability 
2022 CSR Highlights           Recognition           About Us           Business Overview
Our Purpose
Our Mission
To improve human health 
by unlocking the power of 
the genome.
Drive the positive progress 
of genomics to make it 
useful for all.
Our Values
About Illumina
Illumina is a global genomics and human health company powering the future of personalized 
medicine and beyond. 
Innovating at the intersection of technology, biology, and health, we are reimagining what is 
possible for human health and the health of our planet. 
We provide the sequencing innovations that enable researchers and clinicians to discover, 
detect, diagnose, and treat diseases—from cancer to COVID-19, from protecting our natural 
capital to securing a sustainable food supply.
What if One Thing Could Change 
Everything for the Better? 
What causes a cancer 
cell to mutate? 
How do you identify a 
novel virus like COVID-19 
and create a vaccine? 
What effect does 
climate change have 
on biodiversity? 
How do we diagnose a 
rare genetic disease? 
How do we safeguard 
the world’s food supply? 
Driven by our mission, we are committed to making our technology more 
affordable, accessible, and sustainable, realizing health equity 
for billions around the world. 
We are open
Innovation is 
in our DNA 
We are relentless 
in the creation of 
great products
We collaborate 
deeply
We move fast 
and embrace 
change
Oncology
Reproductive Health
Genetic Disease
Research/Applied Genomics
Infectious Disease
Drug Discovery
Multi-Omics
The answer to these and thousands of life’s most pressing questions 
can be found in the world of genomics.
As an engine of genomics innovation, we are enabling tomorrow's discoveries.
APPLICATIONS
That’s 
Genomics.

Appendix
CY’22 CSR Report
9
Message from the CEO
Introduction
Access
Community
People
Operate Responsibly 
People
Operate Responsibly 
CSR Strategy & Governance 
Sustainability 
2022 CSR Highlights           Recognition           About Us           Business Overview
Illumina at a Glance
Where We Operate
Business Overview
Americas
Baltimore, MD, US 4 
Foster City, CA, US 3, 4, 6
Hayward, CA, US 2, 4
Madison, WI, US 2, 4, 6
San Diego, CA, US 1, 2, 3, 4, 5, 6
São Paulo, Brazil 4
Greater China
Beijing, China4
Shanghai, China2, 4
Taipei, China4
EMEA
Berlin, Germany4 
Cambridge, UK2,4, 5, 6
Eindhoven, Netherlands4, 5
Evry, France4
Istanbul, Turkey4 
Mechelen, Belgium4 
Moscow, Russia4
Rennes, France4
Steenoven, Netherlands4, 5
Tel Aviv, Israel4
Dubai, UAE4
Asia Pacific
Melbourne, Australia4 
Osaka, Japan4 
Seoul, South Korea4
Singapore2, 4, 5, 6
Tokyo, Japan4
1Headquarters, 2Manufacturing, 3Clinical, 
4Commercial, 5Distribution Center, 6R&D
10,200 
employees 
$1B 
R&D 
investment 
$4.55B
2022 revenue
9,500+ 
customers
55 
customer Net 
Promoter Score
23,000+ 
cumulative 
sequencing 
installed base
9,178 
patents worldwide
155 
countries receive 
our products
1998 
founding year
Financial Performance
Sequencers
2018
$3.3B
2019
$3.5B
2020
$3.2B
2021
$4.5B
2022
$4.55B
11% 5-YEAR CAGR
71% Consumables
Library prep and proprietary 
sequencing kits such as flow 
cells and reagents for our 
sequencing and microarray 
instruments
12% Service and Other
Warranties and maintenance contracts 
for systems and services undertaken 
in our labs, revenue from intellectual 
property fees, in vitro diagnostic licensing, 
milestones, and informatics
17% Instruments
Sequencing systems that span 
the full range of applications as 
well as a microarray instrument 
to support genotyping
$4.55B
REVENUE 
Revenue Details
22% 
revenue R&D 
investment
NovaSeqTM 6000
MiSeqTM
NextSeqTM 550Dx
MiniSeqTM
NovaSeqTM 6000Dx
iSeqTM 100
MiSeqTM Dx
NovaSeqTM
X Series
LOW-THROUGHPUT
MID-THROUGHPUT
HIGH-THROUGHPUT
DIAGNOSTIC
NextSeqTM 
500
NextSeqTM 
550
NextSeqTM 
1000/2000
Scope of this report reflects core Illumina.

CY’22 CSR Report
10
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Q&A with Our CFO and CPAO           CSR Strategy: Create Unique Impact           2030 Targets           CSR Governance           Stakeholder Engagement and Materiality
Introduction
Appendix
Sustainability 
Message from the CEO
CSR Strategy 
& Governance

CY’22 CSR Report
11
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Q&A with Our CFO and CPAO           CSR Strategy: Create Unique Impact           2030 Targets           CSR Governance           Stakeholder Engagement and Materiality
Q: When the new public affairs function was 
established at Illumina, the ESG function 
shifted from the office of the Chief Financial 
Officer to the office of the Chief Public Affairs 
Officer. Can you both tell us about that move?
A: John When Illumina created a new Public Affairs 
department, it was a natural fit to bring together the 
internal teams of government affairs, corporate social 
responsibility, privacy, ethics, and patient advocacy so 
these groups could work together more closely and take 
advantage of natural synergies. Coming from Microsoft, 
where I most recently led the UN Affairs group, the 
intersection of government affairs, the UN Sustainable 
Development Goals, and our ESG efforts were interwoven, 
and we saw similar opportunities here at Illumina.
A: Joydeep I agree with John’s points, and while the ESG 
team moved from Finance to Public Affairs, our shared 
focus on our investors and risk management is stronger 
than ever. Our functions work very closely together, and 
we expect that to deepen as various mandatory regulatory 
reporting requirements evolve. We see ESG as a key 
strategic driver to delivering value to our shareholders and 
stakeholders as we accelerate the adoption of sequencing 
in existing markets and enable the most impactful, new 
opportunities for genomics. 
Joydeep, you were recently appointed 
Chief Financial Officer, expanding your role 
as Chief Business Strategy and Corporate 
Development Officer. How does Illumina’s 
environmental, social, and governance (ESG) 
approach fit into the overall financial and 
business strategy of the company?
A: Joydeep Furthering our ESG strategy advances our 
business strategy and reinforces our mission to improve 
human health. Stewardship of our fiduciary responsibility 
includes a strong emphasis on managing risk, driving 
performance, and ensuring business integrity. We connect 
our ESG approach to existing finance governance, including 
accountability, risk analysis, internal monitoring, reporting 
transparency, and data assurance.
As CFO, I am looking for ways to ensure we are protecting 
the long-term value of the company, and that includes 
both financial and non-financial inputs related to risk 
and opportunities. ESG provides a lens to evaluate those 
risks and opportunities, incorporating the voices of all our 
stakeholders.
Investing in our ESG initiatives can drive growth, create 
innovation, and contribute to our long-term success.
What are some updates on the ESG/CSR 
governance approach at Illumina?
A: John There is a consensus that directors on boards 
of public companies should be taking a greater role in 
overseeing ESG programs and disclosures; however, 
there remains variation in how boards have chosen to 
approach their oversight. Previously, the Board’s oversight 
of Illumina’s ESG program and the various themes under 
the ESG umbrella were captured under existing committee 
work. Last year, we expanded the remit of the Nominating/ 
Corporate Governance Committee to assist the Board 
in overseeing the company’s ESG matters, except as 
specifically delegated to another Board committee. The 
Compensation Committee continues to oversee and provide 
input to management on diversity and inclusion matters, and 
the Audit Committee continues to oversee cybersecurity. 
Q&A With Our CFO 
and CPAO
This new structure will increase the clarity and level of 
oversight of how we are managing the opportunities and 
risks of our material ESG issues and signifies the importance 
of ESG on the success of our business. 
Given the importance of climate risk to the 
investment community and key stakeholders, 
how is Illumina signaling to these 
stakeholders your plans for climate action?
A: Joydeep As a science-based company, we wanted 
to ground our environmental targets in a science-based 
framework. We created a climate transition plan that is 
time-bound, with quantitative targets based on the best 
climate science recommendations available and aligned 
to the science-based target initiative (SBTi). We received 
external validation from SBTi of our climate transition 
plan, including our emission reduction targets and net 
zero commitments, demonstrating to stakeholders our 
commitment to mitigate our climate impact and provide a 
credible and accountable set of targets to help guide our 
company toward a 1.5℃ climate scenario. 
In addition, our commitment to climate action 
is demonstrated in our NovaSeqTM X launch last 
September. NovaSeqTM X significantly reduces waste and 
environmental impact, reflecting Illumina’s commitment 
to using our technology to support the health of people 
and the planet. NovaSeqTM X features a 90% reduction in 
packaging waste and weight and 50% reduction in plastic 
usage compared to NovaSeqTM 6000. The enablement 
of ambient-temperature shipping of reagents will result 
in nearly 500 tons of dry ice savings per year, while 
significantly reducing waste streams for our customers.
What do you see as the future for ESG/CSR 
at Illumina?
A: John By engaging and empowering all our stakeholders, 
including customers, business partners, employees, and 
communities, we will continue to build resilience, create 
long-term value and support the science that advances 
public health and the health of our planet.
Joydeep Goswami 
Chief Financial Officer, 
Chief Strategy & Corporate 
Development Officer
John Frank 
Chief Public Affairs Officer

CY’22 CSR Report
12
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Q&A with Our CFO and CPAO           CSR Strategy: Create Unique Impact           2030 Targets           CSR Governance           Stakeholder Engagement and Materiality
With our mission to 
improve human health 
by unlocking the power 
of the genome, we are 
committed to making 
our products more 
affordable, accessible, 
and sustainable, realizing 
health equity for billions 
around the world. 
As a purpose-driven company, we 
deliver sustainable, long-term value 
and impact by embedding our CSR 
strategy in the business. 
Our CSR strategy has been influenced 
by materiality assessments and 
ongoing stakeholder engagement. It 
promotes the sustainable stewardship 
of our business by managing ESG 
risks, capitalizing on opportunities, 
driving performance, and ensuring 
business integrity.
CS
R V
ISI
ON
De
epe
n o
ur i
mpa
ct o
n h
um
an h
ealt
h b
y se
rvi
ng a
s a 
cha
mpi
on
for 
pat
ien
ts, 
our
 co
mm
uni
ties
, ou
r p
eop
le, 
and
 ou
r pl
ane
t.
P
UR
PO
SE
Dri
ve t
he 
po
siti
ve 
pro
gre
ss 
of
ge
no
mic
s t
o m
ak
e i
t u
se
ful
 fo
r a
ll.
MISSION
Improve human health by 
unlocking the power of the 
human genome.
          
          
         
      A
cces
s to
        
       
    E
mpo
we
r O
ur  
     
      
      
   I
nte
gra
te  
      
      
     
     
Nur
tur
e O
ur   
       
        
   O
pera
te
          
          
         
     G
eno
mics
       
       
   C
om
mu
niti
es 
      
     
    S
ust
ain
abi
lity
     
      
     
     
 Pe
opl
e   
       
       
     R
esp
onsi
bly
Connecting Our 
CSR Strategy to 
Our Business

CY’22 CSR Report
13
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Q&A with Our CFO and CPAO           CSR Strategy: Create Unique Impact           2030 Targets           CSR Governance           Stakeholder Engagement and Materiality
In this report, we use the terms “material” and “materiality” to refer to topics that reflect Illumina’s meaningful environmental, social, and governance impact. The use of such terms shall not be deemed to constitute an admission as 
to the materiality of any information in this report for purposes of applicable securities laws or any other laws of the United States, nor are we using them as they are used in the context of financial statements and financial reporting.
We are committed to accelerating 
access to genomics to realize 
health equity for billions of people 
around the world. We are driven 
by our conviction that genomics 
should be available to the many, 
not the few.
Accelerate Access 
to Genomics
We are committed to giving back, 
creating shared value through 
our business, and seeking 
opportunities to enable a more 
equitable and sustainable future 
for all. 
Empower Our 
Communities
We are committed to engaging 
extraordinary talent and helping 
them thrive. By focusing on 
diversity, equity, and inclusion, 
investing in our people, and 
enabling a culture of care, 
we magnify the value of that 
collaboration and build community. 
Together our impact is amplified, 
and our potential is unlimited.
Nurture 
Our People
We are committed to integrating 
environmental stewardship into 
the fabric of how we operate. 
Human health and the health of 
our environment are intertwined 
and connected to creating a 
healthy, sustainable future for all. 
Integrate 
Sustainability
We are committed to conducting 
ourselves with honesty, integrity, 
and respect for all. As genomic 
pioneers, we are enabling 
innovation for good, ensuring that 
the technology we create and the 
data we collect are used safely, 
ethically, and responsibly.
Operate 
Responsibly
We prioritize action 
on our most material 
environmental, social, 
and governance (ESG) 
issues, supported by 
robust governance, 
transparency, and 
accountability.
Creating Unique Impact
In this report we outline our 
management approach, 
targets, connection to the UN 
Sustainable Development Goals, 
and performance for each of our 
material ESG issues.
Through managing the risks and 
opportunities related to each 
material ESG issue, we execute 
on our purpose and deliver the 
greatest positive impact to our 
business, our stakeholders, and 
the planet. 
Innovation → 
Pricing and Affordability → 
Democratize Genomics → 
Material Topics
UN SDG
Community Investment → 
STEM Education → 
Material Topics
UN SDG
Climate Action → 
Sustainable Facilities → 
Sustainable Products → 
Sustainable Supply Chain → 
Material Topics
UN SDG
Diversity, Equity, and Inclusion → 
Human Capital Management → 
Employee Health, Safety, and Wellness → 
Material Topics
UN SDG
Data Privacy and Security → 
Corporate Governance → 
Ethics and Transparency → 
Product Safety and Quality → 
Material Topics
UN SDG

CY’22 CSR Report
14
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Q&A with Our CFO and CPAO           CSR Strategy: Create Unique Impact           2030 Targets           CSR Governance           Stakeholder Engagement and Materiality
Our 2030 Targets
Accelerate 
Access to 
Genomics
Target 17.6: Knowledge sharing and 
cooperation for access to science, 
technology, and innovation
Target 3.d: Improve early warning 
systems for global health risks
Target 17.7: Promote sustainable 
technologies to developing countries
Target 17.16: Enhance the global 
partnership for sustainable 
development
Operate 
Responsibly
Target 9.2: Promote inclusive and 
sustainable industrialization
Target 10.3: Ensure equal 
opportunities and end discrimination
Target 17.16: Enhance the global 
partnership for sustainable 
development
Empower Our 
Communities
Target 5.b: Promote empowerment of 
women through technology
Target 10.3: Ensure equal 
opportunities and end discrimination
Integrate 
Sustainability
Target 12.2: Sustainable 
management and use of 
natural resources 
Target 12.5: Substantially reduce 
waste generation
Target 13.2: Integrate climate 
change measures into policy 
and planning
Nurture 
Our People
Target 10.3: Ensure equal opportunities and end discrimination
Our Focus Areas
  Enable $100 genome 
  Support 50,000 patients through philanthropic iHope programming 
  Achieve 2 billion covered lives by 2026 
  Invest in 200+ genomic startups
  Activate Pathogen Genomics Initiative donations enabling our 
$60 million commitments
  Reach at least 25,000 medical education learners annually
  Ensure 100% strategic suppliers committed to reducing their 
environmental footprint
  Achieve 20% spend with diverse suppliers (US)
  Achieve top industry ESG ratings
  Reach 5 million STEM learners 
  Donate 100,000+ volunteer hours 
  Achieve 50% employee participation in giving and volunteering
  Deliver net zero emissions 
(Scope 1,2,3) by 2050 
  Reduce emissions by 46% 
(Scope 1,2)
  Reduce emissions by 46% 
(Scope 3)
  Achieve 100% renewable 
electricity 
  Reach 90% landfill diversion 
at core sites 
  Reach 10% reduction in 
water intensity at core sites 
  Reduce packaging 
by 75% 
  Increase gender representation in global leadership 
  Maintain zero net pay gap 
  Increase minority representation in executive leadership (US) 
  Increase representation of Black, Native, Pacific Islander, 
Hispanic or Latino, 2 or more in US workforce and leadership
  Reduce recordable injury and illness rate
2030 Targets
1. Drive innovation and affordability
2. Catalyze genomic startups to broaden the genomic ecosystem
3. Increase genomic data diversity
4. Democratize genomics
5. Enable catalytic philanthropy
6. Expand reach with payer coverage, genomic literacy, 
and patient advocacy
1. Practice strong corporate governance
2. Maintain a culture of compliance
3. Act with integrity in all that we do
4. Foster a responsible supply chain
5. Uphold high standards for data security and privacy
6. Participate in proactive public policy
1. Provide meaningful and strategic community investment
2. Engage our people to be agents of social change
3. Drive equitable access to STEM education
1. Drive climate action
2. Operate sustainable facilities
3. Foster a sustainable value chain
4. Develop sustainable products
5. Leverage genomics for a healthier planet
1. Practice diversity, equity, and inclusion
2. Invest in our people
3. Create a culture of care
Objectives
UN SDG Target Alignment
  Invest $20 million in 
philanthropic sustainability 
initiatives 
  Have 100% of strategic 
suppliers commit to minimizing 
their environmental footprint
Achieved
In Progress

CY’22 CSR Report
15
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Q&A with Our CFO and CPAO           CSR Strategy: Create Unique Impact           2030 Targets           CSR Governance           Stakeholder Engagement and Materiality
CSR Governance
CSR is integral to how we do business. Our 
governance structure facilitates accountability, 
transparency, and continuous improvement.
Board of Directors
We govern CSR at the highest level with oversight from the full Board of Directors (Board) 
with support from the Nominating / Corporate Governance Committee. 
•	This strong leadership supports the 
management of material environmental, 
social, and governance issues, including 
climate action, diversity, equity, and 
inclusion, human rights, cybersecurity, and 
ethical, responsible business practices 
•	The full Board provides oversight and 
receives updates on current performance 
and future strategic plans at least annually 
or more frequently if material changes 
occur 
•	The Compensation Committee continues to 
oversee and provide input to management 
on diversity and inclusion matters, and 
the Audit Committee continues to oversee 
cybersecurity
•	Select ESG targets are included in annual 
corporate goals and influence executive 
compensation through the management 
performance scorecard. The compensation 
committee continues to oversee all 
compensation matters
In addition to the full Board oversight, we have now expanded the remit of 
the Nominating/Corporate Governance Committee to assist the Board in 
overseeing the company’s material environmental, social, and governance 
matters (ESG), except as specifically delegated to another Board committee.
Learn more about our Board governance, member tenure, 
independence, and diversity in Operate Responsibly →
CSR / ESG Executive Steering Committee
•	Comprised of senior leaders from across the organization and chaired 
by the Chief Public Affairs Officer, the ESG Executive Steering 
Committee provides guidance on ESG strategic plans and practices, 
approves major ESG programs, and monitors progress toward targets. 
•	Members include Chief Medical Officer, General Counsel, Chief of 
Global Operations, Chief People Officer, Chief Technology Officer, 
Chief Marketing Officer, and Global Head of CSR/ESG. 
Giving Governance
•	The Illumina Corporate Citizenship Steering Committee has 
oversight on philanthropic contributions from Illumina. Membership is 
comprised of the CEO, CFO, General Counsel, Chief Medical Officer, 
Chief People Officer, and VP of Treasury. 
•	The Illumina Corporate Foundation Board governs the philanthropy 
associated with the Illumina Corporate Foundation, a separate entity 
and private foundation. The foundation board is comprised of Illumina 
senior leaders including the CEO, CFO, General Counsel, Chief 
Medical Officer, Chief People Officer, and VP Treasury. 
We offer employees the ability to directly participate in our CSR 
program through a variety of grassroots efforts. These teams provide 
a wealth of ideas and support for activation at local levels all aimed 
to link our CSR efforts back to our mission. 
Our External Ethics Advisory Board provides guidance on a range 
of strategic issues, including recommendations on emerging ethics 
matters, policies, and regulations that are relevant to the genomics 
industry. Learn more in Operate Responsibly →
The CSR Functional Group is responsible for strategy development, 
program implementation, and ESG reporting. 
Our cross-functional working group teams engage to operationalize 
and integrate CSR in each of their respective programs.
CEO & Executive Leadership
CSR / ESG Executive 
Steering Committee
Philanthropy Governing Board
Internal Support Groups
Executive Diversity Council • EHS Steering Committee 
Quality Council • Public Policy Committee • Sustainable Product Core Team
Supply Chain Sustainability and Responsibility Working Group 
Supplier Diversity Governance Committee • Privacy Steering Committee
Employee Engagement Groups
Sustainability Green Teams • Illumina Cares Volunteer Champions • Employee Resource Groups
CSR Functional Group
External Ethics Advisory Board
Board of 
Directors
Nom/Gov
Board Committee

CY’22 CSR Report
16
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Q&A with Our CFO and CPAO           CSR Strategy: Create Unique Impact           2030 Targets           CSR Governance           Stakeholder Engagement and Materiality
Stakeholder Engagement and Materiality
Our CSR strategy is continuously informed by engaging our stakeholders around our most material ESG issues. 
Investors
•	ESG Investor Event – We convened our second annual ESG investor 
event to share progress and field questions 
•	Investor Day – We hosted Investor Day for presentations by members 
of Illumina’s executive team and a live Q&A session 
Customers
•	Our Customer Experience team regularly surveys customers to 
understand how we can improve. We conduct biannual relationship 
surveys, leverage machine learning tools, and provide an open channel 
for customer feedback from our field employees. These types of inputs 
even helped inform our design for environment approach. 
Learn more in Sustainability →
Patients 
•	We continue to advocate for the best clinical care for patients 
across the globe, actively engaging with medical organizations and 
governments to ensure that the genetic disease community has not 
only hope but also a voice
Employees
•	Employee pulse surveys are sent out at least bi-annually 
Learn more in People →
Community Partners 
•	Community investment grant recipients complete an impact report 
following completion of projects to help guide future opportunities 
and provide feedback Learn more in Community →
Governments and Regulatory 
•	Illumina connects with governments and organizations around the 
world to engage and educate policymakers and key stakeholders 
on issues that impact our mission and business
Materiality Assessment
•	Our materiality assessment guides our 
CSR strategy by identifying the material1 
issues that matter most to our business 
and our stakeholders, and where we 
are uniquely positioned to create the 
greatest positive impact 
•	In 2021, we refreshed our 2018 baseline 
materiality assessment. The updated 
materiality assessment further 
refined and validated our priorities 
and focus areas 
We engage 
with a wide 
range of 
stakeholders.
GOVERNMENTS & REGULATORY
HEALTH CARE PROVIDERS
COMMUNITY PARTNERS
INDUSTRY LEADERS
CHANNEL 
PARTNERS
CSR PEER GROUPS
DISTRIBUTORS
NONPROFITS
INVESTORS
SUPPLIERS
CUSTOMERS
EMPLOYEES
Reporting Frameworks and External Benchmarking
Engaging Our Stakeholders 
We are committed to operating with transparency and open communication to develop trusted relationships with all our stakeholders. We routinely 
gather feedback on environmental, social, and governance (ESG) topics from our stakeholders and work to create an open dialogue. As part of our 
ongoing engagement, we have used a variety of ways to gather feedback and evolve our program, including customer surveys, employee surveys, 
industry trade group participation, guidance from relevant frameworks, and external benchmarking.
Our Most Material ESG Issues
Environment
Social
Governance
Climate Action
Democratize Genomics
Innovation
Sustainable Facilities
Community Investment and Philanthropy
Pricing and Affordability
Sustainable Products
STEM Education
Data Privacy and Security
Sustainable Supply Chain
Diversity, Equity, and Inclusion
Corporate Governance
Human Capital Management
Ethics and Transparency
Employee Health, Safety, and Wellness
Product Safety and Quality
Learn more about our CSR Strategy →

CY’22 CSR Report
17
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Appendix
Sustainability 
Message from the CEO
Accelerate Access 
to Genomics

CY’22 CSR Report
18
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Strategic Approach 
and Impact
We are committed to accelerating access to genomics to realize 
health equity for billions of people around the world. We are driven 
by our conviction that genomics should be available to the many, 
not the few. 
Realizing the potential of the genome to exponentially improve the human 
condition requires continued innovation and the democratization of genomics.
UN SDGs
1  Drive innovation and affordability
2  Catalyze genomic startups to broaden the genomic ecosystem
3  Democratize genomics 
4  Increase genomic data diversity
5  Enable catalytic philanthropy
6  Expand reach with payer coverage, genomic literacy, and patient advocacy
KEY OBJECTIVES
 To successfully fulfill our mission to improve 
human health, we must expand access to genomic 
technology in medical care to improve outcomes, 
regardless of social status, income, or geographic 
location. We must continue to bridge the gaps to 
ensure the individuals receiving genomic analysis 
represents our global diversity. 
Phil Febbo, MD 
Chief Medical Officer
Achieve 
$100 genome
Support 50,000 patients 
through philanthropic iHope 
programming
Reach at least 25,000 medical 
education learners annually
Activate Pathogen Genomics 
Initiative donations enabling 
our $60 million commitments 
by 2027 
Achieve 2 billion 
covered lives by 2026
Invest in more than 
200 genomic startups
193 new patent 
applications in 2022 
22% revenue invested 
in R&D
9,178 total patents 
issued worldwide
Breakthrough NovaSeq™ X 
series announced
2030 Target
2022 Progress
2022 Highlights
1,704
> 30,000
$11M
1.2B
74
$2001
1~$200, based on US list price, assuming 
120 Gb/genome; compared to NovaSeqTM 6000.

CY’22 CSR Report
19
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Drive Innovation 
and Affordability 
We have proven through focused and continuous innovation that 
unlocking the power of the genome can exponentially improve 
the human condition. As an engine of genomics innovation, we 
understand that the larger we grow our network of partners, the 
more lives that can be impacted.
There is an urgency to our mission because we understand that today’s discoveries have the potential 
to help tomorrow’s patients and address some of the world’s most pressing challenges. Every 
technological breakthrough that reduces cost, improves throughput, decreases turnaround time, or 
improves ease of use helps us realize our potential, improving more lives and protecting our planet.
Lower the cost of sequencing 
and enhance the value beyond 
cost per genome
Invest in strategic acquisitions 
and collaborations 
Deliver breakthrough 
technology and workflows
Catalyze genomic 
startups 
To drive innovation and 
affordability we endeavor to:
Since 2001, the cost of DNA sequencing has 
dropped more than 100,000x from $100 million 
USD per human genome to ~ $2001 USD 
with the NovaSeqTM X sequencers, putting 
our dream of a $100 genome within reach. 
Innovations are enhancing the value beyond 
cost per genome and delivering the most 
comprehensive genomic view.
2001
$100M
2014
$1000
HiSeqTM X
2010
$10,000
HiSeqTM 2000
2020
$600
NovaSeqTM 6000 v 1.5 
Reagent Kit
2022
$200
NovaSeqTM X
2030
$100 genome
1~$200 / genome based on US list price, 
assuming 120 Gb/genome; compared to NovaSeqTM 6000. 
Lower the Cost of Sequencing 
and Enhance the Value Beyond 
Cost Per Genome
$200 
with announcement of 
launch of NovaSeqTM X
$100
genome
2022 PROGRESS
2030 TARGET

CY’22 CSR Report
20
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Throughput, 
Accuracy,  Efficiency
Economics
User Experience
Sustainability
2.5x higher output
60% reduction in cost/Gb*
Ergonomic innovations
90% reduction in 
packaging weight 
and waste
2x faster
~$200 genome
(based on US list price, 
assuming 120 Gb/genome) 
Individually addressable flow cell 
lanes are done onboard the system 
automatically and automated 
lossless data compression
50% reduction of 
plastic mass
Up to 3x greater accuracy 
with the XLEAP-SBS 
chemistry
Lower disposal cost with more 
recyclable plastics, no dry ice, 
no ice packs
Reduced unpacking time and 
maximized storage space with 
compact cartridges and packaging
61% reduction in 
climate change 
impact
The first FDA-registered and CE-marked 
in vitro diagnostic (IVD) high-throughput 
sequencer, delivering the highest 
standards of compliance and driving 
actionable insights for patient care. 
This technology expands the breadth 
of applications and clinical testing in 
countries that require IVD products, 
increasing access to clinical genomics 
with scalable throughput while achieving 
significant reductions in cost/Gb and total 
cost of ownership. NovaSeqTM 6000 Dx is 
an open platform with Research Use Only 
(RUO) and IVD modes and a dedicated 
DRAGEN™ server, resulting in flexible, 
high-quality, automated data processing 
that will minimize the time and labor 
required to complete projects.
At the end of 2022, we introduced the NovaSeqTM 
X series, our most powerful and sustainable high-
throughput next-generation sequencers. Breakthrough 
innovations with new XLEAP-SBSTM chemistry deliver 
revolutionary throughput, scale, sustainability, and 
accuracy with transformative economics. 
Learn more about the sustainability attributes 
in Sustainability ->
NovaSeqTM 6000 Dx
*~$200 (based on US list price, assuming 120 Gb/genome; compared to NovaSeqTM 6000.
Our 2022 Product Innovations
CY’22 CSR Report
20
The NovaSeq
TM X Series
99.87% accuracy score as 
measured by Precision FDA 
Challenge v2
90% less DNA input than current 
long read technology
Simple workflow with automatable 
single-day library preparation
Breakthrough Technology and Workflows
Innovating at the intersection of technology, biology, and health, Illumina is reimagining what is 
possible for clinicians, transforming how they detect, diagnose, and treat cancer as well as other 
rare, infectious, and genetic diseases. We aim to inspire our customers to dream big.
NOVASEQTM X SERIES HIGHLIGHTS
To address the small portion of the 
genome that has historically been 
challenging to map due to highly 
repetitive or highly homologous regions 
of the genome, we developed a novel, 
high-performance longread assay that 
accelerates access to the remaining 
~5% of genic regions, creating our most 
comprehensive genomic view yet.
Illumina Complete Long Read 
Technology
First FDA-registered 
and CE-marked 
IVD high-throughput 
sequencer

CY’22 CSR Report
21
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
At Illumina, we are not just at the forefront of a global genomics 
movement, we are at the center of a transformation in global health. 
The last few years have shown the world the promise of genomics and 
the power of collaboration. Together we can achieve more. Enabling 
innovation and driving affordability goes beyond delivering sequencers 
and data. It includes delivering insights and accelerating the paradigm 
shift toward genomic sequencing as a standard of care to improve 
patient outcomes and drive down overall health care costs. 
Illumina Launches a Research Test Co-developed with Merck to 
Unlock Deeper Insights into the Tumor Genome
The research test builds upon Illumina’s commitment to broadly enable 
comprehensive genomic profiling and enhance research critical to 
realizing precision medicine in oncology. Learn more

Illumina Launches Strategic Research Collaboration with 
AstraZeneca to Accelerate Drug Target Discovery
The research collaboration aims to utilize artificial intelligence (AI)-
based genome interpretation and genomic analysis techniques along 
with industry expertise. Learn more

Illumina and GenoScreen Partner to Expand Access to Genomic 
Testing for Multidrug-Resistant TB
This alliance will help advance the World Health Organization’s strategy 
to end the global tuberculosis (TB) epidemic by 2035. It will also enable 
global access to a package combining Illumina sequencing products and 
the GenoScreen Deeplex® Myc-TB assay, a targeted next-generation 
sequencing (NGS) based test for rapid and extensive detection of anti-
TB drug resistance, to promptly inform treatment decision. Learn more

Illumina Acquires GRAIL, a Previous Spin-Off of Illumina, to Improve 
Early Detection of Cancers (2021)
GRAIL is focused on lifesaving early detection of multiple cancers—all 
through a simple blood test in a doctor’s office. GRAIL’s Galleri® blood 
test can detect more than 50 types of cancer in asymptomatic patients. 
Our acquisition of GRAIL will accelerate access and adoption of this life-
saving test worldwide.1

Illumina Acquires IDByDNA
This company is developing metagenomic technology for infectious 
disease testing and pathogen surveillance. After an alliance for the past 
two years, the acquisition brings in-house a respiratory pathogen panel 
enrichment kit that identifies more than 280 pathogens, including SARS-
CoV-2, and more than 1,200 antimicrobial resistance alleles. It runs on 
Illumina’s NextSeq 550 sequencing system and utilizes IDbyDNA’s Explify 
analysis software.
1GRAIL must be held and operated separately and independently from Illumina pursuant to the interim measures ordered by the European Commission, which prohibited the Illumina/GRAIL 
transaction on 6 September 2022 under the EU Merger Regulation.
•	Illumina Enters Co-Development 
Partnership with Somalogic 
•	Boerhringer Ingelheim 
Companion Diagnostic 
Partnership
•	Illumina Partners with Agendia 
to Expand Genomic Testing in 
Breast Cancer
•	Illumina and Nashville 
Biosciences Announce 
Sequencing Agreement with 
Amgen
Invest in Strategic Acquisitions and Collaborations 
We further support the genomics startup community 
through Illumina Ventures, an independently 
managed firm founded in 2016. It is focused on 
assisting startups that are pioneering genomic 
applications and enabling precision medicine. We 
provide funding and strategic counsel, as well as 
access to the wealth of experience and expertise 
of the world’s leading genomics solutions provider. 
Learn more about Illumina Ventures.
Illumina Invested in Time Boost Capital I LP, 
a £30 million (US $36.8 million) genomics venture 
fund from cornerstone investor LifeArc, other US and 
European investors, Illumina, and Illumina Ventures. 
The fund provides match funding to startups 
graduating from Illumina Accelerator Cambridge with 
the aim to advance breakthroughs in human health. 
Illumina Ventures
•	Illumina Collaborates with 
National Cancer Center Japan
•	Illumina Partners with Centers 
Across France to Advance 
Precision Medicine Approach for 
Patients with Late-Stage Cancer
•	Illumina and Deerfield 
Management Partner to 
Accelerate Drug Development
•	Illumina and GenoScreen 
Partner to Expand Access to 
Genomic Testing for Multidrug-
Resistant Tuberculosis
Additional 2022 Acquisitions, Partnerships, and Collaborations
 In addition to our internal innovation engine, we 
leverage strategic acquisitions and collaborations to 
further support our mission, drive affordability, and 
accelerate access to genomics for all so that the 
potential of personalized medicine can be realized. 
Joydeep Goswami
Chief Financial Officer, Chief Strategy 
& Corporate Development Officer

CY’22 CSR Report
22
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Genomics startups are playing an increasingly important role 
internationally in the expansion of the genomic ecosystem. Illumina aims 
to catalyze this growth by supporting Illumina for Startups and Illumina 
Ventures. The dramatic innovations emerging are helping to drive down 
costs and unlock new areas of biology and market use. 
Our Startup Engines
Rethink Bio Private Limited, 
a synthetic biology 
company from India, is 
focused on harnessing the 
potential of microalgae to 
develop sustainable food 
solutions to benefit the 
planet and people.
Impactful diagnostics to 
detect and prevent disease
Novel drug discoveries 
to treat patients
SCOPE OF PROGRAMS
Catalyze 
Genomic Startups
74 
startups launched since 
program inception 
200+ 
genomics startups 
supported
2022 PROGRESS
2030 TARGET
Startup Spotlights
 The llumina Accelerator 
experience completely 
transformed the way we 
thought about the future 
development of our 
genomics startup. 
Felix Dobbs, Ph.D.
Co-Founder & CEO, Broken 
String Biosciences
Broken String Biosciences
Important agriculture and 
food innovations to feed 
more with less
Illumina Accelerator, 
San Francisco, US
Illumina Accelerator, 
Cambridge, UK
Illumina for Startups, 
Singapore
Illumina for Startups, 
Melbourne, Australia
Sequoia Capital China Intelligent 
Healthcare Genomics Incubator, 
Powered by Illumina, Shanghai, China
Illumina for Startups is focused on creating an innovation ecosystem for the 
genomics industry by partnering with leading venture capital investors and 
entrepreneurs to create, launch, and grow genomics startups. Illumina for Startups 
initiatives include Illumina Accelerator, founded in 2014, and Sequoia Capital China 
Intelligent Healthcare Genomics Incubator, Powered by Illumina, founded in 2021. 
Illumina for Startups 
$1.1B
VC funding 
secured
47%
female 
founders
5
global 
locations
93%
startups raised 
additional capital
New synthetic biology 
approaches for a more 
sustainable future
Software and tools to 
further enable new insights
Consumer-driven 
applications to help us 
better understand ourselves

CY’22 CSR Report
23
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Democratize 
Genomics
We are driven by our conviction that 
genomics should be available to the many, 
not the few. 
Realizing the potential of the genome requires 
education, advocacy, access, and global data 
that is representative of the diversity of our 
populations.
Democratizing genomics and genomic sequencing 
can enable families, communities, and whole 
populations to harness the benefits of next-
generation sequencing (NGS). 
Enable catalytic 
philanthropy
Expand the reach of genomics with payer coverage, 
genomic literacy, and patient advocacy
 
Increase genomic data 
diversity
We are proud to support projects that:

CY’22 CSR Report
24
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
In 2021, we announced an expansion of the 
iHope program with the launch of the iHope 
Genetic Health program under the auspices of 
the nonprofit Genetic Alliance. The expanded 
program is designed to provide cWGS to tens 
of thousands of underserved families across 
the globe with at least half outside the US 
and at least one third dedicated to patients 
in Africa. In 2022, critical infrastructure and 
partnerships were put in place. Learn more 
about iHope Genetic Health.
iHope Genetic Health
Building upon the iHope model, in 2022 we 
announced the launch of our iHope China, bringing 
whole-genome sequencing to those in need with our 
partner, the March of Dimes Birth Defects Foundation 
of China. iHope China aims to provide free genetic 
disease testing funding for 2,000+ families of rare 
disease patients across the country in the next three 
years. Additionally, the program will provide genetic 
disease identification and diagnosis training courses 
for 100+ front-line clinicians in 20 hospitals and 
continue to empower the construction of genetic 
disease specialty in China. 
Families of children with undiagnosed 
genetic diseases often face an uncertain and 
unpredictable future. Their diagnostic journeys 
may take up to seven years in developed 
countries, while in low- and middle-income 
(LMI) geographies, many families never know 
the cause of their child’s suffering. 
	 iHope is a philanthropic effort that provides 
clinical whole-genome sequencing (cWGS) 
to underserved families around the globe. 
It was created in 2017, bringing together a 
wide range of organizations aiming to shorten 
the diagnostic journey and inspire hope. 
Demonstrating the impact of the program 
regardless of location, nearly 60% of the cases 
received in 2022 came from seven iHope 
program sites in LMI countries (Ghana, DR 
Congo, Peru, and Mexico). Patients from iHope 
sites in LMI countries who received a molecular 
diagnosis had comparable rates of change 
management to patients from high-income 
countries. We are excited about the growth and 
expansion that will bring iHope to more families 
in the future. Learn more about iHope.
iHope China with March of Dimes
Bringing iHope™ to More Families 
1Derived from >1000 cohort 22.
iHope Impact
1,704
patients impacted 
since inception
70%
change 
management 
after cWGS1 
40% 
patients receive 
diagnosis after 
cWGS 
28
iHope clinical 
sites worldwide
3
new clinical sites 
in Zimbabwe, 
N. Macedonia, 
and Singapore
Enable Catalytic Philanthropy 
The Illumina iHope program will change the trajectory of genomic medicine worldwide, 
helping patients who may have otherwise been invisible to diagnostic and preventative 
service providers. 
1,704 
patients supported
50,000+ 
patients supported through 
iHope programming
2022 PROGRESS
2030 TARGET
 No child with a genetic 
disease should suffer 
unnecessarily. iHope points 
to a future where every 
patient receives a diagnosis 
and true precision care. 
Ryan Taft
VP, Scientific Research 
iHope™ Lead

CY’22 CSR Report
25
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Building pathogen genomics capabilities globally 
protects the health of everyone since a public health 
threat in one location can quickly become a threat 
everywhere. The UN Sustainable Development Goal 
(SDG) 3 includes targets related to improving early 
warning systems for global health risks. In addition, 
SDG 17 promotes knowledge sharing and cooperation 
for access to science, technology, and innovation. 
	 We are proud to be part of the Pathogen Genomics 
Initiative (PGI), a multi-sector collaboration with global 
funders, industry, NGOs, and public health agencies. 
In October of 2020, the Africa Pathogen Genomics 
Initiative was launched with the aim to enhance 
disease surveillance and public health through 
integrated, cross-continent laboratory networks 
equipped with the tools, human resource capacity 
and data infrastructure to fully leverage critical 
genomic-sequencing technologies. The vision was to 
integrate pathogen genomics and bioinformatics into 
routine public health surveillance systems, outbreak 
investigations, timely response to infectious disease 
threats, responsible data sharing, and improved 
disease control and prevention.
	 The partnership is designed to expand access to 
next-generation genomic sequencing (NGS) tools and 
expertise to strengthen public health surveillance and 
laboratory networks across low- and middle-income 
countries for COVID-19 and other epidemic threats 
and endemic diseases such as AIDS, tuberculosis, 
malaria, and cholera. Pathogen sequencing will also 
contribute to research and development efforts for 
new vaccines, diagnostics, and treatments for current 
and emerging infectious diseases.
	 In 2019, only seven countries in Africa had next-
generation sequencing capacity within their public 
health laboratories. By 2022, that number has grown 
to 31, and Illumina donations have supported 20 of 
these countries. The new infrastructure was put to 
immediate use in 2022 to manage the Ebola virus and 
Mpox outbreaks, among others.
Boost Pathogen Genomics Surveillance in Low- and Middle-Income Countries
	 Illumina has committed $60 million over five years 
with in-kind donations, including NGS platforms, 
reagents, and training support to the initiative. The 
initiative will bring us closer to the vision of an early 
warning system to detect new epidemics and apply 
genomics to benefit all.
	 COVID-19 pathogen surveillance is not the end of 
the story. The UN Environment Program has warned 
of the growing risk of zoonotic disease, infections that 
spread between people and animals due to increased 
urbanization and expansion of industrialized agriculture.
	 Building a global pathogen surveillance system that 
supports a One Health approach and is both versatile 
and adaptable is a vital part of managing these risks 
and a core part of the PGI vision.
	 The Pathogen Genomics Initiative (PGI) is a 
collaboration between the Africa CDC Institute of 
Pathogen Genomics, the U.S. Centers for Disease 
Control and Prevention, the Bill and Melinda Gates 
Foundation, Microsoft, Illumina, and other industry 
partners. The initial Africa PGI commitment included 
$20 million and led to the expansion of a global 
model. Illumina committed an additional $40 million 
of product donations over five years to support the 
global expansion and to other low-and middle-income 
countries, starting in South Asia.
	 The PGI commitment will help create a 
comprehensive pathogen genomic network around the 
world, building critical public health capabilities in areas 
of need.
	 The initiative will bring us closer to the vision of an 
early warning system to improve global health risks 
and apply genomics to benefit all.
Africa PGI Impact
Asia PGI Impact
$9 million 
delivered
$2 million 
delivered
20 
countries
4 
countries
$60 million committed
over five years
TARGET
$11 million 
since program launch
2022 PROGRESS
An African proverb uttered in the halls of the African Union 
captures the ethos of global partnerships and the spirit of 
collaboration: If you want to go fast, go alone. If you want to 
go far, go together.

CY’22 CSR Report
26
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Qatar Genome Program
The Qatar Genome Program (QGP) is using Illumina 
technology to sequence individuals from the general 
population of Qatar, advancing genetic studies in Arab 
and Middle Eastern populations.
Egyptian Genome Project EGP 
This year, the Scientific Research and Technology 
Academy and Ministry of Defense celebrated the two-
year anniversary of the launch of the genome project in 
partnership with Illumina to implement a reference 
genome for Egyptians.
Singapore’s SG100K Project
In 2022, Precision Health Research (PRECISE), the lead 
entity implementing Singapore’s National Precision 
Medicine strategy, partnered with Illumina to launched the 
SG100K Project. The three-year initative aims to aims to 
map the DNA of a diverse group of 100,000 Singaporeans 
who are of Chinese, Malay, and Indian ethnicity. In addition 
to enabling population-based research in groups that have 
been historically underrepresented, PRECISE will use the 
information collected to identify the social, environmental, 
lifestyle, and genetic factors that are associated with 
diabetes, hypertension, cancer, and other important 
diseases in the multi-ethnic population of Singapore. 
Human Heredity and Health in Africa
Illumina supports the Human Heredity and Health in Africa 
(H3Africa). The H3Africa assays use novel, genome-wide 
content from individuals across African populations, built 
on the MEGA Array backbone. These studies use genetic, 
clinical, and epidemiologic methods to identify hereditary 
and environmental contributions to health and disease, 
empowering the ability to address African genomic 
diversity that can improve the health of both African 
peoples and the broader global population.
Genetic Research into Cancer Origins
The New York Genome Center’s (NYGC) 
Polyethnic-1000 Project (P-1000) focuses on cancer 
care inequities in underserved populations, with the 
objective of democratizing and broadening access to 
the power and potential of cancer therapies. Illumina 
provided $2.4 million of in-kind product donations to 
support this initiative and help to identify differences 
between ethnicities that may account for disparities 
in occurrence, response to treatment, and survival 
for different cancer types. Using whole-genome 
sequencing (WGS), the resulting data set will be 
made public to the entire research community, 
creating the largest and most diverse collection of 
full-genome pairs available in oncology.
Native American Genomic Research
Native BioData Consortium (NBDC) is the first 
nonprofit research institute led and staffed by 
indigenous scientists and tribal community 
members in the US. Since its inception in 2018, the 
consortium’s goal has been to ensure that Native 
people can benefit from advances in genetics and 
health research. 
In 2021, to empower the Native community’s 
ability to respond to COVID-19 and future risks, 
we supported the donation of a NextSeq 550, 
consumables, and training to the Cheyenne River 
Sioux Tribe. In addition to COVID-19 surveillance, 
NBDC will be able to study other diseases that 
disproportionately affect their population, such as 
diabetes, cardiovascular disease, and colon cancer.
Australia’s OurDNA Initiative
Australia’s Centre for Population Genomics (CPG), a 
collaboration between the Garvan Institute of Medical 
Research and the Murdoch Children’s Research 
Institute, has launched a new initiative to engage 
diverse communities in genomic research. Supported 
by a AU$10 million (US $6.26 million) grant from 
the Australian government, as well as contributions 
from Illumina and other organizations, the Australian 
Genetic Diversity Database project, called OurDNA, 
will gather data to improve disease prediction, 
diagnosis, and treatment in underserved communities.
Alliance for Genomic Discovery (AGD) 
Illumina and Nashville Biosciences, announced 
a sequencing agreement with Amgen to whole-
genome sequence 35,000 DNA samples primarily 
made up of DNA from African Americans, currently 
a community underrepresented in research for the 
clinical applications of genomics.
Genomic Data That Reflects Everyone, Everywhere 
Genomic data is the blueprint for everything from 
identifying new diseases to precision drug development. 
That means the data sets must be representative to 
ensure the positive impact of genomics is applicable 
for all.
	 Genomics has been integrated into clinical practice 
at a faster rate than almost any innovation in the history 
of medicine, but inequities still exist. Implementation 
has been almost entirely restricted to more developed 
nations, and 87% of individuals included in genomic 
studies of disease risk are of European ancestry. 
	 To ensure that genomes can be interpreted in the 
appropriate context of global diversity, we aim to 
increase the equitable representation of genomic data. 
This allows for therapies and solutions to be attuned to 
a broader set of genomes, decreasing this bias in our 
medicine for the future.
We are proud to support commercial and philanthropic 
efforts to increase diversity in human genetics 
and ensure that genomic representation is part of 
equitable health care in the future.
Increase Genomic Data Diversity
Access to Genomics for Everyone
Increase diversity and 
equity of representation 
in genomic data
Ensure everyone has access 
to lifesaving treatments tailored 
to their individual health needs
Close the gap in 
under-resourced 
communities
Ensure genomes can be 
interpreted in the appropriate 
context of global diversity

CY’22 CSR Report
27
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Global Coverage Snapshot1
Expand Reach of Genomics with Payer Coverage, 
Genomic Literacy, and Patient Advocacy
Expanded reimbursement 
and payer engagement 
Evidence generation 
for clinical utility
Education of health care 
providers and government 
representatives 
Increased adoption
Enabling innovation and driving affordability goes beyond 
delivering sequencers and data. It includes delivering 
insights and accelerating the paradigm shift toward 
genomic sequencing as a standard of care to improve 
patient outcomes and drive down overall health care costs. 
Through evidence generation, education, and community 
outreach, Illumina is committed to advocating for health 
care coverage and accelerating the adoption of genomics 
as a diagnostic tool.
US Coverage Data (EOY 2022)
Increase Patient Coverage and Reimbursement 
Non-Invasive Prenatal Testing
(NIPT)
Total Insured Lives 259.7 M
All Pregnancies 
Covered
224.8 M
87%
Only High-Risk 
Covered
34.3 M
13%
Not Covered
0.5 M
<1%
Somatic Mutation Panels 
(Oncology)
Targeted & 
Expanded Panels 
Covered
273.3 M
86%
Only Targeted 
Panels 
31.0 M
10%
Not Covered
12.9 M
4%
Total Insured Lives 317.3 M
Whole-Exome and Genome Sequencing 
(Genetic Disease)
Only WES 
Covered
167.0 M
64%
Not Covered
30.4 M
12%
   WES & WGS Covered
62.3 M
24%
Total Insured Lives 259.7 M
1.2 Billion
2 Billion
covered lives globally 
by 2026
2022 PROGRESS
2030 TARGET
↑149M YoY growth
986M
536M
↑52M YoY growth
714M
↑62M YoY growth
2022 PROGRESS
2022 PROGRESS
2022 PROGRESS
Based on coverage and reimbursement of NIPT, CGP in advanced cancer, or WES/WGS in genetic disease
1Global coverage numbers represent our tracking of 19 countries globally (US, Canada, Belgium, Czech Rep, Denmark, France, Germany, Ireland, 
Italy, Netherlands, Spain, Sweden, UK, Israel, Japan, S Korea, Australia, China).

CY’22 CSR Report
28
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Strategic Evidence Projects to Engage Health Systems Globally and Demonstrate Clinical Utility
Providence (US) The company is 
performing comprehensive genetic profiling 
(CGP) to demonstrate utility within an 
integrated care system. The collaboration 
has resulted in 10+ abstracts and there are 
multiple peer-reviewed publications due out 
in 2023.
Ballett (Belgium) The study will include 
960 patients across Belgium from 12 cancer 
centers and nine NGS labs using CGP to 
demonstrate utility within a nationalized 
single-payer system.
Baby Lion (Germany) Hanover Medical 
School will evaluate the use of WGS to show 
the positive impact of earlier diagnosis and 
treatment of infants suspected of having 
a genetic disorder while in the neonatal 
intensive care unit (NICU).
Fudan Hospital (China) Children’s Hospital 
of Fudan University in Shanghai is delivering 
a 24-hour rapid WGS diagnosis solution to 
NICU infant patients resulting in China’s first 
expert consensus and first research article 
published for NICU rapid WGS application.
Optum/UnitedHealth Group (US) 
The companies launched multiple 
evidence-generation projects across 
rare disease, oncology, and cardiovascular 
disease to accelerate the generation of 
evidence needed to unlock the promise 
of precise medicine.
Baby Bambi (Israel) Illumina supported a 
pilot program with Israel’s Ministry of Health, 
led by the Genetics Institute of the Tel Aviv 
Sourasky Medical Center, to implement the 
use of whole-genome sequencing (WGS) 
for rapid diagnosis in newborns in critical 
conditions who are treated in NICUs. Clinical 
results have been reported back with a 
diagnostic yield coming close to 50%. Based 
on the positive results of Baby Bambi, the 
Ministry of Health is expected to commission 
a decision for reimbursement for rapid whole-
genome sequencing (rWGS) in the NICU in 
2023, providing the creation of a national 
reimbursement for WGS as diagnostic tool in 
hospitals across Israel.
800+
263
2
peer-reviewed papers in 
strategic clinical segments
Illumina papers were highlighted in AJHG’s Genomic Medicine Year in Review 
as part of the top 10 key advances in applying genomic information to clinical 
care reported in 2022
studies and research collaborations 
across the globe in pipeline

CY’22 CSR Report
29
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
The Adolescent and Young Adults
Researchers at the Netherlands Cancer Institute 
(NKI) and the Dutch AYA foundation are working on 
a national large-scale genomics study. Within that 
study, the teams are exploring how AYA patients 
value and cope with the experience of having their 
whole genome sequenced (WGS). Output of the 
study aims to help inform the future of oncological 
practice as WGS becomes more routine in the clinic 
and to improve care for this population. 
Know Your Biomarker
This campaign was launched by the Global Colon 
Cancer Association to increase awareness about 
biomarker testing and treatment decision making. 
The campaign also features patient stories 
highlighting the impact of biomarker testing on 
outcomes for colorectal cancer patients. 
The Rare Barometer: The Journey to Diagnosis 
for People Living with a Rare Disease
The Rare Barometer is EURORDIS’ signature survey 
program that guides EURORDIS’ patient-driven 
advocacy. The survey currently accesses the 
experiences of over 15,000 people representing 
over 1500 rare diseases in 80 countries across the 
world. Survey results transform the experiences and 
opinions of individuals into collective data that is 
used to influence policymaking, foster information 
exchanges, and raise awareness. In 2022, the survey 
was designed to explore the individual and external 
factors influencing the process of obtaining an 
accurate diagnosis for rare disease. 
We LOVE Rare in Zimbabwe
Recognizing the disparity of access to diagnosis in 
various countries, Child and Youth Care (CYC), a 
Zimbabwean-based private voluntary organization, 
deployed a project to not only raise awareness but 
to physically go out and ‘find’ children and young 
people impacted by rare disease and to start to 
create the database of evidence needed to build the 
value case for prevalence and impact of rare disease 
in Zimbabwe. 
Annual Rare Disease Awareness Campaign #IlluminatingRareDisease
Our employees are passionate about the rare disease community. They 
understand the power of genomics to help end a patient’s diagnostic journey 
and support their care management. Since 2008, Rare Disease Day events 
have taken place around the world on the last day of February to raise 
awareness about rare diseases and highlight their impact on patients’ lives. 
Each year, our employees participate in a campaign and the Illumina Corporate 
Foundation donates to the chosen charities for the year.
Transforming patient outcomes epitomizes the heart 
of our mission. We partner with patients, families, 
and organizations that represent communities to help 
raise awareness, build hope, and create change.
In 2022, we have worked to amplify the diversity 
of patient voices by supporting projects that unite 
single stories into collective evidence of the value of 
genomics in oncology and rare disease. 
Rare Youth Intern Program 
This initiative seeks to empower young people 
affected by rare disease around the world with skills 
and confidence to seek meaningful employment 
and to empower the next generation of advocates. 
This is Illumina’s second year supporting this 
impactful program.
Illumina Patient Ambassadors
Illumina Patient Ambassadors are a coalition of 
patients and family members dedicated to increasing 
awareness of the importance of genetic testing. 
Connecting families to a wider community of people 
with similar experiences helps provide support and 
strength during the search for a diagnosis and can 
improve patient care and management. By sharing 
personal stories about their disease journey, the 
group can educate and motivate an entire ecosystem 
of support. 
Champion Patients

CY’22 CSR Report
30
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Expand Genomic Literacy 
To accelerate access to genomics, we need to accelerate 
awareness. Illumina is committed to increasing the awareness of 
genomics in health care and the advancement of precision medicine. 
We aim to increase genomic literacy by supporting health care 
professionals, government representatives, connecting genomic 
professionals, and inspiring the next generation of scientists, 
innovators, and researchers.
We are committed to expanding understanding and access to 
genomic testing through our outreach to community health systems. 
In 2022, we hosted our inaugural Illumina 
Genomics Forum (IGF), which convened 
more than 800 visionaries, customers, 
and leaders from translational and clinical 
research organizations, government 
institutes, and academia, as well as 
hospital leadership, clinicians, payers, and 
patient advocates. An additional 7,800 
people joined virtually. As an engine of 
genomics innovation, we are reimagining 
what’s possible, inspiring our customers to 
dream big. 
Explore additional Illumina events.
 Illumina is honored to host this 
unique gathering of the brightest 
minds discussing solutions to some of 
today’s biggest challenges, redefining 
what’s possible together. 
Francis deSouza
CEO
Illumina Genomics Forum (IGF)
Expand independent medical 
education (IME) partnerships with 
professional societies and the medical 
community, providing education 
across all clinical segments
2030 TARGET
>30,000  
learners reached 
through IME
2022 PROGRESS
98% 
increase in participant
knowledge and 
competence
>95% 
supported medical education 
programs increase in participant 
knowledge and competence
25,000+
health care professional learners 
reached annually
30,000+
health care professional 
learners reached
Francis deSouza
CEO
In 2022, we partnered with the American Society for Preventive 
Cardiology (ASPC) to create a podcast series which reached 
over 26,000 learners by year-end. We continued support of the 
American Society of Human Genetics (ASHG) online education 
for genetics professionals, and we participated in Becker’s 10th 
annual leadership roundtable on how internalizing genomics can 
help providers achieve key health care goals. Learn more

CY’22 CSR Report
31
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Innovation and Affordability           Genomic Ecosystem           Democratization          Catalytic Philanthropy          Data Diversity           Reach           Impact in Action 
Eight years ago, AJ Patel was diagnosed with advanced lung cancer. The 
Southern California resident and father of three had tumor masses in both lungs. 
AJ met a physician who recommended biomarker testing, an approach that uses 
next-generation sequencing to determine an individual’s cancer-causing genes 
and other markers. When the causal genetic alteration is identified through 
testing, a patient can be eligible for more personalized therapies or beneficial 
clinical trials. For AJ, biomarker testing led to a targeted therapy plan—and it is 
the reason he is still here today, telling his story. Learn more
Baby Fitz’s Lifesaving Diagnosis Through Whole-Genome Sequencing
Impact in Action
Beating Stage IV Lung Cancer:
Biomarker Testing Changed Everything
In 2022, we added a companion diagnostic (CDx) indication 
to our CE-marked in vitro diagnostic TruSight™ Oncology 
(TSO) Comprehensive (EU) test. This single test kit assesses 
multiple tumor genes and biomarkers to reveal the specific 
molecular profile of a patient’s cancer. We continue to focus 
on unlocking the potential of new biomarkers to identify 
those most likely to benefit from precision medicines. This 
CDx claim, developed in partnership with Bayer, is the first 
of a series building upon our broad portfolio of oncology 
partnerships with industry leaders to advance cancer 
diagnostics and precision medicine. Learn more
Illumina Introduced New Pan-Cancer 
Companion Diagnostic to Match 
Patients with Rare Genetic Mutations 
to Targeted Therapy
In June 2019, Christina and Daniel Kettler 
were barely home from the hospital with 
their newborn son when they received an 
urgent phone call. They needed to rush back 
immediately: A routine screening, called the heel 
stick test, had revealed that Fitz, their firstborn 
baby, had severe combined immunodeficiency 
(SCID). SCID is a rare condition also known as 
“bubble boy disease.” Fitz had no functioning 
immune system. Further testing through rapid 
whole-genome sequencing (rWGS) at Rady 
Children’s Institute for Genomic Medicine in San 
Diego, California (US), identified the specific kind 
of SCID Fitz had, known as Artemis, or ART-
SCID. Fitz was able to receive gene therapy in 
San Francisco—a process of extracting his stem 
cells, injecting them with a corrected copy of the 
Podcast series with 
American Society 
for Preventive 
Cardiology reached 
>26,000
learners
Illumina technology has been at the 
forefront of the pandemic since its 
inception and continues to be used 
across the outbreak continuum in 
over 200 countries around the globe.
Continued Efforts and 
Innovation in the Surveillance 
of SARS-CoV-2 Variants
SCID-causing gene, and infusing them back into 
his body. The treatment succeeded in creating 
from scratch an immune system that would 
function properly and support Fitz. This year, Fitz 
celebrates his third birthday as a happy, healthy, 
and active toddler. 
	 On April 25, to help raise awareness for National 
DNA Day, Fitz threw the first pitch with Illumina’s 
Chief Technology Officer, Alex Aravanis, during the 
April 24 San Diego Padres baseball game at San 
Diego’s Petco Park. Tens of thousands of baseball 
fans (and a contingent of proud Illumina employees) 
came together to celebrate Fitz and the victory of 
his health, and to raise awareness for genomics and 
its incredible potential to unlock information that 
improves human health.
Learn More

CY’22 CSR Report
32
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Community Investment           Employee Engagement           Equitable Access to STEM Education           Impact in Action 
Introduction
Appendix
Sustainability 
Message from the CEO
Empower Our 
Communities

CY’22 CSR Report
33
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Community Investment           Employee Engagement           Equitable Access to STEM Education           Impact in Action 
Strategic Approach 
and Impact
We are committed to giving back, 
creating shared value through our 
business, and seeking opportunities 
to enable a more equitable and 
sustainable future for all.
Fostering a culture that empowers our 
employees to give back is integral to our 
mission. Guided by our CSR focus areas, 
we deploy our skills, time, and resources to 
create a positive impact in our communities.
1  Provide meaningful and 
strategic community 
investment
2  Engage our people to 
be agents of change
3  Drive equitable access 
to STEM education 
Reach 5 millions 
STEM learners
Donate 100,000 
volunteer hours
Achieve 50% employee 
participation through Illumina 
Cares programs
49,827
hours1
1.2M
STEM learners1
1,747 causes 
supported globally
10% increase in employee 
participation (giving and 
volunteering) since 2019
46 countries community 
investment
~18 million total 
donations
50%
employee 
participation
1Since 2019 baseline
Employee participation in 
giving and volunteer programs
Volunteering
Giving
Total participation
2019
29%
40%
19%
2020
5%
24%
20%
2021
10%
31%
26%
2022
39%
50%
28%
KEY OBJECTIVES
 I continue to be inspired by the passion of 
our employees to give back and create a path 
for a more just and sustainable future. 
Sharon Vidal 
Head of Corporate 
Social Responsibility
UN SDGs
2030 Target
2022 Progress
2022 Highlights
Future Kings students visiting 
Illumina Baltimore facility.

CY’22 CSR Report
34
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Community Investment           Employee Engagement           Equitable Access to STEM Education           Impact in Action 
Provide Meaningful and Strategic 
Community Investment 
We focus our community impact 
strategy on investments that 
support our CSR efforts for 
patients, our communities, our 
people, and our planet.
We drive collective impact and leverage our 
resources to help address local and global 
needs with philanthropic activities and 
nonprofit partnerships. 
Community Investment Areas
How We Give Back
Illumina 
Corporate
Illumina Corporate 
Foundation
Employee Giving and 
Volunteering
APPROACH
Enable access to genomics for 
patients in need and increase the 
diversity of genomic data.
Learn more 
in Access →
Sustainability and 
Environmental Justice
APPROACH
Invest in sustainability projects and 
efforts to create a just transition to 
a low carbon future.
Learn more 
in Sustainability →
Diversity, Equity, and Inclusion
Local 
Impact
APPROACH
Engage in local efforts to address 
the issues and challenges where 
we live and work and support the 
causes employees care most about.
Learn more 
in Community →
APPROACH
Increase genomic literacy and 
support equitable access to 
STEM opportunities.
STEM Education 
for All
Diversity, Equity, and Inclusion is the foundational lens across all our investments, ensuring we 
consistently prioritize and promote equitable representation and support for vulnerable populations.
Learn more in People →
Learn more 
in Community →
Equitable Access 
to Genomics
SAMPLE PROGRAMMING
•	Illumina Genomic Discoveries
•	DNA Decoded
•	Genomics 101 
•	SD STEM Diversity (SD2)
•	ENLACE SD and Mexico
•	Form the Future, UK
•	CHRF STEM, Bangladesh
•	Cold Spring Harbor, China
•	Junior Achievement
SAMPLE PROGRAMMING
•	iHope 
•	Pathogen Genomics Initiative 
•	Native BioData
•	NYGC Polyethnic Study
•	Red Cross Sickle Cell →
SAMPLE PROGRAMMING
•	iConserve 
•	Illumina Agricultural Greater 
Good Initiative
•	STREAM
•	CSUEB Green Biome Institute
•	GRID Alternatives
•	The Solutions Project
•	World Wildlife Fund
•	SEE Foundation, China
SAMPLE PROGRAMMING
•	Disaster response →
•	Regional Community Grants →
•	Ukraine support →
•	Illumina Cares Ambassadors →

CY’22 CSR Report
35
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Community Investment           Employee Engagement           Equitable Access to STEM Education           Impact in Action 
Engage 
Our People 
to be Agents 
of Change
We strive to create a purpose-
driven culture with opportunities 
for employees to volunteer in their 
community with the organizations 
that matter most to them.
Employee Giving and 
Volunteer Benefits
donation match
$500
hours paid volunteer 
time off (VTO)
16
new hire seed 
donation deposit
$25
Volunteer rewards 
donation earned 
for each hour of 
volunteer work
$10
Individual
San Diego Classroom 
– Keith Rego, Senior 
Director of Global EHS, 
went to his child’s 
classroom to share 
about his work and the 
possibilities of DNA. 
Family
China Wetlands – 48 Illumina Greater China 
volunteers and their family members visited 
the Shanghai Chongming Dongtan Nature 
Reserve for the second habitat cleanup event. 
A total of 250 kg of used plastic bottles and 
Styrofoam were collected and turned into 
recyclable goods.
International Coastal Cleanup – 
100+ Illumina employees, current 
and future, cleaned up local 
beaches. Across the region, over 
4,000 volunteers cleaned 35,000 
pounds of litter and debris.
Region
Volunteering Day – In conjunction with Singapore’s month-long National 
Day Giving Campaign, 253 employees from Singapore, Australia, Japan, 
Korea, India, and other APJ regions came together to give back in a single 
day over five activities in the island city. Our employees provided STEM 
learning opportunities to underprivileged children, contributed resource 
support to at-risk seniors, and enhanced environmental sustainability.
Diversity in Life Science – Each ERG completes a 
social impact project. iLatinX ERG members regularly 
engage in community outreach where they mentor 
students and expose them to STEM concepts and 
careers and are active partners with programs such 
as the Biocom California Institute’s Generation STEAM. 
Learn more in People →
ERG
Team
Site
Pedal the Cause – The 
St. Louis customer success 
team made superhero capes 
for the Pedal Kids Challenge 
ride, supporting Pedal the 
Cause, an organization that 
provides critical funding for 
cancer research.
Singapore Illumina Hair for Hope – 
27 Illumina Singapore employees shaved 
their heads to raise funds and awareness 
for childhood cancer. More than 200 
employees supported the event, which 
raised nearly 38,000 SGD for Children’s 
Cancer Foundation Singapore. 
Cambridge County Day – In 
celebration of the Queen’s Platinum 
Jubilee, Illumina served as the lead 
sponsor of the Cambridge County 
Day. We had our own Illumina marquee 
dedicated to the story of DNA, which 
began in the city in the 1950s.
Rare Disease Day Campaign – For 2022 Rare 
Disease Day, Illumina focused on SLC6A1 Connect 
in the US, ASrid in Japan, NoRo in Romania, and 
Rare Disease South Africa. Five families from each 
organization captured photos representing the 
everyday world of people living with a rare disease. 
Learn more in People →
Company-wide
Giving “Twosday” – Illumina launched 
a worldwide double match campaign to 
commemorate Giving Tuesday. Our recent 
#GivingTWOsday22 campaign raised over 
$230,000 with almost 800 employees 
participating and impacted 580 charities in 
29 countries.
Walk the World to End Cancer – Over 900 employees joined 
a virtual step challenge, walking the world for oncology. We 
featured international oncology charities for this special “Walk 
to End Cancer,” including the ASARGA Fighting Sarcoma, 
KickCancer Curing Kids, Zero – The End of Prostate Cancer, Rare 
Cancers Australia, and BEABA Cancer Education. Each charity 
received a $5,000 donation for a campaign total of $25,000.
We offer a variety of ways for employees to engage in giving back. Employees can volunteer as individuals, with their 
families, teams, local sites, regions, with employee resource groups and through corporate global engagements.

CY’22 CSR Report
36
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Community Investment           Employee Engagement           Equitable Access to STEM Education           Impact in Action 
Enable Educators
Inspiring the next generation of scientists, engineers, and 
innovators, starts with our educators. With the expertise of 
our employees and nonprofit partners, we develop tools and 
curricula for educators to bring genomics into the classroom. 
•	Illumina Genomic Discoveries – In partnership with Biocom 
Institute California, Illumina Genomic Discoveries was 
developed to create an educational community of practice 
where teachers can learn the world of genomics. The program 
provides genomics-focused professional development, real-
world curriculum, in-classroom activations, access to the 
Illumina Virtual Lab training, and industry connections.
•	DNA Decoded – In partnership with Discovery Education, 
DNA Decoded is designed to help educators explore curated 
resources with their students. The resources and guides 
provide educators with an overview of genomics, highlighting 
real-world connections to genomics and instructional 
resources sorted by applications. 
•	Virtual Field Trip – In 2022, DNA Decoded released the 
Genomics: Decoding the Language of Life virtual field trip. 
This free virtual learning experience transports educators 
and students around the world to our labs in San Diego, CA, 
to meet our real-world experts harnessing the power of the 
genome to improve lives and support the conservation of the 
Earth’s natural resources.
Learn more and access our STEM resources.
Drive Equitable 
Access to STEM 
Education
 
DNA Day Campaign: The Future is Bright
In honor of DNA Day, which is celebrated on April 25, we host “The 
Future Is Bright,” a month-long genomic literacy initiative. Illumina 
employees connect with students by hosting career panels, implementing genomics 
curriculum, and leading hands-on experiments. Learn More
90,000+ 
learners
2022 IMPACT:
6 
countries
We are committed to equitable access to STEM 
education with the goal of empowering students 
and enabling educators to inspire the next 
generation of scientists, innovators, and trailblazers.
The future of our mission is reliant on nurturing and equipping the next 
generation. Through direct programming, nonprofit partners, and engaging 
our employees, we aim to enable educators to be advocates of genomics 
and inspire learners to envision themselves as our future STEM leaders. 
1.2 million+ 
STEM learners 
reached globally1
5 million 
STEM learners 
reached globally
2022 PROGRESS
2030 TARGET
Our STEM Strategy
RESULTS
Inspired 
to envision 
themselves as 
future leaders
Empowered to 
be advocates of 
genomics
Students
Educators
AUDIENCE
TACTICS
Provide direct 
programming
Work with nonprofit 
partners
Engage our 
employees
1Since 2019 baseline.
Working to build STEM and genomics into the 
education ecosystem where educators and 
students have access to resources.
53% 
of US classrooms were 
Title 1 schools where 
low-income families 
make up at least 40% 
of enrollment
1,500+ 
employee volunteer hours
2,230 
strawberry DNA 
extraction kits 
donated
1,600+ 
community partners 
and schools
130+ 
events
Educators

CY’22 CSR Report
37
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Community Investment           Employee Engagement           Equitable Access to STEM Education           Impact in Action 
Inspire the Next 
Generation 
We’re committed to inspiring 
the next generation of genomic 
leaders and aim to nurture a 
diverse and inclusive STEM 
workforce for the future. To do 
this, we collaborate with a range 
of community partners and 
engage our employees to reach 
and empower students of all 
backgrounds. 
Junior Achievement BizTown – In 
2022, we opened a storefront in 
Junior Achievement (JA) BizTown in 
San Diego. Biztown, a mini-city, is 
JA’s experiential-based elementary 
school capstone program. The 
Illumina storefront mimics our labs with stations for students to 
become “scientists” and explore careers in the life science and 
biotech industry. Learn More
San Diego Squared (SD2) – We are 
proud to be a founding funder of San 
Diego Squared (SD2). The organization, 
based in our HQ hometown, focuses on 
creating diversity in STEM careers. In 
2021, Illumina committed $500,000 over 
three years to support the program. See 
the recipients of the Illumina 2022 Scholarship Award and read 
more about the launch of the organization.
Center for Marine Biotechnology 
and Biomedicine at Scripps – Illumina 
provided a transfer of equipment and a 
philanthropic grant to Scripps Institution 
of Oceanography at the University 
of California San Diego (UCSD) for 
researchers at the Center for Marine Biotechnology and Biomedicine 
(CMBB). CMBB focuses on research at the intersection of ocean 
sciences and human health. This support from Illumina will be used 
in the development of an automation hub and become a training 
tool for students as they prepare to enter the biotechnology and 
genomics workforce. Illumina is dedicated to creating opportunities 
to invite innovation and work collaboratively. We are thrilled to get 
this automated technology into the hands of future scientists who 
will drive the next era of discovery. With this equipment transfer, and 
supporting $1 million grant, we hope to enable students and support 
the acceleration of discoveries in marine biology that could improve 
both human and planetary health. Learn More
Cambridge Science Center – Over the summer, we sponsored a 
PopUpScience Roadshow with the Cambridge Science Center. 
Students and their families explored space through hands-on 
science exhibits and interactive science shows.
Future Kings – Future Kings delivers immersive STEM 
programs to middle and high school boys from underserved 
communities through a multi-year, hands-on curriculum 
and dedicated mentorship. Students also receive training 
in science communication, entrepreneurship, and project 
research. See their impact
ENLACE – ENLACE (Spanish for “link”) is a program at the UCSD that 
uses science and engineering as a bridge for Mexican high school 
and college students to build professional connections and personal 
friendships. Illumina provided funding to sponsor 14 students to attend 
in 2022 to participate in the mentorship program, enabling them to 
work in fields ranging from marine biology to the physical sciences and 
even get a chance to contribute to published manuscripts. Learn More
Genspace – Genspace, a community biology lab in New York City, 
provides STEAM education programs. In 2022, Illumina and the 
Illumina Corporate Foundation provided in-kind product donations 
and a cash grant totaling over $100,000 to build capacity 
for genomics research supporting students from historically 
marginalized backgrounds. Learn More
Mira Costa Community College Biotech – Illumina provided in-kind 
support to enable genomics lab at the community college level. The 
community college offers a biotechnology program with associate, 
and bachelor’s degrees, and certificates grounded in hands-on, 
contextualized coursework. By providing access to next-generation 
sequencer technology, the program offers advanced specialized 
coursework leading to success from the diverse community it serves.
Child Health Research Foundation – 
Illumina and the Illumina Corporate 
Foundation provided a cash grant 
and in-kind donations valued at 
over $300,000 to the Child Health 
Research Foundation (CHRF), a 
Bangladeshi nonprofit that promotes public health and STEM 
education. The grant will support CHRF’s Building Scientists 
for Bangladesh program, which will introduce young women in 
under-resourced communities around the country to science 
and provide hands-on genomic training for university students 
and early career professionals. Learn More
Mobile Genomics Lab – Illumina and the Illumina Corporate 
Foundation provided funding to the Carl R. Woese Institute for 
Genomic Biology (IGB) at Illinois University to construct, staff, 
and operate a mobile STEM lab. With the mobile lab, the team 
can travel to economically and educationally disadvantaged 
locations. Learn More
Empowering Learners from Curiosity to Career
Through each stage of their educational journey, we empower students to envision themselves as future scientists, innovators, and trailblazers.
Curiosity
Career
Gloucester Marine Genomics 
Institute (GMGI) – Illumina provided 
in-kind donations to support GMGI, 
which addresses critical challenges 
facing oceans, human health, and 
the environment through innovative 
scientific research and education. To advance education in the 
local community, GMGI created the Gloucester Biotechnology 
Academy, which offers seven months of hands-on training and 
a three-month paid biotech internship. Learn More
UNIVERSITY & BEYOND
SECONDARY EDUCATION
PRIMARY EDUCATION
Students

CY’22 CSR Report
38
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Community Investment           Employee Engagement           Equitable Access to STEM Education           Impact in Action 
Impact in Action
Supporting Ukraine
$80K 
Princess Maxima Centre 
for Pediatric Oncology 
Supported pediatric 
cancer patients displaced 
from Ukraine to the 
Netherlands and every 
US state
UKRAINE RESPONSE
$100K 
Eurordis
Rare disease patients 
displaced from Ukraine to 
other parts of EMEA
$100K 
University of Cambridge
Ukrainian medical students
displaced to continue 
studies at the University 
of Cambridge
$250K 
International Committee 
of the Red Cross
Humanitarian aid 
for Ukraine
$128K 
Red Cross, Intl Medical 
Corp, UN Refugee 
Agency, Doctors 
Without Borders 
Employee donation 
and match program
Sickle cell disease is the most common genetic blood 
disease in the US. Most patients with sickle cell disease are 
of African descent and rely on blood given by people of the 
same race/ethnicity. Illumina provided a philanthropic grant to 
support work dedicated to understanding how genetics affect 
health outcomes.
Each summer, Illumina interns put our 
culture of giving back into action by 
completing a social impact project 
with a nonprofit charity partner. 
This year, our interns donated 
over 500 hours and collectively 
completed 15 projects. For the first 
time, we expanded the program 
internationally, including our UK-
based interns as well. 
Intern Skills-Based Volunteering
The birthplace of DNA 
sequencing, Cambridge is one 
of the UK’s most science- and 
technology-intensive clusters 
with a vibrant, growing economy 
that draws an extensive range 
of STEM skills. Illumina is 
proud to be one of the local 
STEM businesses playing a 
pivotal role in helping teachers, 
schoolchildren, and young 
people to experience the 
vast array of available career 
opportunities and support the 
future growth of skills and jobs 
in Greater Cambridge. 
Collaborating with 
Cambridge, UK 
LaunchPad
Illumina Is Proud to Support Sickle Cell 
Initiative with American Red Cross 
Southern California Region
In 2022, we engaged 
two new signatories
Signaling Our 
Commitment 
to STEM for All
Our CEO signed the CEOs for 
Computer Science open letter 
to the Governors and Education 
Leaders of United States with 
Code.org and over 800 leaders. 
The letter called on state 
governments to update the K-12 
curriculum in each state, for 
every student, in every school 
to have the opportunity to learn 
computer science. 
	
Illumina also joined the 
STEMM Opportunity Alliance 
(SOA). In collaboration with 
the White House Office of 
Science and Technology 
Policy, the alliance will be led 
by American Association for 
the Advancement of Science 
and the Doris Duke Charitable 
Foundation to activate a national 
vision to drive transformative 
change across the American 
science, technology, 
engineering, math, and 
medicine (STEMM) ecosystem 
by expanding access and 
opportunities. The alliance aims 
to eliminate systemic barriers 
and elevate equity in STEMM to 
a sustained, national priority.
Ascending One of the Most Challenging Mountain 
Passes in Europe to Support Cancer Charity
To raise awareness and funding 
for cancer research, the Stelvio 
for Life Foundation organizes an 
annual event up the Passo dello 
Stelvio in North Italy.

	
The Stelvio for Life event supports 
cancer research. The research 
implementation is carried out by 
the Center of Personalized Cancer 
Treatment Foundation (CPCT 
Foundation). In 2022, we had several 
brave Illumina colleagues participate 
in this impactful event. The 
sponsorship provided by Illumina, and 
the individual fundraising by individual 
riders, will be used to support 
research for DNA-based personalized 
treatment of cancers through the 
Stelvio for Life Charity.

Appendix
CY’22 CSR Report
39
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
Integrate 
Sustainability

Appendix
CY’22 CSR Report
40
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
40
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Strategic Approach 
and Impact
We are committed to integrating environmental stewardship into 
the fabric of how we operate. 
Human health and the health of our environment are intertwined, connecting 
our mission with our commitment to operate responsibly and sustainably.
We recognize the importance of the environment in creating a healthy, 
sustainable future for all. Our approach to environmental sustainability 
prioritizes taking action on climate change and the implementation of 
sustainable solutions in our facilities, products, and across our value chain. 
As the world seeks innovative solutions to tackle climate challenges and 
protect our natural capital, we recognize the incredible opportunity the field 
of genomics and our technology provides. 
We view sustainability through the lens of continuous improvement, knowing 
there will always be more opportunities for us to protect our planet and do 
our part.
UN SDGs
 Our science-based, verified 
climate action targets are an 
important part of our overall 
business strategy to minimize 
risk associated with climate 
change, build resilience, and 
identify opportunities for long-
term sustainable growth. 
Achieve net-zero emissions 
(Scope 1,2, and 3) by 2050 
Reduce emissions by 46% in our direct 
operations (Scope 1, 2) 
Reduce emissions by 46% in our value chain 
(Scope 3) 
Minimize packaging by 75%
30%
Reach 100% of strategic suppliers to commit 
to minimizing their environmental footprint 
100%
Invest $20 million in sustainability and 
environmental justice initiatives 
$759K
$1.5M Total
Divert 90% of waste from landfill at core sites 
64%
Achieve 100% renewable electricity 
100%
100%
In progress
1    Drive climate action
2  Operate sustainable facilities
3  Foster a sustainable value chain
4  Develop sustainable products
5  Leverage genomics for a healthier planet
Kevin Pegels
Chief of Global Operations
1SBTi Beyond Value Chain Mitigation.
2Learn more on the sustainable product page.
3Since 2019.
KEY OBJECTIVES
2030 Target
2022 Progress
Carbon neutral in direct 
operations (Scope 1, 2) supporting 
the SBTi beyond value chain 
mitigation1 approach
Verified SBTi Net-Zero and 
emission reduction targets
100% renewable electricity
NovaSeqTM X launch 
resulting in 61% reduction2 
in climate impact compared 
to NovaSeqTM 6000
2022 Highlights
↑51%3 
Decrease water intensity at core sites by 10%
↑4%3 
↓9% YoY

Appendix
CY’22 CSR Report
41
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
41
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Our Path to a Science-Based Net-Zero
To ensure we hit critical milestones on our path to net-zero, we created short-, medium-, 
and long-term SBTi-verified targets aligned to the 1.5 °C climate action pathway.
Net-Zero Tar
g
e
t
 
b
y
 
2
0
5
0
Near-Term Emiss
i
o
n
 
R
e
d
u
c
t
i
o
n
 
T
a
r
g
e
t
s
 
↓46% 
Reduce Scope 1, 2 absolute 
GHG emissions 46% by 2030 
from 2019 baseline
Reduce absolute GHG emissions 
from material Scope 3 
categories 46% by 2030 
from 2019 baseline
0 GHG
Reach net-zero GHG 
emissions across Illumina’s direct 
operations (Scope 1 ,2) and our 
value chain (Scope 3) by 2050 
from 2019 baseline levels
↑100% 
Increase annual sourcing 
of renewable electricity 
to 100% by 2030 from 
2019 baseline
Lon
g
-
T
e
r
m
 
E
m
is
si
o
n 
R
e
d
uction Targets 
↓90%
Reduce Scope 1, 2 absolute 
GHG emissions 90% 
by 2050 from 2019 baseline
Reduce absolute GHG emissions 
from material Scope 3 categories 
90% by 2050 from 2019 
baseline
Drive Climate 
Action
Climate change represents a threat to human 
health, the environment, and the global economy.
We ensure that our efforts are aligned with the leading 
practices and organizations addressing climate action:
•	Business Ambition for 1.5 °C 
•	Science Based Targets initiative (SBTi)
•	We Mean Business Coalition 
•	United Nations Race to Zero 
•	The Implementation of UN SDG 13: Climate Change 
•	Task Force on Climate Disclosure (TCFD)
R
e
n
e
w
a
b
l
e
 
E
lectricity
Our Climate Action 
Progress
Among First in the World to Receive Approval of 
Net-Zero Target verification from the Science Based 
Targets Initiative (SBTi)
As a science-based organization, we aim to ground our climate action 
targets in a science-based framework. 
	 In 2022, we were among the first companies in the world and our 
industry, and the first genomics company to receive verification of our 
2050 net-zero emissions targets by the Science Based Targets initiative 
Corporate Net-Zero Standard. 
	 In 2021, our Scope 1, 2, and 3 emission targets were also externally 
verified by SBTi and aligned to the Paris Agreement’s climate ambition 
goal of keeping planetary warming to 1.5°C. We aimed to create an 
approach that helps us demonstrate that our long-term net-zero climate 
targets are credible, ambitious, and accountable.
SCOPE 1 
100% 
reduction
SCOPE 2 
100% 
reduction
SCOPE 3 
51% 
increase
SCOPE 1, 2 
Carbon neutral*
INVEST in sustainability 
and environmental justice 
initiatives
$1.5M
*Scope 1 reductions include our beyond 
SBTi mitigation, applying Green E certified 
Carbon Offsets for our natural gas Scope 1. 
*Scope 2 reductions include the 
combination of on-site solar, purchased 
renewable electricity, and renewable 
electricity credits. 
Learn more in Sustainability 
Impact in Action→

Climate Change Position Statement
CSR Policy

Appendix
CY’22 CSR Report
42
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
42
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Our approach to managing the physical and transition 
risks and opportunities presented by climate change aligns 
with the TCFD framework. Additional details on our climate 
scenario insights are in the TCFD Index → and our 
2022 Climate CDP Response.
EXPLORE OUR CLIMATE OPPORTUNITIES
Identifying Climate Risks and Opportunities 
To deepen our understanding of the potential risks and 
opportunities of climate change, we conducted an assessment 
using the recommendations of the Task Force on Climate-
related Financial Disclosures (TCFD). We engaged with BSR 
(Business for Social Responsibility) to develop three 2030 
climate scenarios linked to global warming by 2100, understand 
the potential implications of climate change for our business, 
and identify opportunities to build resilience.
	 The climate scenario analysis was completed using three 
plausible narrative future representations of our operating 
environment respectively aligned to a well below 2°C, a 3°C, 
and a 4°C level of warming. To map assumptions for each 
trajectory, we utilized standardized third-party climate modeling 
data, such as the Shared Socioeconomic Pathways (SSPs) 
and the Intergovernmental Panel on Climate Change (IPCC) 
Representative Concentration Pathways (RCP).
Managing Climate Risks and Opportunities 
To manage climate-related issues, we are incorporating climate 
resilience across our operations and value chain with a risk 
management structure, our EHS team management system, 
business continuity program management, supply chain risk 
reviews, and periodic audits of related processes. Addressing 
risk at the site level is performed by our site emergency 
management cross-functional group, which plans for and 
reacts to immediate and near-term physical risks caused by 
climate change.
	 We review the environmental management system 
framework annually as part of the global aspect and impacts 
clause. Output from this data influences environmental 
performance and GHG reduction objectives. Illumina also uses 
our ISO14001 environmental management system as one of 
the mechanisms to monitor and reduce our environmental 
impacts from GHG emissions.
Climate Risks
The climate change elements that have most influenced our 
strategy are physical risks to operations, supply chain impact, 
and reputation. These risks have been incorporated into 
business continuity planning, future product development, 
redundancy in supply chain where possible, and site selection 
for future growth. We are actively reviewing opportunities 
to further integrate climate into our processes and paths to 
further expand resilience.
	 We have implemented redundant planning and maintained 
safety stock to provide resilience during severe weather 
events. For financial planning, we include risk and opportunities 
evaluated through our standard budget planning. Investment 
in energy-reduction projects that require capital expenditures 
are evaluated through the Capital Committee planning process. 
Potential indirect costs associated with supply chain, future 
tax, or increased operating costs from extreme weather 
connect with these internal workstreams.
Challenges
We have committed to ambitious science-based climate 
action targets including net-zero commitments that include 
our value chain and absolute based reduction targets. Illumina 
continues to experience strong growth and, with absolute 
based reduction targets, we recognize the challenges that lay 
ahead. In addition, varying levels of climate maturity within 
our supply chain and renewable sources in some markets may 
also provide challenges. We will continue to work through each 
challenge as we do our part on the path to net zero.
Addressing climate change is critical to achieving a sustainable, 
just, and resilient future for all. 
As external conditions evolve, we continue to evaluate our 
approach, recognizing that both physical risks, such as extreme 
weather, and transition risks, such as regulatory and technological 
developments, may affect our operations. We have integrated 
climate risk into our enterprise risk management program.
Climate Risks and Opportunities
Climate Risk Management 
Nature underpins all economic activities and human 
well-being. It is the world’s most important asset. As 
part of our approach to sustainable and responsible 
business operations, we have reviewed potential risk and 
opportunities beyond our climate footprint as part of a 
holistic look at natural capital and biodiversity. Natural 
capital assets are elements in nature that provide the 
goods and services that the economy depends on. We 
reviewed the links between our potential direct impacts 
and dependencies on natural capital. 
	 We will continue to monitor progress from the Task 
Force on Nature-Related Financial Disclosures and the 
new Global Biodiversity Framework. At Illumina, our 
existing environmental-related targets currently include 
efforts that prioritize reducing the impact of our facilities, 
supply chain, and product. We will continue to monitor 
and assess the natural capital elements of our 
environmental footprint. 
	 As evidence of the intersection between biodiversity, 
natural capital, and the economy becomes more defined, 
we recognize there are opportunities for the application of 
genomics and Illumina sequencing to protect and innovate 
in future nature-positive economies. Our technology 
is currently used in research to understand and guide 
conservation of species, to implement more sustainable 
agriculture and food security pathways, and as a tool for 
innovation to create new synthetic materials that minimize 
the use of natural resources or create alternatives to 
natural capital withdrawals. 
Natural Capital and Biodiversity

Appendix
CY’22 CSR Report
43
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
43
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Greening Our Labs 
We have partnered with My Green Lab® to 
improve the sustainability of our laboratories 
around the world. In 
2022, we initiated the 
process of participating 
in the My Green Lab® Certification Program as 
part of our commitment to a net-zero future, 
with efforts continuing into 2023. 
Operate Sustainable Facilities
We approach reducing the environmental footprint of our facilities by focusing on green building design, 
optimizing energy, reducing water and waste, and expanding the use of renewable electricity. 
Emission Reduction 
We regularly evaluate energy-efficiency measures and renewable energy 
projects to reduce our operational carbon emissions. Each of our sites 
maintains a pipeline of energy projects to contribute to emission reductions.
•	San Diego, CA
•	Foster City, CA
•	 Shanghai, China
•	 Singapore, SG
Renewable Electricity1
2019 2020
2021
2022
Emission Intensity2
2019
2020
2021
2022
0.6%
9.8
11.4
5.8
4.2
2%
59%
100%
SBTi Net-Zero Mitigation Hierarchy3 
Illumina follows the recommended mitigation hierarchy with our net-zero commitments. SBTi recommends science-based targets 
for the near- and long-term to address our value chain emissions and implement strategies to achieve these targets as a first 
order of priority and then to invest in mitigation outside the value chains. Under the recommendations of SBTi Net-Zero Standard, 
companies should go beyond their near- and long-term science-based targets to further mitigate climate change by undertaking 
actions or making investments that generate additional co-benefits for people and nature. To further facilitate beyond value chain 
mitigation, Illumina has invested in Nature Based Green-e Certified Carbon Credits while on our journey to net zero. We have 
applied carbon offsets for our natural gas scope 1 as a temporary mitigation.
Regenerative Thermal Oxidizer (RTO) 
Decommission 
At the end of 2022, we began decom-
missioning the RTO at our San Diego 
headquarters. As our manufacturing process 
evolved and hazardous pollutants decreased, 
the local Air Pollution Control District deemed 
the unit was no longer required. Every year, 
the RTO burns an average of 109,000 therms 
of natural gas at a cost of $103,000 and at an 
environmental impact of 580 metric tons of CO2 
emissions. Full decommission is expected to be 
complete in 2023. 
2022 Initiatives
New Singapore Manufacturing 
Site Achieves Green Building 
LEED Gold Certification 
The new facility opened in 2022 and 
has been awarded LEED Gold status, 
reflecting energy conservation, water 
usage reduction efforts, and the use of 
sustainable materials. 
2030 TARGET
2022 PROGRESS
100%
renewable electricity 
achieved
Through onsite generation, purchased 
renewable electricity, and renewable 
energy credits
100% 
46%
reduction in Scope 1 
and 2 emissions
100% 
reduction in Scope 1 and 2 
emissions1
Green Building Design LEED Certified Sites
1Onsite generation, purchased renewable electricity, renewable energy credits, and Green-e certified nature-based carbon credits.
2Scope 1 and 2 emission intensity per million dollars revenue.
3SBTi Beyond Value Chain Mitigation

Appendix
CY’22 CSR Report
44
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
44
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
We continuously seek opportunities to reduce 
our water footprint by improving operational 
efficiencies and assessing potential risks to 
protect this vital natural resource. At our largest 
locations and highest water risk location, 
we employ a variety of water conservation 
applications. We assess our water usage by 
comparing the locations of our sites with the 
baseline water stress risk ranking according to 
the World Resource Institute and its Aqueduct 
Atlas. For facilities that have been identified 
as operating in water-stressed regions, we are 
committed to focusing additional efforts on water 
management planning. 
1 San Diego (i3, HQ, Distribution Center), 
Foster City, Hayward, Madison, UK Illumina 
Centre, Netherlands, Singapore Woodlands.
Singapore Water Efficiency Building (WEB) Certification 
Our Singapore site received a Water Efficiency Building 
Certification (WEB), that recognizes businesses, industries, and 
buildings that adopt water-efficient measures in their premises 
and processes. By installing a total of 85 control flow restrictors, 
water sensors, and water delay fittings, we’ve reduced the monthly water consumption 
of the building by 5%, resulting in .29 million gallons of water saved annually. 
San Diego, CA
Steenoven, NL
Cambridge, UK
Foster City, CA
Madison, WI
Hayward, CA
Singapore, SG
WATER RISK AT CORE SITE LOCATIONS
WATER RISK ASSESSMENT BY SITE
Extremely High
High
Medium-High
Low
Low-Medium
Water Stewardship
9% 
reduction YoY
4% 
increase in water intensity
at core sites from baseline
10%
reduction in 
water intensity 
at core sites
2022 PROGRESS
2030 TARGET
Re-Use Water Cooling Tower 
Our San Diego headquarters completed a project which added 
piping to divert drain water to a storage tank that feeds into HVAC 
cooling towers. This project will conserve 2.2 million gallons of 
water annually. 
2.2M 
gallons estimated 
to be conserved
5%
reduction of monthly 
water consumption
2022 Water Projects 
Reclaimed Water Use
Our San Diego locations continue 
to utilize reclaimed water for 
landscaping, water features, and 
our cooling towers.

Appendix
CY’22 CSR Report
45
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
45
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Hazardous Waste 
Our hazardous waste management program is designed to minimize 
impact and manage materials in the most environmentally responsible 
manner. The process follows a hierarchy that specifies reclamation/
reuse, recycling, waste-to-energy recovery, fuel blending, wastewater 
treatment, incineration, autoclave, and landfill when alternatives are not 
available. 
Producer Responsibility 
We participate in required compliance schemes for producer 
responsibility to ensure proper collection, management, and disposal. 
This includes the recycling of packaging, batteries, and waste electrical 
and electronic equipment (WEEE). Under the EU’s Batteries and 
Accumulators Directive and Packaging Waste Directive and regulations 
in several EU member states, we comply with requirements to finance 
the collection and recycling of batteries and packaging supplied with our 
products at end of life.
Responsible eWaste Disposal 
Through our waste management programs, we aim to reduce the 
environmental impact from electronic waste and ensure responsible 
management at end of life. We partner with E-Steward, R2, and other 
certified recyclers to refurbish, rebuild, and reuse devices to help 
organizations around the world.
Plastics Shedding Pilot 
In an effort to increase the circularity of our products, we conducted 
a pilot in 2022 to test the diversion of consumables waste to be 
repurposed for other plastic applications through a third-party 
partnership. Of the 6,540 pounds of plastic (PP and HDPE) that we 
diverted in the pilot, 5,232 pounds were recovered, resulting in a 20% 
loss of material during the repalletization process. We plan to further 
explore internal processes for the collection of plastics.
90%
landfill diversion at all core sites1
2030 TARGET
64% 
landfill diversion
13% 
improvement since 2019
2022 PROGRESS
1San Diego, Foster City, Hayward, Madison, 
UK Illumina Centre, Netherlands, Singapore.
Waste Management 
We take a hierarchical approach to waste management, where source 
reduction is the most preferable option, and landfill is the least 
preferable. We continue to prioritize innovative waste management 
efforts as part of our 2030 landfill diversion target.
Most preferable
Least preferable
AVOID OR REDUCE
REUSE
RECYCLE
INCINERATE
LANDFILL
How We Tackle Waste 
iRecycle
An employee-led program in our Asia, Pacific, Japan (APJ) region, iRecycle 
aims to minimize the environmental footprint associated with waste from the 
field service engineer teams. During the pilot phase in Australia, Illumina service 
teams sent product parts used in testing back to the office from field visits where 
they are then disinfected and recycled. Since launching in 2022, an estimated 
5,000 kg of electrical waste has been repurposed, recycled, or disposed of in an 
environmentally friendly way annually through iRecycle. With the successful pilot, 
the team plans to expand through the region for deeper impact.
Collect
Ship
Recycle
Repair

Appendix
CY’22 CSR Report
46
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
46
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Develop Sustainable Products 
We develop innovations that reduce the environmental impact 
of our products, technologies, and solutions. 
Designing for the Environment 
We integrate the Design for the Environment (DfE) approach into the core 
of our product development to find more opportunities to shift to a circular 
economy, addressing the full lifecycle of materials and their end of life. We apply 
environmental criteria to resource selection, design, energy use, data processing 
efficiency, size, weight, stability, packaging, shelf life, temperature requirements, 
end-of-life management, and more.
1 100% recyclable in the US and widely recyclable globally. 
End of Life
Resources
Distribution 
& Packaging
Use
Sustainable Resources
We are committed to sourcing sustainable 
materials, including reducing the amount of 
petroleum-based plastic in new product designs. 
We also believe that big science can equal green 
science and actively work to replace the use of 
chemicals of concern with greener alternatives. 
Sustainable Production 
Through our sustainable facilities, we aim to 
make the manufacturing process less energy 
intensive, minimize the use of toxic materials, 
and recycle waste from the production process 
where possible. 
Sustainable Distribution and Packaging 
We work to make the transportation of our products 
more efficient and sustainable. We invest in making 
our packaging recyclable, returnable, and reusable. 
Sustainable Use
When designing our life-
saving innovations, we aim 
to create products that are 
both more powerful and 
more energy efficient.
Sustainable End of Life
While we develop innovations 
that serve our customers for 
long into the future, our design 
process extends to the end of 
life of our products.
30% 
packaging reduction
70%
secondary and 
tertiary recyclable, 
reusable, or 
compostable 
75%
reduction of packaging 
from 2019 baseline
90%
of our secondary and 
tertiary packaging will 
be recyclable, reusable, 
or compostable
2022 PROGRESS
2030 TARGET
•	Recyclable Insulated Containers: A move to 
plant-based paper-insulated containers offered a 
100% curbside recyclable solution1
•	Returnable Insulated Containers: Insulated 
containers used for refrigerated and frozen in 
vitro diagnostic (IVD) product shipments can be 
returned to us for reuse
•	Reusable Bulk Sustainable Solutions: Insulated 
pallet shippers for frozen and refrigerated products 
are validated for multiple uses and returnable 
for refurbishment and reuse. Supports internal 
movement network and customer bulk order
We aim to:
•	Integrate Design for the Environment (DfE) in product development
•	Optimize sequencer power consumption and processing efficiency
•	Reduce amount of petroleum-based plastic in new product designs
•	Replace use of chemicals of concern wherever possible with 
greener alternatives
•	Seek additional opportunities to engage in circular economy
Sustainable 
Production
Learn more about our sustainable facilities→
Learn more about our sustainable value chain→

Appendix
CY’22 CSR Report
47
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
47
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
NO DRY 
ICE OR ICE 
PACKS
Ambient 
temperature 
reagent 
shipping
Impact the World, Not the Environment
The NovaSeqTM X Series Systems announced at the end of 2022 
were purposefully designed to reduce environmental impact. The 
improved robustness and stability of XLEAP-SBS reagents allows 
for shipping at ambient temperatures, and reagent consumable 
plastics are made from sugar-cane based biopolymers. 
Sustainability was at the forefront of NovaSeqTM X design, with an 
aim to move beyond incremental improvements and challenge the 
status quo to benefit our customers and the planet. 
Based on comparison of NovaSeqTM 6000 reagent kits to NovaSeqTM X reagent kits.
Meet the NovaSeqTM X Series
Life Cycle Assessment
A life cycle assessment (LCA) evaluates the 
environmental impacts associated with a 
product over its life cycle, from raw material 
extraction to production, use, and end of life 
(from cradle to grave). 
	
In 2022, we engaged a third party to 
complete a streamlined life cycle assessment 
to further quantify the improved environmental 
impact of the NovaSeqTM X kits. We evaluated 
the NovaSeqTM X 10B 300 cycle kit compared 
to the NovaSeqTM 6000 S4 300 cycle kit and 
used the functional unit of a per gigabase (Gb) 
of genetic code. 
	
Our findings demonstrated a 61% 
reduction in climate change impact* with 
the NovaSeqTM X kit. Armed with data on the 
holistic impact, we will use the information to 
address new opportunities in future design for 
environment applications and sustainability 
product enhancements. 
NovaSeqTMX
NovaSeqTM6000
•	The project aligned with the methodological 
requirements and guidelines of the ISO 
standards ISO 14040 (2006a) and ISO 14044 
(2006b) on LCA and the GHG Protocol 
Product Life Cycle Accounting and Report 
Standard (WRI/WBCSD, 2011). However, as it 
is a streamlined LCA study, it does not fulfill 
all of the reporting requirements of these 
standards. 
Emissions per gigabase (Gb)
NovaSeqTM 6000
NovaSeqTM X
0.09 kg CO2 e
0.04 kg CO2 e
50% 
less cartridge volume
50% 
less plastic mass 
and volume
90% 
less packaging 
weight and waste
Plant-based 
bio-polymer 
plastics
Data storage 
optimized for 
reduced storage and 
energy requirements
Designed 
for cartridge 
disassembly  and 
recycling with no 
tool required
 We radically redesigned and transformed the technology and 
chemistry with sustainability principles at the core. 
Alex Aravanis MD, PhD
Chief Technology Officer, 
Head of Research and Product Development
FUNCTIONAL UNITS ASSESSED
•	NovaSeqTM X 10B 300 cycle kit vs. 
NovaSeqTM 6000 S4 300 cycle kit 
•	Sequencing + Primary analysis + Secondary 
analysis
•	1 gigabase (Gb) of genetic code
61%
reduction in 
climate impact* 
 * Based on end market assessment NY, US

Appendix
CY’22 CSR Report
48
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
48
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
17% Category 2:
         Capital Goods
10% Category 15:
          Investments
8% Category 7:
        Employee 
        Commuting
8% Category 6:
        Business Travel
19% Category 4:
         Upstream 
         Transportation
         & Logistics
31% Category 1:
          Purchased 
          Goods & 
          Services
0.1%  Category 5: Waste Generated 
            in Operations
0.6% Category 8: Upstream
            Leased Assets
1.0%  Category 12: End-of-Life 
            Treatment of Sold Products
3.0% Category 3: Fuel- and
            Energy-Related Activities
3.0% Category 11: Use of Sold Product    
Scope 3   87% 
Scope 1    5% 
Scope 2    8% 
Foster a Sustainable Value Chain
As a global organization, we 
recognize our environmental footprint 
extends beyond our facility walls.
Our most material Scope 3 categories 
of focus include:
•	Upstream transportation and distribution 
•	Purchased goods and services 
•	Capital goods
•	Investments 
•	Business travel 
•	Employee commuting
For each category, we work with relevant functional groups on 
projects to further drive down the value chain impact. 
Scope 3 Emissions 
Based on our first Scope 3 emission inventory assessment 
completed in 2021, 87% of our global emissions are 
attributable to elements in our value chain associated with 
our baseline year of 2019. We assessed all 15 Scope 3 
categories and identified the most material contributors to 
our emission inventory. Categories that represented 7% or 
more were defined as material and accounted for 92% of 
our total Scope 3 footprint. 
51% 
Increase since 2019
46%
reduction in Scope 3 emissions
2022 PROGRESS
2030 TARGET
Shifting from Air to Ocean 
Transportation 
Following a successful air-to-ocean 
transition of key inbound raw 
materials from APAC to the US in 
2019, we further strengthened our 
commitment in 2022 to leverage 
significant Scope 3 emissions 
reductions via the usage of ocean 
freight as a mode for our major 
global freight lanes. 
Sustainable Investments Policy 
We modified our investments policy 
to eliminate investing in energy and 
utilities sector bonds unless the 
associated issuance is identified 
as a Green, Social or Sustainability 
(GSS) Bond. We were able to adjust 
our approach without any expected 
impact on our returns. 
2022 Ocean Freight Pilot
In 2022, we successfully 
qualified the intercompany 
movement of manufactured 
goods from Singapore to 
the US via a pilot program 
of three ocean shipments. 
With the success of the 
pilot, we now have the 
platform for regular monthly 
intercompany ocean 
shipments throughout 
2023. Our network strategy 
from 2024 onward will see 
the usage of ocean over 
air further develop on a 
continuous growth plan. 
2019 Baseline Scope 1, 2, 3
Sustainable Business Travel 
At Illumina, we enable employees to 
effectively avert travel for business 
meetings with a host of virtual 
tools, reducing carbon emissions. 
For our most traveled routes, we 
are curating preferred partnerships 
with airlines where sustainable 
aviation fuel and increased aircraft 
efficiency are options. We partner 
with an electric car consortium 
called SWOOP that allows for 
electric car transfers in our high 
transfer routes of Chicago/Madison 
and San Diego/Los Angeles. 
Sustainable Suppliers 
Through our strategic suppliers 
scorecard program, we assess 
environmental sustainability 
commitments made by our 
suppliers. Our goal is to empower 
our suppliers to reduce their 
collective carbon footprint and 
encourage transparent reporting 
on their progress.
Sustainable Shipping
The 2022 breakthrough innovation 
of NovaSeqTM X allows for ambient 
shipping and elimination of 
cold chain transportation. First 
shipments of NovaSeqTM X began 
in 2023. Learn more→
Sustainable Employee Commute
We support employees with a 
variety of regional commute 
options. Learn more→
Sample Reduction Efforts
We recognize the challenges associated with an absolute reduction 
target in an environment where Illumina continues to grow year over 
year. We remain committed to our net-zero path and have a number of 
initiatives that will impact our trajectory as they implement and mature.
1For full data on all Scope 3 categories, see Appendix.
2022 Scope 31
Material 
Categories 
of Focus
Category 1:
Purchased Goods & Services
37% Contribution
↑81% since 2019 
↓5% year over year
Category 15: Investments
0% Contribution
↓100% since 2019 
↓0% year over year
Category 4:
Upstream Transportation 
& Logistics
24% Contribution
↑86% since 2019 
↑25% year over year
Category 7: 
Employee Commuting
4% Contribution
↓17% since 2019 
↑97% year over year
Category 2: Capital Goods
23% Contribution
↑108% since 2019 
↑4% year over year
Category 6: Business Travel
6% Contribution
↑4% since 2019 
↑406% year over year

Appendix
CY’22 CSR Report
49
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
49
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
We expect our suppliers to: 
•	Comply with local regulations 
and applicable US and 
international regulations 
•	Uphold employee human rights and 
the Illumina Human Rights Policy 
•	Ensure a safe and healthy workplace 
•	Demonstrate social and 
environmental responsibility 
•	Conduct business in an 
ethical manner 
•	All new suppliers are required to 
acknowledge the Supplier Code 
of Conduct to complete the 
onboarding process
Learn more about our supplier 
engagement efforts in the 
Responsible Supply Chain section of 
the Operate Responsibly chapter →
1In 2022, we embedded the requirement in our Supplier Code of Conduct and require our strategic suppliers to accept this with issuance of any purchase order.
Sustainable Supply Chain 
We consider it business-critical to work with suppliers and partners across our value chain 
who share our commitment to the environment. 
	 We engage with strategic suppliers and business partners on climate-related issues, 
hold them to the same high standards of business conduct that we set for ourselves, 
and require them to commit to reducing their own environmental footprint. Social impact 
and environmental screening are included in our Request for Information (RFI) tools when 
evaluating potential suppliers. 
	 All new suppliers are required to acknowledge the Supplier Code of Conduct to complete 
the onboarding process. Our Supplier Code of Conduct is consistent with commitments we 
made both as a signatory of the United Nations Global Compact and as a member of the 
Dow Jones Sustainability World Index. 
100%
100%
of strategic suppliers commit to 
minimizing their environmental footprint
2022 PROGRESS
2030 TARGET
Partnering with Amazon Web Services on 
Shared Sustainability Commitments
The amount of genetic data generated from 
next-generation sequencing that we securely 
store in the cloud has grown tremendously—
from 1 petabyte to 100 petabytes in just 
eight years. We partnered with AWS and 
leveraged their Amazon Simple Storage 
Service (Amazon S3) 
Intelligent-Tiering that 
allows for automated 
storage cost savings 
by moving data when 
access patterns change, 
while still maintaining 
data security. It also 
improves sustainability 
by storing less volatile data on technologies 
designed for efficient long-term storage. Since 
implementing this project in 2021, there has 
been a 90% reduction in our carbon emissions 
associated with genomic data storage on the 
cloud. Learn more
90% 
reduction in our 
carbon emissions 
associated with 
genomic data 
storage
1

Appendix
CY’22 CSR Report
50
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
50
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Leveraging Genomics for a Healthier Planet
The positive power of genomics is 
helping to identify, measure, and 
solve some of the planet’s most 
challenging and pressing issues.
Today, our technology and the use 
of genomics are being leveraged 
by scientists for studies around the 
world on biodiversity, endangered 
species protection, ecosystem 
conservation, sustainable agricultural 
practices, climate change research, 
and innovation.
Conservation genomics focuses on characterizing 
the genetic diversity of endangered species and 
applying molecular tools like Illumina sequencing 
to support sustainable management of threatened 
species and populations. 
Conservation Genomics
Agrigenomics
Agricultural genomics, or agrigenomics, has and will 
continue to drive sustainable productivity and offer 
solutions to the mounting challenges of feeding a 
growing global population. Using modern technology, 
farmers, breeders, and researchers can easily 
identify the genetic markers linked to desirable traits, 
informing cultivation and breeding decisions. 
eDNA sequencing is a rapidly emerging method for 
studying biodiversity and monitoring ecosystem 
changes. As organisms shed DNA into their 
environments, eDNA analysis can provide clues 
about the species present without disrupting the 
ecosystem. Potential applications of eDNA include 
port monitoring, biodiversity surveys, ballast 
water testing, soil testing, and more. Scientists are 
utilizing our technology and environmental eDNA to 
gain insights to develop innovative environmental 
solutions. Learn more 
Biodiversity and eDNA Sequencing
Agrigenomics and the Agricultural 
Greater Good Initiative
Greater Good Initiative
Launched in 2011 and awarded 
annually, The Illumina Agricultural 
Greater Good Initiative grant spurs 
critically needed research that 
will increase the sustainability, 
productivity, and nutritional density 
of agriculturally important crop and 
livestock species. Grant recipients 
receive donations of Illumina products 
to support their projects.
2022 Recipient: SENAI Innovation Institute for 
Biosynthetics
The 2022 Agricultural Greater Good Initiative 
recipient was SENAI Innovation Institute for 
Biosynthetics, based in Rio de Janeiro, Brazil. The 
institute focuses on seaweed cultivation to explore 
the genetic potential for carbon sequestration and 
environmental services, and food security.
	 By leveraging the power of molecular genetics, 
the institute studies the impact of environmental 
change on macroalgae distribution and biodiversity 
and defines metabolic pathways relevant to carbon 
fixation, bio stimulants, food industry, methane 
reduction, environmental services, and more. 
	 Seaweed aquaculture supports several of the 
United Nation Sustainable Development Goals as it 
enriches marine biodiversity, fights climate change, 
promotes local economies, and helps to clean 
seawater. Learn more

Appendix
CY’22 CSR Report
51
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
51
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Marine Conservation 
In 2022, Illumina and the Minderoo Foundation announced 
a three-year, $28 million partnership to improve surveillance 
of marine ecosystems using the power of high-throughput 
sequencing with Illumina technology. Learn more
Protecting Biodiversity
Studying the Health of STREAMs
Pollution, drought, and climate change are taking their 
toll, making watershed monitoring more important 
every year. Using eDNA and Illumina technology, 
Sequencing the Rivers for Environmental Assessment 
and Monitoring (STREAM) samples freshwater rivers 
throughout Canada. STREAM partners with citizen 
scientists, local groups, and Indigenous communities 
that have strong interests in preserving their waterways to help 
collect samples throughout the watersheds being studied. In turn, by 
democratizing the data, the Indigenous communities are empowered 
with vital information. Many of them rely on fishing, and the organisms 
STREAM monitors are literally fish food. Learn more
Profiling Endangered Plants
California State University, East Bay, located in the 
same community as our Hayward manufacturing 
location, has launched the Green Biome Institute 
using genomics to profile California’s endangered 
plants. The Institute aims to create molecular profiles 
of nearly 380 threatened or endangered plant species 
to promote conservation and document their biology, 
ecological interactions, and potential human benefits.
	
The Illumina Corporate Foundation provided the Institute with a 
$50,000 grant for the advancement of genomic literacy and STEM 
education through hands-on genomics research for high school, 
undergraduate, and graduate students, while contributing to the 
knowledge and preservation of California’s endangered flora.
Protecting Koalas
The University of Sydney’s Australasian Wildlife 
Genomics Group is using genomics to battle 
decreased genetic diversity threatening koalas. 
Illumina whole-genome sequencing technology 
provides insights to researchers to help protect the 
species from climate change, disease, and other risks. 
Learn more
iConserve Initiatives
iConserve seeks to bring the community together to accelerate 
wildlife conservation.
How Genomics Will 
Support Gorilla 
Conservation
Sequencing 
to Save 
the Lemurs 
Bottlenose Dolphin 
Genome Made Available 
to Researchers 
A new genomic atlas could help save endangered elephants
Data from this international partnership will assist biologists in 
protecting the herds they study
The population of wild African elephants is in dangerous decline, but a 
partnership between Illumina’s iConserve program, the San Diego Zoo 
Wildlife Alliance, and the universities of Copenhagen and Illinois are here to 
help. Using a library of 400 DNA samples from elephants across Africa, the 
team will use whole-genome sequencing to create a “genomic atlas” that can 
show which groups are most in danger from ivory poaching, reproductive 
scarcity, and conflict with humans. The partnership also aims to make 
sequencing tools available to biologists working in the field, empowering 
local communities to make a real difference. 
Learn more about this iConserve project here 
Learn more about our other iConserve efforts:

Appendix
CY’22 CSR Report
52
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
Message from the CEO
CY’22 CSR Report
52
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Climate Action           Sustainable Facilities           Sustainable Products           Sustainable Value Chain           Leveraging Genomics           Impact in Action
Introduction
Sustainability 
To support Black Climate Week, an 
annual event hosted by The Solutions 
Project designed to raise the profile of 
Black voices in climate action, Illumina 
provided a $40,000 grant to honor the 
groundbreaking climate solutions and 
environmental justice work being led by 
Black and Indigenous communities and 
people of color.
Plant GARDEN, led by Japan’s Kazusa DNA Research 
Institute, is an online database that collects plant 
genomes. Unlike other similar databases, the intent is 
to make the data available to everyone. The Illumina 
DRAGEN™ Bio-IT Platform provided a new solution to 
overcome many of the challenges the research team 
were experiencing in compiling plant genomes. With 
Plant GARDEN, researchers have been able to identify 
new variants and study their expression and function in 
a variety of plant species. Learn more
Honoring a Just Transition to a Carbon-Free Future 
Impact in Action
The Solutions Project
Illumina customer, LanzaTech can transform greenhouse gas into ethanol 
and other useful chemicals. Their goal is to turn carbon emissions into 
valuable material commodities. LanzaTech, a biotech company based in 
Illinois, has the goal of turning carbon emissions into valuable material 
commodities. LanzaTech found that an anaerobic bacterium called 
Clostridium autoethanogenum possesses an ancient pathway that could 
ferment both CO and CO2, effectively converting it into ethanol under 
the right conditions. Illumina’s sequencing technology helped LanzaTech 
identify and modify the microbial genes responsible for making acetone. 
LanzaTech’s have produced over 50 million gallons of ethanol from 
industrial emissions, which is the equivalent of keeping over 200,000 tons 
of carbon from entering the atmosphere. Learn more
We offer a variety of regional 
commuter benefits including 
vanpool programs, free electric 
shuttles to local transit, and 
over 250 free electric vehicle 
charging stations globally.
Carbon Capture Through Hungry Bacterium 
Sustainable 
Commute Options
Let It Grow: A DNA Database for Plants
Reduce carbon emissions 
by 6,568 tons—the 
equivalent of 24 million 
pounds of coal 
Save families in San Diego 
and the Bay Area around 
$2.7 million through 
the lifetime of their solar 
projects 
Expand job training in San 
Diego and Washington, 
training 93 people so far
Learn more
We’ve partnered with GRID 
Alternatives, a nonprofit 
organization providing access 
to clean, affordable renewable 
energy, transportation, and 
jobs to the communities most 
often harmed by systemic 
oppression across the nation, 
to help further advance climate 
and environmental justice. The 
Illumina Corporate Foundation 
provided a $500,000 grant to 
support projects near each 
of our main campus locations 
to provide clean energy, solar 
industry job training, and job 
placement to low-income and 
tribal communities in San Diego, 
the San Francisco Bay Area, 
Washington, DC, and Wisconsin.
Our grant has enabled GRID to:
We are a contributing 
member of the Earth 
Biogenome Project, a 
massive undertaking that 
aims to sequence the 
genomes of all species on 
Earth to help uncover the 
solutions for preserving 
and restoring biodiversity.
WATCH 
How the NovaSeq 
6000 Is Empowering 
Agrigenomics Across 
the Globe

CY’22 CSR Report
53
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Nurture 
Our People 
EMEA Human Resources Team

CY’22 CSR Report
54
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Aimee Hoyt
Chief People Officer
Strategic Approach 
and Impact
UN SDGs
 Inclusion is core to our purpose. 
It is essential to the work we do, the 
communities we serve, the partners we 
choose, and the teams we build. 
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
1  Practice diversity, equity, and inclusion
2  Invest in our people
3  Create a culture of care
We are committed to creating a workplace 
centered on innovation and care, a 
workplace that values the unique talents 
of the individual, brings forward the best 
of the collective, and delivers on Illumina’s 
mission at a global scale.
An extraordinary mission requires extraordinary 
people at every level. By nurturing 
an inclusive and caring culture we magnify the 
value of collaboration and building a community. 
Together our impact is amplified and our 
potential is unlimited.
KEY OBJECTIVES
41%
↑2%4
Increase gender representation in 
global leadership1 
13%
↑3%4
Increase representation of Black, Native, 
Pacific Islander, Hispanic or Latino 
communities, 2 or more in our US leadership1 
18%
↑1%4
Increase representation of Black, Native, 
Pacific Islander, Hispanic or Latino 
communities, 2 or more in our US workforce 
Increase minority representation 
in executive leadership (US)2,3
Maintained
Maintain zero net pay gap
.23
↓from .564
Reduce recordable injury and illness rate
2030 Target
2022 Progress
45% female workforce 
representation 
Launched new disability ERGs
52% minority representation 
in US workforce
80 Net Promoter Score on 
Executive DEI Training Program
5% increase in female 
executive leadership in last 
three years
85% average satisfaction rate 
from leaders on professional 
development programming
Launched new mental health 
benefit program (US)
2022 Highlights
30% 
↑9%4
4th consecutive year
1Leadership: Manager, equivalent, and above.
2Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more.
3Executive Leadership: Director, equivalent, and above.
4Since 2019 baseline.

CY’22 CSR Report
55
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Everyone at Illumina is driven by the power 
of genomics to positively impact the 
world. We seek opportunities. We embrace 
challenges. We work tirelessly to move 
genomics and humanity forward. 
APAC
2,456
AMR
6,342
EMEA
1,459
Gender Representation (Global)
Male
LGBTQ
Female
Other/
Undisclosed
Persons with
Disabilities
Veterans
Employee Age Distribution (Global)
Over 50
Under 30
30-50
Our People
Additional Identities (US)
Total global employees (FTE)
10,257
54%
3%
45%
4%
1%
3%
15%
19%
66%

CY’22 CSR Report
56
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Increase gender representation in global leadership2 
Increase representation of Black, Native, Pacific Islander, 
Hispanic or Latino communities, 2 or more in our US leadership2 
Increase representation of Black, Native, Pacific Islander, 
Hispanic or Latino communities, 2 or more in our US workforce 
Increase minority representation in executive 
leadership3,4 (US) 
2030 TARGET
2022 PROGRESS
41% | ↑2%1
13% | ↑3%1  
18% | ↑1%1  
30% | ↑9%1  
Women in management roles in revenue-generating function
35%
36%
42%
42%
Revenue-generating roles held by women
41%
36%
48%
48%
Women in STEM-related roles (as % of total STEM positions)
37%
37%
39%
39%
IT workforce that are women
24%
23%
24%
24%
Engineering workforce that are women
37%
36%
29%
29%
Gender Representation Trends (Global)
2019
2020
2021
2022
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Workforce Diversity
and Representation Data
Support to 
Entry Professional
0%
50%
100%
Intermediate to 
Senior Professional
Director and Above
Manager to 
Associate Director
Minority Representation By Level (US)
White/Caucasian
Asian
2 or More
Native, Hawaiian/Other Pacific Islander
Hispanic/Latino
Not Disclosed
American Indian/Native Alaskan
Black/African American
52%
44%
Minority Representation 
in Workforce (US)
4%
Minority
representation3
Declined
to state
Self-identified
as white
1Since 2019 baseline.
2Leadership: Manager, equivalent, and above. 
3Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more.
4Executive Leadership: Director, equivalent, and above.
Gender Representation by Level (Global)
Support to 
Entry Professional
Intermediate to 
Senior Professional
Supervisor to 
Associate Director
Director & Sr. Director
VP
SVP/C-Suite
Board of Directors
Male
Female
Other/Undisclosed
0%
50%
100%

CY’22 CSR Report
57
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
The following groups are in place to support DEI governance.
Our DEI Governance 
Practice Diversity,
Equity, and Inclusion
We relentlessly practice diversity and inclusion in all 
we do to advance equity and belonging. 
Board of Directors 
Compensation 
Committee
Employee Resource Groups (ERGs)
Dedicated Vice 
President, Head of DEI
CSR/ESG Executive 
Steering Committee
Executive Diversity 
Council
DEI Functional 
Group
CSR/ESG Functional 
Group
Diversity Council
Working Groups
Our DEI Strategy
DEI Beyond Our Workforce
We strive to foster a diverse and inclusive 
culture in which all employees feel valued and 
appreciated. This kind of environment helps people 
engage at their best, knowing they have an equal 
opportunity to grow and succeed based on their 
performance, fueled by their individual differences.
Our DEI strategy goes beyond just our internal workforce, people, and 
culture. It is integrated across our business and is foundational to each 
of our CSR focus areas.
Key Programs
•	 DEI Ambassador Program
•	 Strengths Training
•	 ERG Program
•	 Self-serve DEI Learning
 Our DEI program is anchored in the philosophy of practice. 
We invite everyone to start where they are and continue to 
work, appreciating that there is always more to learn. 
Dr. Lisa Toppin
Global Head of Diversity, Equity, and Inclusion
 I knew when I joined Illumina the company held an intentional belief 
that diverse perspectives are needed to drive innovation. What I didn't 
know at the time was how much that company belief would impact my 
own journey to better understanding diversity dynamics and becoming 
a stronger DEI champion. After participating in the DEI Ambassadors 
Program, I find myself motivated to find new ways to lead change and 
consider the areas I can have the most impact. I've been asked to look 
inward to see the outside world more accurately. 
Jennifer Pellegrini
Sr. Staff Brand Manager
Build Inclusive 
Leadership
Communicate 
with 
Transparency
Enhance 
Equitable 
Processes
Acquire and 
Develop 
Diverse Talent
As part of our commitment to DEI, we are the proud signatories of: 
•	 UN Women Empowerment Principles
•	 CEO Action for Diversity and Inclusion
•	 UN Global Compact 
•	 Disability:IN CEO Signatory
•	 'Bright Minds' Executive 
DEI Training
•	 Global Smart Program
•	 HR Team DEI Training 
CSR Focus Area
DEI Intersection
Accelerate Access 
to Genomics
Read more in Access→
Increase the diversity 
of genomic data
Empower our 
Communities
Read more in 
Communities→
Empower diverse learners 
to be future STEM leaders 
Integrate 
Sustainability
Read more in 
Sustainability →
Invest in environmental 
justice initiatives
Nurture our People
Read more in People→
Practice DEI in all we do
Operate Responsibly
Read more in Operate 
Responsibly→
Target spend with 
diverse suppliers

CY’22 CSR Report
58
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
2022 ERG HIGHLIGHTS
Introduced
2 New Disability ERGs
participants engaged
5,400+
ERG chapters globally
17
Employee Resource Groups (ERGs)
ERGs as Career Development and the 
Cornerstone of Our DEI Engagement
They deepen our respectful, inclusive culture by engaging 
employees and providing an opportunity to connect, 
celebrate, and learn with peers and allies. The ERGs are 
also a key lever to identify, develop, and retain talent. 
Our ERG Program Philosophy 
Each ERG at Illumina is structured around four contribution 
pillars: community service, career development, 
education, and business impact to ensure programming 
supports ERG member needs and aligns with Illumina 
values. This focused work educates our teams about the 
value of difference and uses the power of diversity to 
drive innovative problem-solving for our business. To read 
more about the ERG contributions to our philanthropic 
efforts, see the People Impact in Action section, the 
Access chapter, and the Community chapter.
 Leading the social impact project for my ERG connected 
me with an organization that I became passionate about 
and ultimately led to an invitation to join their Board of 
Directors. The ERG created an opportunity for community 
service and professional development.  
 I appreciate Illumina for raising awareness 
through ERG iPRIDE events that our company 
values our employees based on their abilities. 
Alexa Tralla
Sr. PCP Program Manager
Seki Norihiro
Sr. EHS Specialist
Our Employee Resource Groups
COMMUNITY SERVICE
Support our communities 
by engaging with nonprofits 
where we live and work
CAREER DEVELOPMENT
Focus on building the 
careers and skills of diverse 
employees into future 
leaders
BUSINESS IMPACT
Enhance innovation with 
diverse teams identifying 
and solving business 
challenges
Employee Resource Groups (ERGs) Program Pillars
EDUCATION
Create more understanding 
and deeper collaboration

CY’22 CSR Report
59
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
We monitor our pay equity status and market competitiveness on 
an annual basis.1 For a fourth consecutive year, we are proud to 
confirm a zero net gap in pay.2
	
Our pay practices are designed to compensate employees 
based on factors such as job performance, expertise, and 
experience relevant to individual geography. Everyone should be 
paid equitably, regardless of gender, race, age, ethnicity, sexual 
orientation, national origin, or any attribute that does not relate to 
their job and contribution. 
1Equal pay refers to paying a woman and man equally for the same or similar work. 
2Zero net gap in pay means no statistically significant difference in pay for the same or similar work, regardless of gender, ethnicity, or race. 
Expanding Pay Transparency
As part of our commitment to pay equity and equitable 
processes, open communication, and leadership accountability, 
we are providing salary range transparency on all US job postings 
effective Jan. 1, 2023. To ensure fairness and consistency, we 
will also be providing all employees with access to the salary 
range for their current position in 2023 via our HR people system.
Pay Equity
Maintained for 4th 
consecutive year 
Maintain a zero 
net pay gap
2022 PROGRESS
2030 TARGET
We support the elimination of discriminatory practices with respect to employment. We are 
committed to fair and respectful treatment of all employees, promoting equal opportunity 
and diversity in the workplace and in all aspects of our business. Our policies prohibit 
discrimination based on race, color, age, gender, sexual orientation, marital status, gender 
identity and expression, ethnicity, religion, physical or mental disability, medical condition, 
genetic information, veteran status, national origin, or any protected class.
Equal Opportunity and Nondiscrimination Policies

CY’22 CSR Report
60
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Invest in Our People
Development is the catalyst for how we achieve 
success and become more than we ever thought 
possible—as individuals, as teams, and as an 
organization. We aim to create the opportunities and 
environment to unlock the full potential of our people.
We are committed to engaging extraordinary talent and helping them thrive. 
To ensure that our employees enjoy long and fulfilling careers at Illumina, we:
Development Happens Every Day
At Illumina, everyone can achieve and become more than they thought 
possible. Regardless of work arrangements or location, opportunities exist 
for continuous learning and growth. Development at Illumina is an intentional, 
everyday activity that prepares employees for success in their work now and 
for opportunities in the future. It is available to all, accessible in many formats, 
and contributes to a meaningful career experience at Illumina.
*Directors and above
Provide high-impact 
development opportunities
Invest in 
our talent
Reward employees 
meaningfully
 Every day, we engage in conversations that shape 
our expectations, relationships, and outcomes. We 
approach work with curiosity and passion, and, 
supporting a mission that truly matters, you will grow 
in ways you never imagined.” 
Karen Wetherholt
Global Head of Talent
Individuals own their development and are empowered 
to grow their strengths, learn beyond their discipline, and 
pursue their own personal and professional growth path
Illumina invests in experiences, tools, and 
programs that help people achieve their 
aspirations and create a culture of development
Leaders guide and support 
development by helping to define the 
path, providing access to resources, 
and growing individuals through 
coaching
Development
Guided and Supported at Every Step
roles filled with internal candidates 
49%
new hires referred by Illumina employees
average hours of annual training per employee
28%
62
executive roles* filled with internal candidates
41%

CY’22 CSR Report
61
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Development Programs, Resources, and Solutions 
Employee Development 
Talent Discussions and Succession – Achieving our mission requires constantly 
developing the right talent. Talent assessments and succession planning allow us to get 
the right people and programs in the right places to ensure we are supporting the vision 
of Illumina for today and tomorrow. 
Team Enablement – Highly effective teams invest in harnessing the strengths of the 
individual and bringing forward the best of the group. Team enablement provides teams 
with self-guided resources that create team cohesion and a strong foundation for 
future success.
Performance Enablement – Great performance requires an ongoing dialogue of 
how individuals are doing and where we’re headed. Shifting from annual reviews, 
our performance enablement creates a quarterly proactive connection opportunity 
for individuals and their leaders to align on priorities, discuss development, and use 
coaching and feedback—all in support of individuals’ achievement and growth.
Learning and Leadership Development – From early career to senior leadership, Illumina 
employees have unlimited opportunities to grow in the ways they never imagined. 
Learning and leadership development supports individuals at all stages in their careers 
with the tools, resources, and programs to be successful at every step.
We support Illumina employees from early career through senior 
leadership with a variety of programs, tools, and solutions. 
Resources
Learning and development resources are curated so 
that employees can explore, share, plan, and act to 
get on the path that is the best fit for them.
Illumina improves by deeply understanding our people. Employee listening, including iPulse, allows us to capture our 
people’s successes, needs, and overall experiences in a timely way to take action and improve the employee experience. 
•	 External speaker series 
•	 Open career panel discussions 
•	 TEK Talks (technical education knowledge) 
•	 Anytime, informal feedback tools as well as 
formal assessments
•	 Tuition assistance/financial assistance for 
job-related education 
•	 Workday learning, LinkedIn Learning, and other on-demand 
learning resources
•	 360-degree and 180-degree assessments, Valence, and Strengths 
for Teams are available for individual and team feedback.
Quarterly career development 
and performance conversations 
Quarterly 
promotion cycles
employees are provided opportunities for regular 
performance and career development reviews 
100%
95% 
are proud to work for Illumina
90% 
feel their manager supports efforts 
to balance work and personal life
86% 
engagement index
81% 
have confidence in the continued 
growth and success of Illumina 
81% 
trust & confidence index
86% 
would recommend Illumina as a 
great place to work 
83% 
believe Illumina really cares about 
their well-being
83% 
feel they belong at Illumina
87% 
feel it is safe to be vulnerable 
We ask our employees to complete regular iPulse surveys. In 2022, we conducted one assessment.
Listening to Our People

CY’22 CSR Report
62
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Power Hours – A leadership development program 
for frontline leaders, run by subject matter experts, 
to develop the skills and knowledge required to lead 
teams effectively 
Discussion and Lean In Circles – Our business 
leaders host discussions on important topics such 
as “Moving into Management” and “Managing Your 
Career.” We also support Lean in Circles through our 
Women at Illumina (WIN) ERG
Mentoring Programs – The Horizons ERG hosts 
Jedi-Padawan buddy programs, connecting early 
career professionals with seasoned employees, and 
the Women in Illumina (WIN) ERG offers a mentor 
program called iMentor 
Culture of Coaching – Our Coaching Learning Path 
highlights a variety of options to help leaders learn, 
practice, and build their coaching skills
Leaders in Action – Leaders helping leaders grow 
their skills and expand their impact
Thrive New Leader Orientation – Targeted to newly 
hired and promoted leaders at Illumina, this centers 
on our global new leaders and provides insight into 
leading at Illumina and our leadership philosophy
Leadership Development at Illumina
Leaders actively prepare for the future through a variety of formal development offerings.
Recognizing Success
We have designed several 
programs to recognize 
employees’ outstanding 
achievements, including:
2x
Illumina female inventors 
compared to the national rate 
of women receiving patents 
30%
Singapore inventors 
are women 
34%
UK inventors 
are women 
26%
US inventors 
are women 
Total 
inventors 
422
28%
Female
inventors 
39%
US inventors 
are minorities 
192
First-time 
inventors
Illumina Inventors by the Numbers
In 2022, Illumina employees filed a record 193 new 
patent applications. Illumina has a total of 9,178 
patents worldwide.
•	 Over 1,000 participants in Strengths-Based 
Training Program 
•	 70% of leaders attend at least one development 
program each year with an average satisfaction 
rate of over 85%
•	 Leaders have access to over 18,000 on-demand 
learning courses
Ignite – This leadership series brings external thought 
leaders on leadership topics to provide ongoing and 
regular development
Elevate for Executive Leaders – Over a several 
week journey, Directors and Sr. Directors engage 
with peers around the globe in a cutting-edge social 
and interactive learning experience. Leaders learn 
from other executives through activities and guided 
discussions, share expertise, and deepen insights 
with a dedicated executive coach 
Strengths-Based Training Program – Using the 
Clifton Strengths Finder Assessment tool, the 
program is designed to build self awareness of 
strengths and an appreciation for what colleagues 
contribute, helping drive DEI through our work.
Bright Minds Executive DEI Training - A program 
designed for Executives to learn how they can lead 
change in every aspect of our talent life cycle engine.
•	 Innovation Award – Recognizes 
this core element of our culture 
and success by annually 
celebrating our pioneering 
scientists for their extraordinary 
contributions 
•	 Inventor Award – Recognizes 
employee inventors who 
annually contribute to our 
patent applications 
•	 Values Award – Presented 
to individuals and teams 
nominated by their peers for 
exemplifying our values

CY’22 CSR Report
63
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Attracting Extraordinary Talent
Illumina's talent acquisition strategy plays a critical role in supporting 
our mission. We integrate our DEI principles in our recruiting efforts to 
find top talent who share our values, and have diverse backgrounds 
and unique skill sets to join us and help deliver on the transformative 
power of genomics.
Learn more about our employee engagement and intern 
skills based volunteer program here.
Intern Cohort
22%
Conversion 
Rate (US)
64%
Minorities
 (US)
54%
AMR Women
57%
EMEA Women
Attracting Diverse Future Talent
As a global organization, the perspectives from diverse 
backgrounds and experiences are core to our talent 
strategy. Supporting and engaging with underrepresented 
student groups continues to be a key priority as we invest 
in the future. Examples of student organizations include 
school chapters of Society of Women Engineers, National 
Society of Black Engineers, and Society of Professional 
Hispanic Engineers, among others. In 2022, we met over 
500 students in the US through key diverse student 
organizations through in-person events, campus visits, and  
virtual sessions.
Internship Program
We know that students and graduates are innovators, 
creators, and the future of Illumina. Annually we welcome 
an extraordinary group of interns, work experience 
students, and apprentices around the globe. These 
dedicated students learn, grow, and become more 
than they ever thought 
possible as fully integrated 
members of the team. Our 
programs provide endless 
opportunities for impactful 
work, professional 
development, and 
volunteer projects. Interns 
are empowered to practice 
leadership, observe the 
direct impact of their work, 
overcome challenges, and 
navigate new situations. 
Illumina Alumni Network
We aim to broaden the genomic 
ecosystem and create a community 
to forge the future of genomics 
together. When joining Illumina, you 
become part of the Illumina family. 
If your journey takes you away from 
the company, we stay connected 
through the Alumni Network. With 
over 7,000 alumni representing 600+ 
companies across the globe, we 
recognize the potential of our alumni 
to advance thought leadership 
and fill talent pipelines within 
the biotechnology community. 
Launched in 2021, the alumni 
network provides former employees 
an opportunity to make connections 
with fellow alumni, sharing industry 
trends, thought leadership and 
extending the network of genomics 
influencers.
Intern, Graduate, and Early-in-Career Talent
Nurturing and investing in future talent is critical to Illumina’s growth 
strategy. Robust engagement with key universities provides an 
opportunity for us to create long-term relationships with students, 
graduates, professors, and university faculty. We create meaningful 
student experiences through special events, professional development 
workshops, technical talks, and campus ambassador programs. Our 
hybrid approach meets students where they are by offering both virtual 
and in-person sessions across all time zones. 
Intern          Graduate          Early in Career          Employee          Alumni

CY’22 CSR Report
64
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Create a Culture of Care
Building extraordinary teams and breakthrough innovations starts with caring 
for our employees and putting their welfare at the heart of all we do.
We offer a wide range of benefits as innovative as our work, including healthcare, access to genomics 
sequencing, and family planning. Our goal is to enable all employees to take advantage of the benefits that are 
most meaningful to them and their loved ones.
Employee Benefits 
We offer a world-class portfolio of benefits and 
well-being programs, and we extend these benefits 
to employees, spouses, domestic partners, and 
dependent children.
	 Every day, our technology is being used to improve 
human health—enabling advancements that were not 
possible just a few years ago. Our employees receive 
access to these new technologies, such as workplace 
genomics, reproductive health programs, and cancer 
testing to help better inform their health care decisions. 
	 Our employee benefits, which vary by country and 
region, recognize the tremendous value our people 
bring to the business with an array of meaningful 
programs. 
Workplace Genomics Program* 
Through our partner, Genome Medical, we provide 
access to genetic experts who can provide 
consultations, guidance, and facilitate testing for 
employees and their families. In addition, we offer 
financial support for cancer tests, reproductive health 
tests, and clinical whole-genome sequencing (cWGS) 
for rare and undiagnosed diseases. 
Cancer Early Detection Testing (US)
The GalleriTM multi-cancer early detection test is available 
at no cost to eligible US employees and their dependents 
as part of our Workplace Genomics Program. 
Supporting Growing Families* 
Employees, their spouses, and domestic partners 
may be eligible for the company-sponsored 
reproductive health program either through 
insurance or financial support:
• In vitro fertilization
•	Pre-implantation genetic testing
•	Non-invasive prenatal testing
Through our partner, Progyny, we offer a compre-
hensive fertility benefit program to eligible US-based
employees that provides coverage for fertility 
preservation, providing equitable access to care for 
our diverse employees, including those pursuing 
nontraditional paths to parenthood.
Providing Time to Recharge 
•	Flexible time off 
•	Two days of paid volunteer time off 
•	Minimum 10 days of holiday paid time off
•	Company-wide shutdowns in July and December 
•	Compassion and Care Time Off
Fostering Wellness Inside and Out 
•	Medical, dental, and vision coverage 
•	Pre-tax spending accounts 
•	Employee assistance program (EAP) 
•	Wellness rooms for nursing, meditation, and prayer 
•	Business travel medical insurance 
•	Gym access or membership 
•	Ergonomic workstations, abundant natural light, 
and opportunities to work outdoors 
•	Cafeterias offering sustainable, healthy food 
options, including vegetarian choices 
•	Genetic counseling 
•	Global well-being activities 
Health Solutions (US) 
•	Cancer support and expert advisory review 
through Access Hope 
•	Expert guidance for diagnosis, treatment, or finding 
the best physician through Included Health (US) 
•	Digital musculoskeletal (MSK) physical therapy care 
solution through Hinge Health 
•	Comprehensive mental health program for 
employees, dependents and all household 
members through Lyra 
Investing for the Future 
•	Employee stock purchase program 
•	Retirement savings plans 
•	Pensions (EMEA) 
•	Life and accident insurance 
•	Disability insurance 
•	Independent financial advice 
•	Tuition assistance 
Additional Perks and Benefits 
•	Site amenities, including car washing, dry cleaning, 
mobile salons, food service, mindfulness, and self-
improvement courses 
•	Employee referral program 
•	Donation matching program 
•	Special interest clubs 
•	Commuter support 
•	Broadband allowance (hybrid + remote employees) 
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
*Some services only available in the US.

CY’22 CSR Report
65
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
We are committed to a safe and healthy work 
environment for all our employees, contractors, and 
the communities in which we operate. Through a risk-
based approach, our policies outline a process for the 
assessment, evaluation, elimination, and mitigation 
of EHS risks while adding value and efficiency across 
our operations globally.
Global EHS Management System 
We continue to develop global processes under 
international voluntary standards for environmental 
and occupational health and safety management 
systems. Our Singapore site attained recertification 
to ISO 14001 and ISO 45001 and obtained a 
Workplace Safety Health Innovation Award.
We embrace our mission through the establishment, 
implementation, and maintenance of an integrated 
EHS management system. Read more in our 
EHS policy.
Prevention and Preparedness 
EHS’s Global IIPP describes basic processes our employees can take to 
maintain a safe and compliant workplace. Our Emergency Action teams 
work together to create awareness and lead regular preparedness drills and 
activities. This precautionary approach2 is embedded in our risk assessments, 
our environmental aspects/impacts, our EHS Policy, product stewardship, and 
the engagement of our people.
EHS Programs 
Our vision is for every Illumina employee to be an 
environmental, health, and safety leader. This year 
we championed a series of safety projects and 
initiatives that drive continuous improvement and 
program maturity. 
1Core Sites – San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre, Netherlands, and Singapore Woodlands. 
2The UN Global Compact Principle 7 and The UN Global Compact Principle 15 state in order to protect the environment, the precautionary approach shall be applied.
•	 Completion of EHS Regulatory Assessments at all 
core sites1 
•	 Implementation of an updated Ergonomic 
Risk Reduction program to further enable our 
employees to identify and address ergonomic risk 
factors to drive mitigation actions
•	 Standardization of a global process for Hazardous 
Material Management including EHS review for 
hazardous material procurement and a chemical 
inventory conducted at all core sites1 
Workplace Health and Safety
*Reduction reflects year over year comparison between 2021 and 2022
2022 Safety Performance 
Prevention reports
2,010
EHS risk assessments 
completed globally
215
Ergonomic evaluations 
completed
324
Recordable injury 
and illness rate
.23
Hours of EHS-related 
training
>45,000 
Reduction in days away, 
restricted, or transferred rate*
40%
Learn More
EHS Policy
14001 Certificate
45001 Certificate
Injury and Illness Prevention Program (IIPP)
Environmental, Health, and Safety Trends
Recordable Injury 
& Illness Rate
2019
.52
2020
.34
2021
.53
2022
.23
2020
.18
2021
.22
2022
.12
Lost Time Illness Rate
2019
.74
2020
.18
2022
.17
Days Away, Restricted, 
Or Transferred (DART)
2021
.43
.34
2019
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action

CY’22 CSR Report
66
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Appendix
Sustainability 
Message from the CEO
Through consistent 
innovation in 
next-generation 
sequencing (NGS) 
technologies, and 
relentless efforts to 
combat COVID-19 
worldwide, Illumina distinguished itself from other 
multi-national companies in the Technology Review 
Top 50 Award in China.
To support an inclusive place for all, we host sessions linked to current events in 
order to foster conversations that promote healing, learning, and the deepening 
of connections amongst our community. This year, one of the most impactful 
sessions was "Woman, Life, Freedom" and the impact of recent events on our 
Iranian community. Employees shared their experiences, showed support for the 
community, and were provided resources to learn more about the rich and brave 
history of the Iranian Women. 
Throughout the year, opportunities for wellness 
activities are offered to employees, including global 
5K walks and runs, Wellness Wednesdays, Wellness 
Fairs, and virtual walk the world for charity events 
through our wellness fitness platform.
Our EMEA HR Team expanded these efforts with a 
focus on mental health and well-being efforts, such 
as the mental health advocates program, mental 
health awareness session for leaders, sponsoring 
the annual well-being day, and partnering with a UK 
charity offering employee wellness session. 
Illumina Singapore was recognized with 
an award on innovation in workplace 
health and safety. The project included 
developing automation to support 
assembly and manufacturing of heavy 
equipment. Reducing risk, eliminating 
lifting hazards, and improving 
efficiencies and safety earned external 
acknowledgment from the Workplace 
Safety and Health Council and the 
Ministry of Manpower (MOM).
As part of the ERG program 
pillars, each group completes 
a community service social 
impact project. In 2022, the 
initiatives included STEM 
outreach to underrepresented 
communities, creating care 
packages and notes for teens 
with gender dysphoria, career 
mentoring for transitionaing 
veterans, and many more. 
The ERGs put our culture 
of giving back into action 
connecting our mission, 
their ERG focus, and 
community service.
Healthy Selfie Campaign
ERG Community 
Impact Project
Impact in Action
Care and Connection Sessions
Illumina Ranked One of 
50 Smartest Companies in 
China by MIT Technology Review
Singapore Workplace Safety 
Health Innovation Award
To promote self care for our employees and their loved ones, we 
offered a $500 Health and Lifestyle Allowance to all employees 
globally. To foster connection, we held a #HealthySelfie campaign 
to have employees share how this is positively impacting their 
healthy lifestyle.
Strategic Approach and Impact           Our People           Practice Diversity, Equity, and Inclusion           Invest in Our People           Create a Culture of Care           Impact in Action
Nurturing a Culture of Care 
with Employee Wellness

CY’22 CSR Report
67
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Introduction
Appendix
Sustainability 
Message from the CEO
Operate 
Responsibly

CY’22 CSR Report
68
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Gwen Chapman 
Chief Compliance Officer
1  Practice strong corporate governance
3  Act with integrity in all that we do
5  Foster a responsible supply chain
2  Maintain a culture of compliance
4  Uphold high standards for data security and privacy
6  Participate in proactive public policy
Strategic Approach 
and Impact
We are committed to conducting ourselves with honesty, 
integrity, and respect for all.
Doing the right thing is core to who we are. Our role as a genomics 
pioneer brings with it the responsibility to enable innovation for 
good, ensuring that the technology we create and the data we 
collect are used safely, ethically, and responsibly. 
UN SDGs
 For us, doing the right thing is more than 
just compliance. It is having a deep sense 
of integrity and honoring the trust placed 
in us by employees, patients, customers, 
shareholders, and communities. 
Position Illumina as the most trusted 
company in genomic privacy and ethics
Ongoing
Achieve top industry ESG ratings
Ongoing
100% strategic suppliers committed to 
reducing their environmental footprint 
100%
Achieve 20% spend with diverse suppliers (US) 
18%
72 approvals from 
58 regulatory agencies
Completed first Human 
Rights Impact Assessment
100% Illumina core facilities 
participated in third-party 
audit programs1
Industry Leader in multiple 
ESG rating and ranking 
indices including DJSI, 
Sustainalytics, and CDP
33% Board members are women 
$269 million (US) 
diverse supplier spend 
33% Board members represent 
racial/ethnic diversity
Achieved ISO 27701 for Privacy 
Information Management 
on Illumina's six cloud-based 
products
KEY OBJECTIVES
2030 Target
2022 Progress
2022 Highlights
1Core facilities defined as San Diego, Bay Area, Madison, Cambridge, UK, and Singapore.

CY’22 CSR Report
69
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Robert S. Epstein, MD
Scott Gottlieb, MD
Caroline Dorsa
Frances Arnold, PhD
Francis deSouza
Sue Siegel
Gary S. Guthart, PhD
John W. Thompson (Chair)
Philip Schiller
Board of Directors
Board Profile
More details about the Board can be found in our Proxy and on our corporate website.
Female 
representation
33%
Minority 
representation
33%
Average Board 
tenure
6.6 Years
Practice Strong 
Corporate Governance
By exercising strong corporate governance, we aim to inspire 
confidence in the work we do and in our company’s future.
Board of Directors
Our Board of Directors is a diverse group of leaders 
who champion scientific innovation. The Board’s aim 
is to ensure the company is equipped with the tools 
it needs to accelerate the power of genomics. The 
Board has adopted Corporate Governance Guidelines 
which are founded on a commitment to building 
shareholder value, with an emphasis on responsible 
governance. These guidelines, together with the 
Code of Conduct and Board Committee Charters, 
provide the framework for corporate governance 
at Illumina.
Board ESG Governance 
The full Board provides ESG oversight, and this past 
year we expanded the remit of the Nominating/ 
Corporate Governance Committee to assist the 
Board in overseeing the Company’s material 
environmental, social, and governance matters (ESG), 
except as specifically delegated to another Board 
committee. The Compensation Committee continues 
to oversee and provide input to management on 
diversity and inclusion matters, and the Audit 
Committee continues to oversee cybersecurity. 
Learn more in Governance →
Diverse and Independent Board 
As stipulated in our Corporate Governance 
Guidelines, our company seeks to achieve a mix 
of Board members that represents a diversity of 
background and experience, including with respect 
to age, gender, international background, race, and 
specialized experience. 
	 Our Corporate Governance Guidelines also require 
that independent directors constitute at least a 
majority of the Board. In order to be independent 
directors of the Company, directors must meet the 
criteria for director independence established by the 
Nasdaq Stock Market. 
Our Board has established four standing committees. 
Learn more in each committee charter: 
Audit Committee
Compensation Committee 
Nominating/Corporate Governance Committee
Science and Technology Committee
Independent 
directors
89%

CY’22 CSR Report
70
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Maintain a 
Culture of 
Compliance
We take pride in conducting our 
business with honesty, transparency, 
and in accordance with legal 
standards and ethical principles.
Our culture of compliance and ethics starts at the 
Board level and is incorporated into every level of our 
business. Our policies guide employees on how to 
apply a culture of compliance to their daily work.
Illumina Code of Conduct
The Illumina Code of Conduct promotes honest and 
ethical conduct, compliance with applicable laws 
and regulations, and protection of our business 
interests. The code applies to all Illumina employees, 
consultants, temporary workers, officers, and 
members of the Board of Directors, regardless of 
location, seniority level, business unit, function, or 
region. Key topics of our Code of Conduct include 
fraud prevention, bribery and corruption, anti-
discrimination, anti-harassment, human rights, 
diversity and inclusion, employee safety, corporate 
social responsibility, marketing and sales claims, and 
government interactions and political activity. 
Illumina’s Compliance and Fraud Prevention Hotline 
is available to both employees and third-party 
partners, 24/7 by phone or online. 
Training
We provide annual training on our Code of Conduct 
and Anti-Bribery and Anti-Corruption Policies for all 
employees globally and more focused training on 
other Illumina compliance-related policies.
	 All employees receive training when onboarded 
and are annually certified through our enterprise 
learning management system. On an annual basis, 
all employees are assigned Code of Conduct training 
through our enterprise learning management system 
and are required to electronically acknowledge that 
they have read, understood, and will abide by our 
Code of Conduct. 
Expanded Oversight for Clinical Environments 
At Illumina, we are at the forefront of the evolution 
of genomics from pure research to in vitro 
diagnostic (IVD) medical devices. With this 
evolution, we operate in the ever-changing, highly 
regulated IVD market and often interact with 
health care professionals and government officials, 
representatives, and agencies that regulate the 
markets in which we do business. Illumina is 
committed to high standards of ethical business 
conduct, including compliance with all applicable 
anti-bribery/corruption and anti-kickback laws, as 
well as relevant medical device industry codes.
Compliance Committee 
Illumina’s Compliance Committee is a standing 
committee responsible for ensuring that the 
company continues to conduct its operations and 
activities ethically, with the highest level of integrity, 
and in compliance with all legal and regulatory 
requirements. The Compliance Committee oversees 
the development, maintenance, and monitoring of 
global, legally-sound, practical, and sustainable 
programs (collectively the Compliance Program) 
intended to satisfy the company’s legal compliance 
obligations and to foster a culture of compliance 
with laws, regulations, industry standards, and 
company policies. 
Ethics and Compliance Reporting 
We are committed to fostering a culture in which 
employees feel comfortable raising compliance and 
ethics concerns without fear of retaliation. We promote 
an open-door policy that encourages our employees 
to raise concerns to their managers, HR, and the 
Compliance Department directly. We have established 
a third-party Compliance and Fraud Prevention Hotline 
and website that Illumina employees and others may 
use to report concerns anonymously.
	 Illumina takes the obligation to investigate reports 
of potential violations of law, non-compliance with 
Illumina’s Code of Conduct and corporate policies, 
and unethical conduct very seriously. The company 
is committed to impartially investigating all such 
reports where warranted and in remediating any such 
violations in a fair and consistent manner. Illumina 
takes all reasonable steps permissible to protect 
reporting or cooperating parties from retaliation. 
Code of Conduct 
Compliance Program Framework 
Anti-Corruption/Anti-Bribery
Anti-Competitive Behavior
Interactions With Healthcare Professionals
Compliance Information
Ethics Information 
Ethics Advisory Board Charter
Ethics Advisory Board Members
KEY POLICIES
*Including FTEs, contractors, consultants, and interns
98% completed the web-based training 
and certified they have read and understand the 
code in 2022
100% of employees* are assigned training annually
TRAINING
12 languages
CODE OF CONDUCT

CY’22 CSR Report
71
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Business and Finance
Operational
Legal and Regulatory 
Brand and Reputation 
Product Quality
Employee
Environmental, Health, and Safety
Climate (physical and transition)
Learn more about our risk factors in our 10K. 
Climate Resilience 
At Illumina, we believe addressing climate change is one of the 
key topics to achieving a sustainable, just, and resilient future 
for all. We are committed to climate action and the integration of 
climate resilience planning into our risk management program. See 
Sustainability → for additional information and the Appendix → for 
additional details on our Task Force on Climate-related Financial 
Disclosures (TCFD) index. 
Anti-Bribery/Corruption 
We prohibit bribery and corruption in any form. We 
comply with applicable anti-corruption laws in the 
countries in which we conduct business, including 
laws that prohibit bribery of government officials 
and employees of commercial organizations. Illumina 
personnel and our sales channel partners worldwide 
are prohibited from directly or indirectly offering, 
promising, paying, giving, or authorizing the giving 
of any financial or other advantage, or anything of 
value, to any other person or organization in order to 
exert improper influence over the recipient, induce 
the recipient to violate his or her duties, secure an 
improper advantage for the company, or improperly 
reward the recipient for past conduct. We require 
our business partners (e.g., channel partners, and 
consultants) to maintain the same standards when 
acting on our behalf. 
Risk Management 
Illumina has adopted a company-wide approach, through various 
mechanisms, to assess and manage risks. We endeavor to ensure 
that all employees adhere to our ethics and compliance protocols. Our 
Enterprise Risk Management (ERM) framework has been established 
to anticipate, assess, monitor, manage, and report on risks that could 
impede our business and identify emerging issues and opportunities. 
	 We have implemented a corporate, global, Business Continuity 
Planning (BCP) program to reduce risk exposure and mitigate negative 
events to business operations. The ISO 22301:2019 standard is used 
as a business continuity framework for this program. Additionally, the 
Internal Audit Department independently and objectively assesses risk 
and reports insights to the Audit Committee of the Board of Directors 
on a quarterly cadence.
Our risk assessments consider various quantitative and qualitative 
inputs, including: 
Anti-Competitive Behavior 
We work to compete and succeed in a fair and 
honest marketplace. We do not engage in unethical, 
unfair, or illegal communications with competitors. 
We always deal fairly with customers, suppliers, 
competitors, and employees. We do not take 
unfair advantage of anyone through manipulation, 
concealment, abuse of privileged information, 
misrepresentation, or any other unfair-dealing 
practice. We do not enter into formal or informal 
agreements with competitors to engage in any 
anti-competitive behavior, including setting prices 
or dividing up customers, suppliers, or markets. We 
comply with all laws related to competition, antitrust, 
and the gathering of competitive information. In order 
to promote fair and honest competition, we minimize 
contacts with competitors and always avoid sensitive 
subjects, including those relating to competition 
between the company and others.

CY’22 CSR Report
72
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Act with Integrity
We are committed to reflecting the very best of our people, practices, and purpose. 
Integrity and fairness are central to how we operate in the workplace and the marketplace.
Ethics Advisory Board 
We seek guidance from our Ethics Advisory Board on a 
range of strategic issues, including recommendations 
on emerging ethics matters, policies, and regulations 
that are relevant to the genomics industry. We meet with 
the Ethics Advisory Board on a quarterly basis. Work 
includes providing strategic advice to Illumina about:
Ethical Use of Genomic Technologies 
Illumina is steadfast in our commitment that genomic 
technologies should be used to benefit humanity, 
and we will only work with partners who further this 
mission. Our Human Rights Policy and customer 
agreements outline our expectations regarding 
ethical business conduct, the use of our technology, 
and the steps we can take in the event of a possible 
violation. We have expanded and enhanced our 
oversight and accountability processes to monitor 
and enforce these commitments and prevent sales 
that could result in misuse or human rights concerns 
before they happen. Illumina is committed to 
investigating potential reports of product misuse 
and will not hesitate to cease sales to business 
partners in the event of a confirmed ethics or 
human rights concern.
Emerging policies and 
regulations relevant to 
the genomics industry 
and the company’s 
interests 
Ethical issues 
arising from 
specific technology 
or products 
•	Ethics Advisory Board
•	Human Rights 
Oversight and 
Accountability 
Framework
•	Human Rights 
Response Playbook 
for Product Misuse 
•	Human Rights Impact 
Assessment
•	Illumina Connected 
Analytics Impact 
Assessments (includes 
ethical AI, privacy, and 
human rights analysis)
•	International Best 
Practices for Genomic 
Data Sharing
•	Genomic Ethics 
Documentary Series
Nita Farahany, JD, 
PhD
Charmaine Royal, 
MS, PhD
Freda Lewis-Hall, MD, 
DFAPA, MFPM
Glenn Cohen, JD
Leslie Biesecker, MD
Clement Adebamowo,
BM, ChB, ScD, FWACS, FACS
Ethical Business and Use of Genomics 
•	Transparency 
•	Diversity, 
nondiscrimination, 
and fairness 
•	Values-driven design 
•	Accountability
Ethical Artificial Intelligence Principles 
Illumina is dedicated to improving human health by 
unlocking the power of the genome. Our mission 
drives everything we do, including the technology 
we develop. Illumina creates and uses artificial 
intelligence (AI) systems to power industry-leading 
sequencing quality, fuel data insights, improve 
understanding of genomic variation in relation to 
health and disease, and advance genomic science. 
We define AI systems to include machine learning, 
deep learning, and predictive modeling. Illumina is 
committed to developing and using AI according to 
applicable laws and the following guiding principles:
  
Learn More
Privacy Policy
Privacy Principles
Privacy Transparency Report
Responsible Stem Cell Use Position Statement 
Animal Testing Position Statement 
Ethical Artificial Intelligence Principles
KEY INITIATIVES

CY’22 CSR Report
73
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
The claims we make about our products must be 
truthful and accurate. All information we provide 
to our customers about our products, including 
those that are involved in providing health care 
services, must be consistent with the applicable 
label and consistent with local legal and regulatory 
requirements. 
Ethical Marketing
Affordability and Pricing 
Transparency 
Illumina is committed to offering prices that enable 
broad access to genomic technology. We maintain 
a responsible approach to pricing our products. We 
negotiate and partner with health care systems, 
payers, and research institutions to provide 
availability of our products at a fair net price. 
To support our customers and increase access, 
Illumina has:
•	Launched the NovaSeqTM X, a new production-
scale sequencer that will push the limits of what is 
possible with genomic medicine, enabling faster, 
more powerful, and more sustainable sequencing
•	Partnered with GenoScreen to expand capabilities 
for countries impacted by tuberculosis to more 
effectively detect and combat multidrug-resistant 
TB (MDR-TB). This will help advance the World 
Health Organization’s (WHO) strategy to end the 
global TB epidemic by 2035
•	Continued to expand the open offer program, which 
ensures a level playing field in the clinical oncology 
NGS market
	 Illumina sets and adjusts list prices based on 
several factors, including but not limited to costs, 
inflation, and market dynamics. Prices are available 
to customers through their account managers or 
online on myIllumina.com. Prices are also visible to 
customers on their invoices and billing statements. 
	 As in past years, Illumina’s price increases were at 
or below inflationary indices, while absorbing many 
of the temporary cost increases driven by global 
supply chain issues. For example, in the US in 2022, 
the Illumina annual price change was below the US 
Consumer Price Index (CPI). 
	 Illumina pricing reflects its value proposition and 
enables the company to continue to innovate for our 
customers and accelerate access to genomics for all.
Our Responsibilities 
•	Represent our products and services fairly, 
truthfully, and accurately. Promote them only for 
their approved uses
•	Do not create by statement or omission any 
misleading impressions in any advertising, 
marketing or sales materials, or in any presentations
•	Do not overstate the efficacy of our products, 
downplay or minimize the risks associated with 
our products, or make false or illegal claims about 
or comparisons to the products or services of a 
competitor
•	All advertising and promotional materials must 
adhere to our advertising and promotional materials 
guidelines and policies
•	Do not use messages or marketing materials that 
have not been properly reviewed and approved 
following company policy and procedure

CY’22 CSR Report
74
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
We are committed to respecting human rights and 
treating every stakeholder with dignity and respect. 
	 We acknowledge and respect the fundamental 
principles contained in the International Bill of Rights 
(i.e., United Nations Universal Declaration of Human 
Rights, International Covenant on Civil and Political 
Rights, and International Covenant on Economic, 
Social, and Cultural Rights), the International Labor 
Organization’s Declaration on Fundamental Principles 
and Rights at Work, and the United Nations Guiding 
Principles on Business and Human Rights. As a 
member of the United Nations Global Compact, 
Illumina is committed to integrating these principles 
into our strategy, our culture, our operations, and our 
relationships with business partners
KEY POLICIES
Human Rights Policy
Human Rights Policy—Japanese
Conflict-Free Minerals Policy
California Transparency in Supply Chains Act, UK Modern Slavery Act, 
& Australian Modern Slavery Act Disclosure Statement 2022
Upholding Human Rights 
for All Stakeholders
Key Pledges of Our Human Rights Policy 
•	Ethical business conduct 
•	Supplier Code of Conduct 
•	Right to exercise freedom of association 
•	Fair wages and working hours 
•	Protection of privacy 
•	Safe workplace 
•	Elimination of child and forced labor 
•	Equal opportunity
Read the full Human Rights Policy here
In 2021, we initiated a human 
rights impact assessment in 
alignment with the UN Guiding 
Principles. The assessment 
continued into 2022 as we 
evaluated internal policies, 
external disclosures, and worked 
to map actual and potential 
salient human rights impacts.
	 In 2022, we continued the 
evaluation with the goal of 
identifying Illumina's salient 
human rights impacts, Illumina's 
current practices for protecting 
and promoting these rights, 
and ways in which Illumina can 
continue to build on its human 
rights practices.
	 We reviewed the International 
Bill of Human Rights, the 
International Labor Organization's 
Declaration on Fundamental 
Principles and Rights at Work, 
and the United Nations Guiding 
Principles on Business and 
Human Rights.
We identified four salient human 
rights impacts:
•	Right to equality and non-
discrimination
•	Right to privacy
•	Right of everyone to the highest 
attainable standard of health 
and to enjoy the benefits of 
scientific progress and its 
applications
•	Right to Freedom from Forced 
Labor and Modern Slavery
	 We engaged with internal 
stakeholders across Illumina's 
departments to understand how 
Illumina impacts these salient 
human rights and to identify 
opportunities for growth relevant 
to each area.
	 We will continue to work across 
the business to continuously 
improve and support existing 
efforts.
Human Rights Impact Assessment

CY’22 CSR Report
75
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Our Privacy Principles 
Our Privacy Policy defines how we may use, maintain, protect, 
disclose, or transfer certain types of personal information in 
the provision of our products and services. How we handle 
personal information is aligned to our four fundamental privacy 
guiding principles: 
•	 Transparency 
•	 Ethical Use 
Key Initiatives in 2022
•	The cross-functional Privacy Core Team and Privacy Steering 
Committee brought together leaders from across the 
business to advance Illumina's privacy program
•	Submitted EU Binding Corporate Rules application (controller 
and processor) as a privacy program maturity effort regarding 
cross-border data transfers within the group
•	Achieved ISO 27701 certification for Illumina’s six cloud-based 
products for Privacy Information Management
•	Revised Illumina’s privacy and employee privacy policies to 
align with California’s Privacy Rights Act and evolving global 
privacy regulations
Uphold High Standards 
for Data Security and Privacy
As we expand access to genomics 
around the world, we must also 
respect and properly secure the 
resulting data.
Genomics data is powering positive progress 
around the world. We are committed to developing, 
upholding, and promoting high standards for genomic 
data privacy. We develop, implement, and review 
privacy-related policies, practices, and contractual 
language and ensure the integration of privacy as a 
priority throughout the company. Our Privacy Policy 
defines the way we use, maintain, protect, disclose, 
and transfer personal information.
•	 Responsible Stewardship 
•	 Accountability 
Learn More
Privacy Policy
Privacy Principles
Privacy Transparency Report

CY’22 CSR Report
76
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
The Five Pillars of Our Cybersecurity Commitment
1 

Program Governance
•	 Led by Chief Information Security 
Officer (CISO)
•	 CISO reports at least quarterly to the 
Board of Directors’ Audit Committee
•	 Annual assessment against 
National Institute of Standards and 
Technology (NIST) Cybersecurity 
Framework
•	 Employees and contractors trained 
annually
•	 Third-party work requires 
cybersecurity risk assessment prior 
to engagement
3 

Secure Product Design 
and Placement
•	 Products and systems secured and 
maintained throughout life cycle 
•	 Risk mitigation at earliest stages of 
product design and placement 
•	 Security design requirements 
•	 Cloud-based products aligned with 
ISO 27001 
•	 Privacy by design 
•	 Strong encryption standards 
•	 Strict data access controls
2 

Partnerships
•	 Healthcare Information Sharing and 
Analysis Center (H-ISAC)
•	 Domestic Security Alliance Council 
(DSAC)
•	 Information 2 Systems Security 
Association International (ISSA)
•	 Society for Information Management 
San Diego (SIM)
•	 Chief Information Security Officer 
Roundtable
•	 InfraGard
4 

Risk Analysis and 
Security Testing 
•	 Continuously assess cybersecurity 
risk 
•	 Perform internal and external 
security testing for all cloud software 
products 
•	 Regularly put cloud software 
products through static analysis 
•	 Incident response plan and team 
in place to handle cyber-related 
disruption with business continuity 
and contingency plans 
•	 Internal vulnerability analysis 
conducted 
•	 Internal tests deployed to represent 
simulated hacker attacks
5 

Data Protection 
•	 Data protected in compliance with 
applicable laws and cybersecurity 
best practices 
•	 Data privacy and data protection 
align with standards set by GDPR, 
CCPA, HIPAA, other regulations, and 
our Privacy Policy 
•	 CLIA laboratories ensure data quality 
and security with CLIA and regular 
HIPAA framework assessments 
•	 Backup capabilities encrypt and 
store data in immutable formats for 
data confidentiality and integrity 
•	 Amazon Web Services (AWS) hosts 
the Illumina BaseSpace Suite with 
additional security features
Cybersecurity Framework 
Our technologies and services inherently involve handling large amounts 
of genomic and health data that must be protected, making cybersecurity 
integral to achieving our company’s mission. 
KEY REFERENCES 
•	NIST Cybersecurity 
Framework 
•	ISO 27001 
•	ISO 13485 
•	General Data Protection 
Regulation (GDPR) 
Each October, we recognize 
Cybersecurity Awareness 
Month (CSAM), which provides 
heightened awareness regarding 
cybersecurity events, threats, 
attacks, and best practices that 
all employees can follow to help 
keep Illumina and its data safe 
from cyber threats.
2,486 
employees participated in 
our Cybersecurity Aware­
ness Month activities 
10% 
increase in total 
participation. Unique 
participants increased 
35% YOY
CYBERSECURITY 
AWARENESS MONTH 
•	California Consumer Privacy 
Act (CCPA) 
•	Health Insurance Portability 
and Accountability Act 
(HIPAA) 
•	Clinical Laboratory 
Improvement Amendments 
(CLIA) 
Learn More 
Cybersecurity Illumina Security Resources and Best Practices
Carissa Rolins
Chief Information Officer
 Strong cybersecurity measures are a necessary component of modern 
IT systems. Maintaining a safe and trustworthy platform for our customers 
and the communities we serve is fundamental to our business.

CY’22 CSR Report
77
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Foster a Responsible Supply Chain
Our suppliers are critical to our mission. Together, we magnify the positive 
impact to the customers we serve and the communities where we operate.
Supply Chain Overview 
Illumina’s global supply chain consists of suppliers, 
sub-contractors, channel partners, manufacturing 
sites, distribution centers, and customers. We 
consider it business-critical to work with suppliers 
who share our commitment to integrity and who 
support an ethical and compliant culture. We view 
our suppliers as partners in our effort to work 
toward a more equitable and sustainable future 
for all. 
We hold our suppliers to the same standards 
of business conduct that we set for ourselves. 
We require them to comply with the standards 
of behavior outlined in our Supplier Code of 
Conduct and exhibit social responsibility and 
environmental stewardship.
The Supplier Code of Conduct is consistent with 
commitments we made both as a signatory of the 
United Nations Global Compact and as a member 
of the Dow Jones Sustainability World Index. 
We expect our suppliers to: 
•	 Comply with local regulations and applicable US 
and international regulations 
•	 Uphold their employees’ human rights and the 
Illumina Human Rights Policy 
•	 Ensure a safe and healthy workplace 
•	 Demonstrate social and environmental 
responsibility 
•	 Conduct business in an ethical manner 
Social impact and environmental screening are 
included in our Request for Information (RFI) tools 
when evaluating potential suppliers. 
All new suppliers are required to acknowledge 
the Supplier Code of Conduct to complete the 
onboarding process. 
In 2022, we embedded the requirement for suppliers 
to commit to reducing their environmental footprint 
in our Supplier Code of Conduct and require our 
strategic suppliers to accept this with issuance of 
any purchase order.
Our suppliers range from off-the-shelf packaging 
material to highly sophisticated reagents. We define 
our supplier base by categories, segments, and 
classification. The categories include direct and 
indirect, with subcategories such as a segment 
classified as Strategic Suppliers. Classifications of 
suppliers depend on the product or service they 
provide, such as finished medical devices, spec, 
off the shelf, and services. We source components, 
software, equipment, and services from over 75 
countries across the world.
919
active diverse 
suppliers
$269M
diverse supplier 
spend
$694M
direct supplier 
spend
>$1B
estimated payments 
to suppliers 
3,323
suppliers across 
the supply chain
OUR SUPPLY CHAIN

CY’22 CSR Report
78
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Transparency in Supply Chains and UK 
Modern Slavery Act 
Illumina is committed to conducting its business 
lawfully and with integrity. We work to continually 
strengthen our practices to ensure no human 
trafficking, slavery, or forced or compulsory labor 
occurs in any part of our supply chains and global 
operations. We also seek to ensure that our global 
business partners do not use modern slavery in any 
of its forms in providing goods or services. In 2022, 
we updated our California Transparency in Supply 
Chains Act and UK Modern Slavery Act disclosure 
statements to include disclosures for the Australian 
Modern Slavery Act 2018. Additional information is 
available in our California Transparency in Supply 
Chains Act, UK Modern Slavery Act, and the 
Australian Modern Slavery Act disclosure statements. 
Conflict-Free Minerals 
Illumina supports international efforts to ensure 
no conflict minerals directly or indirectly benefit 
armed groups in the Democratic Republic of 
Congo or adjoining countries. To this end, Illumina 
expects all suppliers to commit to the Responsible 
Business Alliance (RBA) Code of Conduct. Through 
our Conflict-Free Minerals Policy we expect all 
our suppliers to establish their own due diligence 
program to ensure supply chains are free of conflict 
minerals and make those due diligence measures 
available to us upon request. Illumina routinely 
evaluates its suppliers to ensure they are adhering to 
our expectations and values.
Verification and Due Process 
We only build relationships with business partners 
that share our commitment to fulfilling all legal and 
ethical obligations. We never knowingly conduct 
business with business partners that employ 
underage individuals, employ forced labor, or use 
corporal punishment to discipline employees, 
regardless of whether such practices are permitted 
by law. 
	
We perform due diligence on new business 
partners to verify that they meet our standards. 
This process involves conducting initial risk 
assessments when onboarding new suppliers and 
conducting periodic assessments of performance. 
In addition, for supply chain areas of higher risk, we 
take steps to enhance our risk mitigation strategies. 
Prior to engaging in business with any supplier, we 
utilize tools that provide up-to-date sanction lists 
from governments around the world that identify 
companies and individuals involved in criminal 
activities such as money laundering, financing 
paramilitary groups, etc. In addition, we utilize 
tools to continuously monitor our supplier base for 
potential risk elements such as financial stability, 
leadership changes, global news, and others. 
	
We encourage all employees and business 
partners to report potential violations or concerns 
through a variety of formal channels, including 
our legal team and/or our Compliance and Fraud 
Prevention Reporting website or hotline.
Channel Partners 
Our products are available around the globe through 
a robust channel partner network. Our partners not 
only offer critical access to our products throughout 
the world but also provide the same level of sales, 
marketing, service, and support that we offer to 
customers directly. The Illumina Channel Partner 
Code of Conduct requires that channel partners 
match the Illumina commitment to business integrity, 
ethical conduct in the marketplace, adherence to all 
applicable laws, and the fundamental elements of 
human rights. Illumina is a member of the Advanced 
Medical Technology Association (AdvaMed) and 
MedTech Europe. Channel Partners are required to 
adhere to the applicable provisions of the AdvaMed 
Code of Ethics and MedTech Europe Code of Ethical 
Business Practice.
Supplier Sustainability 
In 2022, we assessed 100% of our supply chain as 
part of our Scope 3 emission data collection. 
Learn more about Supplier Sustainability →
Learn More 
Channel Partner Code of Conduct
California Transparency in Supply Chains Act & 
UK Modern Slavery Act Disclosure Statement 
Conflict-Free Minerals Policy

CY’22 CSR Report
79
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Supplier Diversity 
Our supplier diversity efforts aim to cultivate a supplier 
base that reflects the diversity of our communities, 
customers, employees, and the local economies where 
we operate. 
	
We recognize that a diverse supplier base provides a 
competitive business advantage by harnessing suppliers’ 
unique experiences and creative solutions. Our program, 
overseen by a Supplier Diversity Governance Committee, 
promotes partnership opportunities for suppliers in the 
US that are at least 51% owned, managed, and controlled 
by a qualifying diverse group.
These include, but are not limited to:
•	Woman-owned 
•	Minority-owned 
•	Veteran-owned 
•	Disabled person-owned 
•	LGBTQ-owned

	
Globally, we encourage the use of local businesses 
wherever possible to support the economies where our 
employees work and live. Our program is expanding to 
include woman-owned businesses in APAC and small 
businesses in Great Britain. 
	
As part of our operational controls to embed supplier 
diversity in our supplier management, we require a 
mandatory internal training certification on supplier 
diversity for our procurement sourcing managers through 
our learning management system (LMS). In 2023, we 
plan to include diversity screening in our Request for 
Information and Request for Proposal process further 
strengthening the operational controls to support 
diverse suppliers. 
Learn More
Supplier Code of Conduct 
Supplier Diversity Program
•	Socially and 
economically 
disadvantaged-
owned businesses 
•	Certified small 
businesses 
25% of total diverse 
supplier spend attributed 
to woman-owned 
businesses 
Active diverse 
suppliers 
2019: 400
2022: 919
Diverse supplier 
spend (US)
2019:  $190M
2022: $269M
20% 
spend with diverse 
suppliers (US) 
2030 TARGET
2022 PROGRESS
18% 
spend
35% of total diverse 
supplier spend attributed 
to minority-owned 
businesses

CY’22 CSR Report
80
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Supplier Quality Vision and Values 
To ensure the quality of our products, we have to 
ensure the quality of the components that we source. 
That is the rationale behind the Illumina Supplier 
Quality Vision, which is to construct and foster a 
leading supplier base that ensures safe and quality 
products every time. 
	 The supplier quality management life cycle 
incorporates the following phases: 
•	Initial risk assessments 
•	Qualification 
Working with our suppliers, we focus on the customer 
experience, continual improvement, effectiveness 
of our quality management system, and compliance. 
All Illumina Direct Tier 1 suppliers are subject to 
onboarding and qualification per Illumina Purchasing 
Controls. All products have traceability, and inventory 
is tracked via our inventory management system, 
SAP. Products may contain bar code, lot numbers, 
and/or unique identifiers.
Product Quality
Illumina is dedicated to being the leading provider of 
integrated solutions that advance the understanding 
of genetics and health. We achieve this through our 
focus on the customer experience, our commitment to 
continual improvement, maintaining the effectiveness 
of our quality management system, and complying 
with regulatory requirements. 
	 During 2022, we issued zero medical device 
product recalls that were reported to the FDA. 
There was one medical device voluntary recall 
that was not required to be reported to the FDA. 
There were five voluntary medical device recalls/
field actions that were reported to non-US national 
regulatory authorities and removed from the market 
or corrected. 
Learn More 
Supplier Quality Manual 
Quality Policy Statement
•	Audits 
•	Monitoring 
Quality Management Systems 
The following locations are certified to the ISO 
13485 Standard, which specifically covers the 
quality of medical devices: 
•	Foster City, CA 
•	San Diego, CA 
•	Hayward, CA 
•	Madison, WI 
•	The Netherlands 
•	Singapore 
•	Cambridge, UK 
Supplier Quality Management Cycle
A quality management system is a critical aspect at 
every stage of the product life cycle to ensure that 
policies and objectives are in place and product 
quality standards are of the highest caliber.
•	Supplier selection & evaluation
•	Supplier qualification
•	Supplier monitoring
•	Component qualification
100% 
Illumina core facilities1 participated in third-
party audit programs
1Core facilities defined as San Diego, Bay Area, Madison, 
Cambridge, UK, and Singapore.

CY’22 CSR Report
81
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Introduction
Appendix
Sustainability 
Message from the CEO
Strategic Approach and Impact           Corporate Governance           Compliance           Ethics and Integrity           Data Security and Privacy           Responsible Supply Chain           Public Policy
Make Responsible 
Public Policy Decisions
Illumina participates in the political and public policy 
process with governments and organizations around 
the world to engage and educate policymakers and 
key stakeholders on issues that impact our mission 
and business. 
	 Our interactions with policymakers must align 
with our core values, ethical responsibilities, and 
legal obligations. The Illumina Nominating/Corporate 
Governance Committee of our Board of Directors 
oversees our political policies and contribution 
practices. The Committee maintains responsibility 
for ensuring all Illumina political activities promote 
ethical and transparent engagement, advance the 
company’s mission, and comply with applicable laws 
and reporting requirements. On an annual basis, we 
provide an update on our public policy priorities, 
political contributions, lobbying expenditures, and 
information about significant memberships. Our 
Global Government Affairs team is responsible for 
advocacy activities. Illumina does not have a Political 
Action Committee but does retain outside strategic 
advisors who support our global engagement 
with policymakers and key stakeholders. These 
advisors may also provide expertise on policy and 
specific regional issues. 
	 Illumina complies with all applicable laws and 
requirements in connection with our global political 
and public policy activities. These laws generally 
require reporting on lobbying activities and compliance 
with applicable gift laws. 
	 Reports filed on behalf of Illumina are publicly available 
in the following government-hosted databases: 
Office of the Clerk, US House of Representatives 
Secretary of the Senate, US Senate
Lobbying Disclosure, California Secretary of State
Transparency Register, European Commission
Texas Ethics Commission
Advocating for public policies that ensure and enable 
broad access to genomic technologies is a priority. 
In 2022, we focused engagement with public policy 
stakeholders around: 
•	Advancement of precision medicine 
•	Adoption and reimbursement for genetic testing 
•	Adoption and reimbursement for NIPT 
•	Adoption and funding for genomic infectious disease 
surveillance 
•	Promoting STEM opportunities 
Proactive engagement with public policy stakeholders enables 
sharing accurate and reliable information about genomics and 
advocating for policies that promote broad access.
Learn More 
Political Contribution Policy
Political Contributions Spend Report, Trade 
Association and Significant Membership Report →
Trade Associations and Memberships 
Illumina participates in various trade associations for 
collaboration and the exchange of ideas. We pay annual 
dues to a number of trade and industry associations, 
some of which use a portion of membership dues for 
nondeductible state and federal lobbying and political 
expenditures. We disclose memberships in trade 
associations for which we contributed over $5,000 in 
the immediately preceding year, as well as the total 
amount of such dues. 
	 For trade association payments in excess of 
$50,000, we also disclose the portion of 
payments that are nondeductible under Section 
162(e)(1)(B) of the Internal Revenue Code, such 
as payments to organizations designated as 
501(c)(4) and 501(c)(6).
John Frank
Chief Public Affairs Officer
 As Illumina’s impact on clinical healthcare 
grows, government and industry stakeholders 
expect that we will engage with them on 
how genomics can better serve patients, 
individually and at global scale.

CY’22 CSR Report
82
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Appendix

CY’22 CSR Report
83
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
About this Report
Our report has been designed to provide a comprehensive and integrated view of our 
commitments, progress, and activities related to our corporate social responsibility 
program and most material environmental, social, and governance (ESG) themes. 
Boundaries and Exclusions
The boundary of this report includes only core Illumina activities. 
In 2021, Illumina acquired GRAIL. GRAIL must be held and operated separately 
and independently from Illumina pursuant to the interim measures ordered by 
the European Commission, which prohibited the Illumina/GRAIL transaction on 6 
September 2022 under the EU Merger Regulation. Data contained in this report 
does not reflect any GRAIL operations, financial results, or ESG data. 
Reporting Period
January 1, 2022, to December 31, 2022, unless otherwise indicated. 
Baseline Year
2019, unless otherwise indicated. 
Materiality
Based on the materiality assessment refreshed in 2021.
Currency References
US Dollars
Signatory Participation
•	United Nations Global Compact (UNGC)2
•	We Mean Business Coalition 1.5º 
•	UN Race to Zero
•	CEO Action for Diversity & Inclusion
•	UN Women Empowerment Principles
•	STEMM Opportunity Alliance
•	CEOs for Computer Science 
Reporting Frameworks
•	In accordance with the GRI standards
•	Sustainability Accounting Standards Board (SASB)
•	Task Force on Climate-related Financial Disclosures (TCFD)
•	UN Sustainable Development Goals
•	UN Global Compact
•	UN Universal Declaration of Human Rights
•	Dow Jones Sustainability Index
•	CDP1
•	Bloomberg Gender Equality Index
•	HRC Corporate Equality Index
•	ISO 26000 as reference to provide guidance for integration 
of social responsibility
Relevant Memberships 
•	Business for Social Responsibility (BSR)
•	World Economic Forum
•	Association of Corporate Citizenship Professionals (ACCP)
•	Chief Executives for Corporate Purpose (CECP)
•	CSR Board.Org
•	World 50
•	Sustainable Packaging Coalition
•	My Green Labs
Learn More
Illumina CSR and ESG microsite
Illumina ESG Reporting Hub
Contact
We welcome your feedback at csr@illumina.com
2In 2023, the UNGC has updated the Communication on Progress reporting to an online portal. To access Illumina's participant page Learn More.
1To access Illumina’s public facing CDP submission Learn More.
Re-statements
We conduct ongoing data review to ensure accuracy and consistency. 
Any material data changes would be identified. 
Assurance
Limited assurance has been provided in accordance with ISAE 3000 
and ISAE 3410 on the following topics: 
•	Scope 1, 2, and 3 GHG emissions data
•	Energy data
•	Water data
•	Human capital data
ESG Appendix Contents
	83	 About This Report
	84	 2030 Targets
	85	 Recognition
	86	 Key Performance Indicators
	
86	 About Illumina
	
86	 Accelerate Access to Genomics
	
86	 Empower Our Communities
	
87	 Integrate Sustainability
	
90	 Nuture Our People
	
97	 Operate Responsibly
	100	 GRI Index
	103	 SASB Index
	104	 TCFD Index
	105	 Assurance Statements
	106	 Disclosures

CY’22 CSR Report
84
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Our 2030 Targets
Accelerate 
Access to 
Genomics
Target 17.6: Knowledge sharing and 
cooperation for access to science, 
technology, and innovation
Target 3.d: Improve early warning 
systems for global health risks
Target 17.7: Promote sustainable 
technologies to developing countries
Target 17.16: Enhance the global 
partnership for sustainable 
development
Operate 
Responsibly
Target 9.2: Promote inclusive and 
sustainable industrialization
Target 10.3: Ensure equal 
opportunities and end discrimination
Target 17.16: Enhance the global 
partnership for sustainable 
development
Empower Our 
Communities
Target 5.b: Promote empowerment of 
women through technology
Target 10.3: Ensure equal 
opportunities and end discrimination
Integrate 
Sustainability
Target 12.2: Sustainable 
management and use of 
natural resources 
Target 12.5: Substantially reduce 
waste generation
Target 13.2: Integrate climate 
change measures into policy 
and planning
Nurture 
Our People
Target 10.3: Ensure equal opportunities and end discrimination
Our Focus Areas
  Enable $100 genome 
  Support 50,000 patients through philanthropic iHope programming 
  Achieve 2 billion covered lives by 2026 
  Invest in 200+ genomic startups
  Activate Pathogen Genomics Initiative donations enabling our 
$60 million commitments
  Reach at least 25,000 medical education learners annually
  Ensure 100% strategic suppliers committed to reducing their 
environmental footprint
  Achieve 20% spend with diverse suppliers (US)
  Achieve top industry ESG ratings
  Reach 5 million STEM learners 
  Donate 100,000+ volunteer hours 
  Achieve 50% employee participation in giving and volunteering
  Deliver net zero emissions 
(Scope 1,2,3) by 2050 
  Reduce emissions by 46% 
(Scope 1,2)
  Reduce emissions by 46% 
(Scope 3)
  Achieve 100% renewable 
electricity 
  Reach 90% landfill diversion 
at core sites 
  Reach 10% reduction in 
water intensity at core sites 
  Reduce packaging 
by 75% 
  Increase gender representation in global leadership 
  Maintain zero net pay gap 
  Increase minority representation in executive leadership (US) 
  Increase representation of Black, Native, Pacific Islander, 
Hispanic or Latino, 2 or more in US workforce and leadership
  Reduce recordable injury and illness rate
2030 Targets
1. Drive innovation and affordability
2. Catalyze genomic startups to broaden the genomic ecosystem
3. Increase genomic data diversity
4. Democratize genomics
5. Enable catalytic philanthropy
6. Expand reach with payer coverage, genomic literacy, 
and patient advocacy
1. Practice strong corporate governance
2. Maintain a culture of compliance
3. Act with integrity in all that we do
4. Foster a responsible supply chain
5. Uphold high standards for data security and privacy
6. Participate in proactive public policy
1. Provide meaningful and strategic community investment
2. Engage our people to be agents of social change
3. Drive equitable access to STEM education
1. Drive climate action
2. Operate sustainable facilities
3. Foster a sustainable value chain
4. Develop sustainable products
5. Leverage genomics for a healthier planet
1. Practice diversity, equity, and inclusion
2. Invest in our people
3. Create a culture of care
Objectives
UN SDG Target Alignment
  Invest $20 million in 
philanthropic sustainability 
initiatives 
  Have 100% of strategic 
suppliers commit to minimizing 
their environmental footprint
Achieved
In Progress

CY’22 CSR Report
85
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Recognition 2022
Workplace
•	Glassdoor Best Place to Work
•	BioSpace Best Place to Work
•	Refinitiv Top 100 Global D&I Index
•	Just Capital Top 100 US Companies 
Supporting Healthy Communities & Families
•	Just Capital Workforce Equity & Mobility
•	Wall Street Journal Top 250
Regional
•	SANDAG Green Commute Award San Diego
•	AmCham Cares CSR Singapore 
•	MIT Tech Review 50 Smartest Companies in China 
•	Water Efficiency Building (WEB) Singapore
•	Best Employer Straits Times Singapore
•	Workplace Safety Award Singapore
Leadership
•	Most Responsible CEO | Francis deSouza
•	Top Chief Human Resources Officer | Aimee Hoyt
•	Savoy Most Influential Black Exec | Kathryne Reeves
•	Forbes 50 over 50 | Susan Tousi
1 | 1 | 3

CY’22 CSR Report
86
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Key Performance Indicator Summary
Introduction
General
2022
Name of organization
Illumina, Inc.
Location of headquarters
San Diego, California, US
Number of global locations
33
Nature of ownership and legal form
Public Corporation
Revenue
$4.55 billion
Total capitalization (stockholder’s equity) market value as of 12/31/2021
$6.6 billion
5Y CAGR
11%
10Y CAGR
15%
R&D % revenue investment
22%
R&D spend
$1.1 billion
Building footprint1
2,649,068 square feet
Facility additions2
7
Facility closures3
2
Expand Access to Genomics
Access to Genomics
2022
Cost per genome4
~$200 
iHope™ patients supported in 2021
439
Total iHope™ patients supported since program inception
1,704
Clinical iHope™ network sites
28
Professional healthcare learners
>30,000
Illumina Accelerator companies funded through December 2021
74
NGS coverage outlook: total insured lives
1.2 billion
Footnotes:
1Average square feet during reporting year.
2Added lab support facilities in UK, commercial locations in Milan, Dubai, and Israel, and new manufacturing locations in 
Shanghai and Singapore.
3Moved warehouse from Eindhoven to Steenoven and moved Brazil office.
4Announced launch in 2022 based on US list price, assuming 120 Gb/genome, compared to NovaSeqTM 6000.
5 In order to be included in the Causes Database, an organization must meet their country’s NGO guidelines. Organizations are 
then evaluated against 1,200 watch lists and a number of National Taxonomy of Exempt Entities Codes (NTEE) that are also 
excluded from matching eligibility. Illumina currently blocks charitable organizations that have been found to discriminate 
against a specific race, religion, ethnicity, sexual orientation, or gender identity.
Empower Our Communities
Total Giving
2019
2020
2021
2022
Illumina, Inc. + Illumina Corporate Foundation + employee giving
$1,185,088 
$13,829,496 
$14,966,331 
$18,239,858
Illumina, Inc. + Illumina Corporate Foundation 
$873,088 
$13,255,768 
$14,446,500 
$17,676,194
Number of causes supported5
1,021
1,034
1,345
1,747
Illumina, Inc. Giving
2019
2020
2021
2022
In-kind product donations + cash grants
$560,088
$7,146,450
$9,409,966
$12,379,381
Illumina Corporate Foundation Giving
2019
2020
2021
2022
Employee giving
$312,000 
$573,728 
$519,831 
$563,664
Employee participation (giving)
19%
20%
26%
28%
Foundation match & volunteer rewards (Dollars for Doers)
$208,000 
$721,111 
$546,884 
$606,597
Charitable grants
$105,000 
$5,388,207 
$4,489,650 
$4,887,885
Total Foundation giving (not including employees)
$313,000 
$6,109,318 
$5,036,534 
$5,860,477
Volunteer Hours
2019
2020
2021
2022
Employee hours
13,980
4,236
8,772
20,142
Employee volunteering
29%
5%
10%
39%
Intern hours
140
1,237
800
520
Employee Participation
2019
2020
2021
2022
Total employee participation (giving + volunteering)
40%
24%
31%
50%
Summary of International Giving (Outside US)
2019
2020
2021
2022
Illumina, Inc.
NA
$2,894,129 
$7,044,842 
$5,994,599
Illumina Corporate Foundation
NA
$635,126 
$1,089,892 
$1,980,646
Number of countries
24
29
44
46
STEM
2019
2020
2021
2022
Number of teachers and students engaged in Illumina STEM programs
306,170
195,000
315,000
396,865

CY’22 CSR Report
87
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Footnotes:
1Renewable energy credits purchased for all non-renewable electric consumption.
General Notes:
* Denotes data has been assured.
• Boundary definition for energy and Scope 1 & 2 emission inventory: sites >30,000 square feet or contain manufacturing, distribution, or significant R&D activities.
• Boundary definition sites represent our jurisdictional control plus material locations accounting for 96% of our total 2019 baseline footprint.
• The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard is utilized as the methodology to calculate Scope 1 and Scope 2 emissions.
• Some segments may not add up to total due to rounding. 
Energy Consumption (Units: Gigajoules)
2019
2020*
2021*
2022*
Total fuel consumption from non-renewable sources
247,576
390,564
403,211
375,516
Total fuel consumption from renewable sources
0
0
0
0
Generation from renewable sources consumed by the organization
1,566
3,333
2,417
2,966
Total energy consumption from non-renewable sources
503,658
561,258
581,067
228,7121
Total energy consumption from renewable sources
1,566
3,333
9,077
375,516
Total energy consumption
505,224
564,591
590,144
604,228
Energy Consumption by Activity and Region (Units: Gigajoules)
2019
2020*
2021*
2022*
Total electricity (purchased + generated)
257,648
174,028
187,297
231,678
Purchased electricity
256,082
170,694
184,882
228,711.6
Generated electricity (on-site solar)
1,566
3,333
2,417
2,966.4
Total fuel
247,576
390,564
403,211
375,516
Natural gas
247,576
390,564
403,211
375,516
Total steam
0
0
0
0
Electricity, heating, cooling, steam sold
0
0
0
0
Total energy consumption AMR region
380,106
445,190
469,104
473,893
Total energy consumption EMEA region
47,779
35,072
36,358
36,308
Total energy consumption APAC region
75,752
80,996
84,681
94,026
Renewable Electricity Consumption
2019
2020
2021*
2022*
Percentage of global electricity consumption that is renewable
0.6%
2%
59%
100%
On-site solar generation
0.6%
2%
1%
1%
Renewable electricity purchased
0%
0%
3%
37%
Covered by Renewable Energy Credits
0%
0%
55%
62%
Emissions (Units: Metric Tons CO2e)
2019
2020*
2021*
2022*
Total Scope 1 & 2 (market-based) GHG emissions
34,404
36,573
26,265
18,902
Total Scope 1 & 2 (location-based) GHG emissions
34,404
36,573
36,914
39,924
Gross direct GHG emissions (Scope 1)
12,489
19,701
20,296
18,902
Gross market-based energy indirect GHG emissions (Scope 2) 
21,915
16,872
5,968
0
Gross location-based energy indirect GHG emissions (Scope 2) 
21,915
16,872
16,618
21,022
Regional Emissions Market-Based (Units: Metric Tons CO2e)
2019
2020*
2021*
2022*
Scope 1 & 2 AMR region
22,903
25,207
25,060
18,159
Scope 1 & 2 EMEA region
3,014
2,253
864
743
Scope 1 & 2 APAC region
8,488
9,113
341
743
Country-Specific Scope 1 Emissions (Units: Metric Tons CO2e)
2019
2020*
2021*
2022*
China
0
0
0
0
Netherlands
73
73
74
55
Singapore
0
0
0
0
United Kingdom of Great Britain and Northern Ireland
1,132
801
768
688
United States of America
11,284
18,827
19,454
18,159
Country-Specific Scope 2 Market-Based Emissions 
2019
2020*
2021*
2022*
China
388
518
0
0
Netherlands
384
368
8
0
Singapore
8,099
8,595
341
0
United Kingdom of Great Britain and Northern Ireland
1,425
1,011
14
0
United States of America
11,619
6,380
5,605
0
Integrate Sustainability
Key Performance Indicators
(Units: Metric Tons CO2e)

CY’22 CSR Report
88
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Greenhouse Gas Breakdown (Units: Metric Tons CO2e)
2019
2020*
2021*
2022*
CO2 Scope 1
12,475
19,681
19,884
18,518
CH4 Scope1
7
10
375
349
N20 Scope 1
6
10
37
35
Emission Intensity Ratios (Scope 1 & 2)
2019
2020*
2021*
2022*
GHG emission intensity per million dollars revenue
9.8
11.4
5.8
4.2
GHG emission intensity kgCO2e/square feet
13.8
15.1
10.4
7.5
GHG emission intensity per employee
4.4
4.7
2.9
1.8
Emission Intensity Ratio (Scope 3) 
2019
2020*
2021*
2022*
GHG emission intensity per million dollars revenue
72.6
71.3
66.1
78.8
Facility-Specific Emissions1,2
(Units: Metric Tons CO2e)
Scope 1
Scope 2 
Market-Based
Scope 2 
Location-Based
2021*
2022*
2021*
2022*
2021*
2022*
Cambridge, United Kingdom
749
681
0
0
903
971
Eindhoven, Netherlands
72
04
0
04
203
04
Foster City, California
1,359
1,506
1,403
1,403
1,906
Hayward, California
634
624
592
0
592
673
Madison, Wisconsin
1,458
1,554
2,138
0
2,138
2,695
Northcoast, Singapore
N/A
05
N/A
05
05
247
San Diego Headquarters, California
15,248
13,910
1,291
0
1,580
3,443
San Diego i3, California
756
564
134
0
200
325
San Diego Warehouse, California
0
0
47
0
74
96
Shanghai, China
0
0
0
0
358
220
Steenoven, Netherlands
2
55
8
0
218
541
Watson, United Kingdom
19
7
14
0
23
26
Woodlands, Singapore
0
0
341
0
8,927
9,556
Scope 3 Emissions (Units: Metric Tons CO2e)
2019
2020
2021*
2022*
Purchased Goods and Services (Category 1)3
72,915
100,351
138,563
131,929
Capital Goods (Category 2)3
39,940
44,057
79,530
83,071
Fuel- and Energy-Related Activities (Category 3)
6,956
5,785
9,048
8,590
Upstream Transportation & Distribution (Category 4)3
46,327
48,256
68,934
85,993
Waste Generated in Operations (Category 5)
236
617
1,055
1,275
Business Travel (Category 6)3
19,350
8,913
3,959
20,040
Employee Commuting (Category 7)3
18,012
7,567
7,616
15,027
Upstream Leased Assets (Category 8)
1,480
733
547
830
Downstream Transportation & Distribution (Category 9)
Assessed, not relevant
Processing of Sold Products (Category 10)
Assessed, not relevant
Use of Sold Products (Category 11)
6,968
4,850
9,221
11,865
End-of-Life Treatment of Sold Products (Category 12)
2,368
2,245
5,230
31
Downstream Leased Assets (Category 13)
Assessed, not relevant
Franchises (Category 14)
Assessed, not relevant
Investments (Category 15)3
23,559
19,038
0
0
Total Scope 3 Emissions 
238,110
242,411
323,702
358,651
Scope 3 Emissions: % of Total Scope 3 Emissions
2019
2020
2021*
2022*
Purchased Goods and Services (Category 1)3
31%
41%
43%
37%
Capital Goods (Category 2)3
17%
18%
25%
23%
Fuel- and Energy-Related Activities (Category 3)
3%
2%
3%
2%
Upstream Transportation & Distribution (Category 4)3
19%
20%
21%
24%
Waste Generated in Operations (Category 5)
0.1%
0.3%
0.3%
0%
Business Travel (Category 6)3
8%
4%
1%
6%
Employee Commuting (Category 7)3
8%
3%
2%
4%
Upstream Leased Assets (Category 8)
0.6%
0.3%
0.2%
0%
Use of Sold Products (Category 11)
3%
2%
3%
3%
End-of-Life Treatment of Sold Products (Category 12)
1%
0.9%
2%
0%
Investments (Category 15)3
10%
8%
0%
0%
Footnotes: 
1Facilities included in Scope 1 & 2 GHG Scope Boundary.
2Energy emission factor for fuel based on 2018 Climate Registry Default Emission Factors. Metric tons 
CO2e; GWP Reference: IPCC Fifth Assessment Report (AR5 – 100 year).
3Scope 3 material categories included in SBTi emission reduction and net zero targets.
4Eindhoven, Netherlands DC closed and moved to Steenoven, Netherlands.
5Northcoast, Singapore new facility opened in 2022.
General Notes: 
* Denotes data has been assured.
• Boundary definition for energy and greenhouse gas emission inventory: sites >30,000 square feet or contain manufacturing, distribution, or significant R&D activities. 
These sites represent our jurisdictional control plus material locations. This scope accounts for 96% of our total 2019 estimated baseline footprint.
• Refrigerant-specific data is not included.
• Some segments may not add up to total due to rounding.
• The Greenhouse Gas Protocol: A Corporate Value Chain (Scope 3) Accounting and Reporting Standard is utilized as the methodology to collect activity data and 
calculate Scope 3 emissions.
Integrate Sustainability continued
Key Performance Indicators

CY’22 CSR Report
89
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Water (Units: Megaliters)
2019
2020
2021*
2022*
Interactions with water: total water withdrawal (potable + recycled)
225
294
268
256
Water withdrawal (potable)
147
208
195
213
Water withdrawal (recycled)
78
86
74
43
Percentage of total water withdrawal in water stressed regions1
63%
62%
70%
66%
Water intensity (kiloliters by rentable square feet for core locations)2
0.10
0.12
0.11
0.10
% water consumption in AMR
97%
97%
97%
92%
% water consumption in EMEA
2%
1%
1%
2%
% water consumption in APAC
1%
2%
2%
6%
Total Waste (Units: Metric Tons)
2019
2020
2021
2022*
Total (hazardous + non-hazardous)
4,934
4,979
5,975
7,503
Global average non-hazardous diversion from landfill
51%
49%
49%
64%
Regional Waste Data AMR (Units: Metric Tons)
2019
2020
2021
2022*
Non-hazardous waste total
2,619
2,869
3,326
4,802
Hazardous waste total
902
699
605
594
Madison Site % diversion3
39%
43%
43%
43%
Foster City % diversion3
54%
48%
49%
66%
Hayward % diversion3
32%
22%
22%
70%
San Diego % diversion3
33%
36% 
31% 
42%
Regional Waste Data EMEA (Units: Metric Tons)
2019
2020
2021
2022*
Non-hazardous waste total
451
397
590
569
Hazardous waste total
67
35
55
79
Cambridge, UK % diversion3
100%
100%
100%
100%
Netherlands % diversion3
100%
100%
100%
100%
Regional Waste Data APAC (Units: Metric Tons)
2019
2020
2021
2022*
Non-hazardous waste total
424
437
504
750
Hazardous waste total
471
542
894
710
Singapore % diversion3
100%
100%
100%
100%
General Notes:
* Denotes data has been assured. (Units: Metric Tons CO2e).
Effluent & Waste by Type and Disposal Method
2019
2020
2021
2022*
Non-Hazardous Waste
Non-hazardous waste total
3,494
3,703
4,421
6,119
Reuse
0
0
0
0
Recycling
887
872
937
3,338
Composting
149
203
259
267
Recovery (including energy recovery)
760
729
977
366
Incineration
0
0
0
0
Deep well injection
0
0
0
0
Landfill
1,698
1,899
2,247
2,224
On-site storage
0
0
0
0
Other
0
0
0
0
Hazardous Waste
Hazardous waste total
1,440
1,276
1,552
1,075
Reuse
0
0
0
0
Recycling
413
489
332
65
Composting
0
0
0
0
Recovery (including energy recovery)
850
707
1,169
943
Incineration
62
34
41
47
Deep well injection
0
0
0
0
Landfill
37
20
6
8
On-site storage
0
0
0
0
Other
77
26
4
12
Integrate Sustainability continued
Key Performance Indicators
 (Units: Metric Tons)
Footnotes:
1 Water stressed regions listed on page 44.
2Core locations: San Diego HQ, i3 and Warehouse, Hayward, Foster City, Madison, Netherlands, Cambridge, and Singapore.
3% Diversion calculated using non-hazardous waste and % diverted from landfill.

CY’22 CSR Report
90
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Footnotes:
1 Percentage of all part-time employees.
2 Leadership: Manager, equivalent, and above. 
3 Executive leadership: Director and above.
Workforce Data
2019
2020
2021*
2022*
Total employees
7,802
7,828
9,191
10,257
Full-time employees
7,749
7,782
9,137
10,195
Part-time employees
53
46
54
62
Contingent workers
1,247
1,459
1,647
1,578
Age Group
Employees under 30
1,527
1,363
1,820
1,963
20%
17%
20%
19%
Employees 30–50
5,090
5,235
5,992
6,748
65%
67%
65%
66%
Employees over 50
1,185
1,230
1,379
1,546
15%
16%
15%
15%
AMR
Total employees
4,973
4,937
5,668
6,342
Full-time employees
4,954
4,918
5,650
6,324
Part-time employees
19
19
18
18
Contingent workers
971
1,182
884
726
APAC
Total employees
1,883
1,871
2,238
2,456
Full-time employees
1,882
1,871
2,238
2,456
Part-time employees
1
0
0
0
Contingent workers
164
146
588
726
EMEA
Total employees
946
1,020
1,285
1,459
Full-time employees
913
993
1,249
1,415
Part-time employees
33
27
36
44
Contingent workers
112
131
175
186
Gender Data
2019
2020
2021*
2022*
Workforce
Total women
3,334
3,342
4,076
4,596
43%
43%
45%
45%
Full-time women
3,293
3,305
4,036
4,543
43%
43%
45%
45%
Part-time women1
41
37
40
53
79%
80%
76%
86%
Temporary women
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Leadership
Women in leadership2
571
610
746
898
39%
40%
42%
41%
Women in executive leadership3
112
136
174
217
33%
36%
38%
38%
Women on Board of Directors
3
3
3
3
33%
30%
33%
33%
Total Women by Region
AMR
2,071
2,067
2,474
2,813
APAC
847
826
1,037
1,124
EMEA
416
449
565
659
Women in Leadership by Region
AMR
404
421
506
613
APAC
95
104
135
153
EMEA
72
85
105
132
Functional Group
Women in revenue-generating roles
41%
36%
48%
48%
Women in revenue-generating roles—management
35%
36%
42%
42%
Women in STEM-related roles (% of total STEM roles)
37%
37%
39%
39%
Women in IT roles
24%
23%
24%
24%
Women in engineering roles
37%
36%
29%
29%
Nurture Our People
Key Performance Indicators
General Notes:
* Denotes data has been assured. 
• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers. 
• Some segments may not add up to total due to rounding.

CY’22 CSR Report
91
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Footnotes:
1Minority defined as any EEOC category that is non-white/non-Caucasian. Does not include those who choose not to specify a race/ethnicity. 
2Leadership: Manager, equivalent, and above. 
3Executive leadership: Director and above.
General Notes:
* Denotes data has been assured. 
• Some segments may not add up to total due to rounding.
Percentage Female of Each EEOC Category (US)
2019
2020
2021*
2022*
White/Caucasian
41%
41%
43%
44%
Native Hawaiian or Other Pacific Islander
31%
27%
33%
31%
American Indian or Native Alaskan
50%
45%
50%
50%
Asian
44%
44%
45%
46%
Hispanic or Latino
39%
40%
44%
43%
Black or African American
37%
41%
45%
46%
2 or More
45%
46%
51%
51%
Choose not to self disclose
40%
40%
41%
37%
Percentage Male of Each EEOC Category (US)
2019
2020
2021*
2022*
White/Caucasian
59%
59%
57%
56%
Native Hawaiian or Other Pacific Islander
69%
73%
67%
69%
American Indian or Native Alaskan
50%
55%
50%
50%
Asian
56%
56%
55%
54%
Hispanic or Latino
61%
60%
56%
57%
Black or African American
63%
60%
55%
54%
2 or More
55%
54%
49%
49%
Choose not to self disclose
60%
60%
59%
63%
EEOC Minority Summary (US)
2019
2020
2021*
2022*
Total employees identifying in minority race and ethnicity statistics1
2,429
2,422
2,830
3,213
Minority of total employees1
49%
49%
50%
52%
Non-Minority of total employees1
46%
46%
45%
44%
Decline to state of total employees
5%
5%
5%
4%
Representation of Black, Native, Pacific Islander, 
Hispanic or Latino, 2 or more communities in workforce
17%
17%
17%
18%
Representation of Black, Native, Pacific Islander, 
Hispanic or Latino, 2 or more communities in leadership2
10%
11%
12%
13%
Minority representation in executive leadership3 
21% 
23%
27%
30%
EEOC Minority by Category (US)
2019
2020
2021*
2022*
White/Caucasian
2,284
2,253
2,514
2,756
46%
46%
45%
44%
Native Hawaiian or Other Pacific Islander
62
56
67
64
1%
1%
1%
1%
American Indian or Native Alaskan
10
11
13
15
<1%
<1%
<1%
0%
Asian
1,601
1,601
1,863
2,097
32%
33%
33%
34%
Hispanic or Latino
447
435
510
588
9%
9%
9%
9%
Black or African American
121
121
130
146
2%
2%
2%
2%
2 or More
188
198
248
303
4%
4%
4%
5%
Choose not to self disclose
240
238
294
241
5%
5%
5%
4%
Veteran
143
141
145
157
3%
3%
3%
3%
Disabled
248
235
230
223
5%
5%
4%
4%
Nurture Our People continued
Key Performance Indicators
Percentage Gender by Level 2022*
Male 2022*
Female 2022*
Undisclosed 2022*
Support to Entry Professional
51% 
49%
1%
Intermediate to Senior Professional
55%
44%
1% 
Supervisor to Assoc Director
56%
44%
1%
Director and Senior Director
59%
41%
1%
VP
63%
37%
0%
SVP / C suite
64%
36%
0%
Board of Directors
67%
33%
0%
Learn More: Federal Employer Information EEO-1 Report

CY’22 CSR Report
92
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
EEOC Data by Level (US)
2019
2020
2021*
2022*
Support to Entry Professional
White/Caucasian
261
226
264
255
24%
23%
23%
23%
Native Hawaiian or Other Pacific Islander
29
31
34
29
3%
3%
3%
3%
American Indian or Native Alaskan
3
2
3
4
<1%
<1%
<1%
<1%
Asian
489
452
514
485
45%
45%
45%
44%
Hispanic or Latino
173
160
185
191
16%
16%
16%
17%
Black or African American
48
38
38
36
4%
4%
3%
3%
2 or More
57
56
65
83
5%
6%
6%
7%
Choose not to self disclose
38
34
35
26
3%
3%
3%
2%
Intermediate to Senior Professional
White/Caucasian
1,403
1,389
1,555
1,721
50%
48%
48%
46%
Native Hawaiian or Other Pacific Islander
22
16
21
22
1%
1%
1%
1%
American Indian or Native Alaskan
4
6
7
9
<1%
<1%
<1%
<1%
Asian
895
938
1,078
1,292
32%
33%
33%
34%
Hispanic or Latino
199
201
243
300
7%
7%
7%
8%
Black or African American
51
56
63
75
2%
2%
2%
2%
2 or More
105
115
150
181
4%
4%
5%
5%
Choose not to self disclose
143
146
191
147
5%
5%
6%
4%
EEOC Data by Level (US)
2019
2020
2021*
2022*
Manager to Associate Director 
White/Caucasian
413
421
452
508
54%
56%
55%
54%
Native Hawaiian or Other Pacific Islander
11
9
11
12
1%
1%
1%
1%
American Indian or Native Alaskan
2
2
1
0
<1%
<1%
<1%
0%
Asian
182
174
214
243
24%
23%
26%
26%
Hispanic or Latino
65
61
70
82
9%
8%
8%
9%
Black or African American
17
21
22
26
2%
3%
3%
3%
2 or More
22
21
23
28
3%
3%
3%
3%
Choose not to self disclose
46
48
51
49
6%
6%
6%
5%
Director and Above
White/Caucasian
207
217
243
272
75%
75%
70%
67%
Native Hawaiian or Other Pacific Islander
0
0
1
1
0%
0%
<1%
<1%
American Indian or Native Alaskan
1
1
2
2
<1%
<1%
1%
<1%
Asian
35
37
57
77
13%
13%
16%
19%
Hispanic or Latino
10
13
12
15
4%
4%
3%
4%
Black or African American
5
6
7
9
2%
2%
2%
2%
2 or More
4
6
10
11
1%
2%
3%
3%
Choose not to self disclose
13
10
17
19
5%
3%
5%
5%
General Notes:  * Denotes data has been assured.    • Some segments may not add up to total due to rounding.
Learn More: Federal Employer Information EEO-1 Report
Nurture Our People continued
Key Performance Indicators

CY’22 CSR Report
93
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
New Hire Data
2019
2020
2021*
2022*
New Hire by Age Group1
Employees under 30
458
380
990
860
30%
28%
54%
44%
Employees 30–50
716
586
1,358
1,320
14%
11%
23%
20%
Employees over 50
89
88
156
140
8%
7%
11%
9%
New Hire by Gender2
New female employee hires
566
490
1,185
1,049
17%
15%
29%
23%
New male employee hires
684
560
1,262
1,240
15%
12%
25%
22%
New Hire by Region
AMR new employee hires
707
629
1,479
1,315
14%
13%
26%
21%
APAC new employee hires
376
249
621
621
20%
13%
28%
25%
EMEA new employee hires
180
176
404
384
19%
17%
31%
26%
Percentage New Hire per EEOC (US)
White/Caucasian
44%
47%
40%
39%
Native Hawaiian or Other Pacific Islander
1%
<1%
1%
1%
American Indian or Native Alaskan
<1%
<1%
<1%
<1%
Asian
32%
33%
34%
35%
Hispanic or Latino
10%
7%
10%
11%
Black or African American
2%
4%
2%
3%
2 or More
7%
6%
7%
6%
Choose not to self disclose
5%
3%
6%
4%
Promotion Data
2019
2020
2021*
2022*
Total number of employees promoted
1,502
1,568
2,583
2,436
Promotion Rate by EEOC (US)
2019
2020
2021*
2022*
White/Caucasian
22%
20%
34%
26%
Native Hawaiian or Other Pacific Islander
19%
10%
34%
24%
American Indian or Native Alaskan
0%
29%
33%
21%
Asian
23%
20%
37%
25%
Hispanic or Latino
19%
19%
34%
17%
Black or African American
14%
15%
33%
25%
2 or More
20%
18%
37%
38%
Choose not to self disclose
21%
22%
35%
21%
Veteran Data (US)
2019
2020
2021*
2022*
Number of US employees, regardless of whether 
they have any military connection
4,908
4,866
5,561
6,210
Number of employees as defined by the federal government 
as meeting the criteria for protected veteran status
87
87
90
92
Number of veteran and active duty employees, 
regardless of protected status
143
141
145
157
Number of disabled veteran employees
2
2
3
3
Number of women veteran employees
24
20
26
27
Number of minority veteran employees—minority veterans include, 
but are not limited to, people of color, women, LGBTQIA+, and (non) 
religious minorities
67
68
75
80
Percentage of Veterans (US)
3%
3%
3%
3%
Other Identities Self Reported (US)
2019
2020
2021*
2022*
LGBTQ (US)
1%
1%
2%
3%
Disabilities (US)
3%
5%
4%
4%
Footnotes:
1 Percentage data for new hire by age represents the percentage of the total age group headcount for the reporting year. 
2Represents percentage of new hires out of all female employees. 
Nurture Our People continued
Key Performance Indicators
General Notes:
* Denotes data has been assured. 
• For all gender statistics, percentage of women is based on number of employees who identify as male or female, not total number of Illumina employees.
• Some segments may not add up to total due to rounding.

CY’22 CSR Report
94
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Employee Turnover Data
2019
2020
2021*
2022*
Total Turnover
Total number of employee turnover
856
1,028
1,154
1,246
Rate of employee turnover
11%
14%
14%
13%
Total number of voluntary turnover
644
714
1,048
1,050
Rate of voluntary turnover
9%
9%
12%
11%
Turnover by Age
Employees under 30
229
224
246
308
15%
16%
15%
16%
Employees 30–50
489
638
749
787
10%
12%
13%
12%
Employees over 50
138
166
159
151
12%
14%
12%
10%
Voluntary employee turnover under 30
195
182
233
279
13%
13%
15%
15%
Voluntary employee turnover 30–50
366
456
686
654
7%
9%
12%
10%
Voluntary employee turnover over 50
82
76
129
117
7%
6%
10%
8%
Turnover by Level
Voluntary turnover support to entry professional
11%
11%
14%
16%
Involuntary turnover support to entry professional
3%
5%
1%
2%
Voluntary turnover intermediate to senior professional
8%
8%
12%
9%
Involuntary turnover intermediate to senior professional
2%
4%
1%
2%
Voluntary turnover manager to associate director
6%
8%
11%
10%
Involuntary turnover manager to associate director
4%
4%
2%
1%
Voluntary turnover director and above
6%
13%
17%
9%
Involuntary turnover director and above
4%
4%
3%
2%
General Notes:
* Denotes data has been assured. 
• Some segments may not add up to total due to rounding.
Employee Turnover Data
2019
2020
2021*
2022*
Total Turnover by Region
AMR
530
666
763
646
11%
13%
14%
11%
APAC
223
261
251
405
12%
14%
12%
17%
EMEA
103
101
140
195
11%
10%
12%
14%
Voluntary Turnover by Region
AMR
384
442
701
586
8%
9%
13%
10%
APAC
188
207
224
315
10%
11%
11%
13%
EMEA
72
65
123
149
8%
7%
11%
11%
Voluntary Turnover Percentage by EEOC (US)
White/Caucasian
8%
10%
13%
9%
Native Hawaiian or Other Pacific Islander
11%
10%
5%
17%
American Indian or Native Alaskan
0%
0%
25%
7%
Asian
7%
8%
13%
11%
Hispanic or Latino
8%
7%
14%
10%
Black or African American
11%
12%
16%
12%
2 or More
6%
11%
21%
9%
Choose not to self disclose
6%
8%
13%
13%
Nurture Our People continued
Key Performance Indicators

CY’22 CSR Report
95
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Parental Leave
2019
2020
2021
2022
Total number of employees who were entitled to 
parental leave
4,714
4,900
5,302
5,916
Total number of employees who took parental leave, 
by gender
Female 116
Male 65
Female 181
Male 121
Blank 1
Female 173
Male 89
Female 236
Male 128
Blank 1
Total number of employees who returned to work in the 
reporting period after parental leave ended, by gender
Female 116 
Male 65
Female 191 
Male 138 
Blank 1
Female 166
Male 123
Female 226
Male 121
Blank 1
Total number of employees who returned to work after 
parental leave ended that were still employed 12 months 
after their return to work, by gender
Female 100
Male 54
Female 177
Male 123
Blank 1
Female 150
Male 107
Female 192
Male 102
Blank 1
Return to work and retention rates of employees who 
took parental leave, by gender
Return to Work: 
Female 100%
Male 98%
Retention:
Female 86%
Male 83%
Return to Work: 
Female 100%
Male 98%
Retention:
Female 86%
Male 83%
Return to Work: 
Female 98%
Male 99%
Retention:
Female 93%
Male 89%
Return to Work: 
Female 97%
Male 100%
Retention:
Female 85%
Male 84%
Benefit Plan and Other Retirement
2019
2020
2021
2022
Percentage of salary contributed by employee 
or employer
US 401(k): Employee elected between 0–80%, Illumina matching contribution 
of 50% up to the first 6% employee election (3% of eligible salary)
Level of participation in retirement plans, such as 
participation in mandatory or voluntary schemes, 
regional or country-based schemes, or those with 
financial impact
US 401(k): 97% employee 
voluntary participation
US 401(k): 98% employee 
voluntary participation
Employee Bonus and Stock Program
2019
2020
2021
2022
Employees eligible for annual VCP bonus
All employees
Employees eligible to participate in employee stock 
purchase plan
All employees
Average Compensation Ratio—Women to Men
2019
2020
2021
2022
Across all employee categories
100%
100%
100%
99%
Support to entry professional
102%
102%
101%
100%
Intermediate to senior professional
100%
100%
99%
99%
Supervisor to associate director
98%
99%
100%
99%
Director and above
101%
98%
99%
98%
Annual Compensation Ratio
2019
2020
2021
2022
Ratio of annual total compensation for the organization's highest-paid 
individual in each region to the median annual total compensation for 
all employees
Refer to 
Proxy Filing 
Refer to 
Proxy Filing 
Refer to 
Proxy Filing 
Refer to 
Proxy Filing
Training
2019
2020
2021
2022
Average hours of training per employee per year
60
64
64
62
Hours of training by gender: Male
60
66
66
63
Hours of training by gender: Female
61
61
63
60
Hours of training by employee category: Individual Contributor
64
68
68
66
Hours of training by employee category: Middle Management
71
76
76
70
Hours of training by employee category: Senior Management
38
38
44
39
Hours of training by employee category: Executive Leadership
22
24
30
26
Hours of training by functional category: Commercial Operations
50
46
52
51
Hours of training by functional category: General Operations
23
25
27
25
Hours of training by functional category: Manufacturing
91
104
98
96
Hours of training by functional category: Research & Development
53
57
62
58
Total number of hours devoted to training on human rights
1,737
5,578
3,333
4,726
Applicable employees certified to Code of Conduct
99%
98%
97%
97%
Footnotes:
1 Following the birth of a child or placement of a child for adoption or foster care, we provide 100% pay continuity to eligible US-based employees for up to 
six weeks to help ensure peace of mind during this essential time. In some cases, a mother could receive up to 28 weeks of pay continuity depending on 
the combination of leaves associated with childbirth. Our parental leave policies in the other locations where we operate either meet or exceed local legal 
entitlements. 
2 Employee survey participation rates in 2019 are calculated using an average of two surveys per year (Q2 and Q4 of each year). For 2020, the participation 
rate is based on an average of three quarterly surveys (Q2–Q4). For 2021, the participation rate is based on an average of four quarterly surveys (Q1-Q4). For 
2022, one survey was completed.
General Notes:
• For all training hour metrics, the values include only regular Illumina employees, not contingent workers.
Nurture Our People continued
Key Performance Indicators
Performance & Career Development Review
2019
2020
2021
2022
Percentage of employees receiving regular 
performance and career development reviews 
(includes all administrative, production, technical, 
middle management, and senior management)
100%
100%
100%
100%
Employee Survey2
2019
2020
2021
2022
Participation rate for employee iPulse survey
89%
79%
80%
86%

CY’22 CSR Report
96
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Health & Safety
2019
2020
2021
2022
Global recordable injury or illness incident rate (incident per 
100 employees)
0.52
0.34
0.54
0.23
Lost time incident rate
0.74
0.18
0.23
0.12
Days Away Restricted Time (DART)
0.34
0.18
0.43
0.17
Environment, Health & Safety notices of violations
0
0
0
0
Environmental fines
0
0
0
0
Prevention reporting statistics
3,611
3,018
1,452
2,054
Employee Safety
2019
2020
2021
2022
Number of work-related fatalities
0
0
0
0
Rate of work-related fatalities
0
0
0
0
The number of high-consequence work-related injuries and 
illnesses (excluding fatalities)
49
29
51
23
The rate of high-consequence work-related injuries and 
illnesses (excluding fatalities)
0.62
0.39
0.16
0.24
The number of recordable work-related injuries and illnesses
49
29
51
23
The rate of recordable work-related injuries and illnesses
0.62
0.39
0.16
0.24
The main types of work-related injury and illness
Ergonomics, 
strains, 
contusions, 
and sprains
Ergonomics, 
strains, 
contusions, 
and sprains
Ergonomics 
and strains 
Ergonomics, 
strains, 
contusions, 
and sprains
The number of hours worked
15,647,395
15,344,520
15,946,780
19,462,592
Safety Workers Who Are Not Employees but Whose Work 
and/or Workplace is Controlled by the Organization
2019
2020
2021
2022
Number of work-related fatalities
0
0
0
0
Rate of work-related fatalities
0
0
0
0
The number of high-consequence work-related injuries and 
illnesses (excluding fatalities)
0
3
2
3
The rate of high-consequence work-related injuries and illnesses 
(excluding fatalities)
0
0.07
0.13
0.18
The number of recordable work-related injuries and illnesses
0
3
2
3
The rate of recordable work-related injuries and illnesses
0
0.07
0.13
0.18
The main types of work-related injury and illness
Ergonomics, 
Strains, 
Contusions, 
and Sprains
Ergonomics, 
Strains, 
Contusions, 
and Sprains
Fractures 
and strains
Ergonomics, 
strains, 
contusions, 
and sprains
The number of hours worked
2,741,396
2,798,888
2,986,473
3,296,423
General Notes:
• Recordable injury & illness rate calculated using total hours worked from employees + contingent workers.
• Contingent workers: workers who are not employees but whose work and/or workplace is controlled by the organization.
• Lost time incident rate calculated using total hours worked from employees—contingent workers.
• High-consequence work-related injuries are defined as all recordable injuries.
• Rates have been calculated based on 200,000 hours worked.
• DART: Days Away, Restricted, Or Transferred.
• Ergonomic injuries include repetitive stress injuries.
Nurture Our People continued
Key Performance Indicators
Environmental, Health & Safety Training
Total hours of EHS training
26,758
30,054
43,066
45,022
Average hours per employee
3.7
3.4
4.1
4

CY’22 CSR Report
97
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Governance
2019
2020
2021
2022
Non-compliance with environmental laws and regulations; Significant 
fines and non-monetary sanctions for non-compliance with 
environmental laws and/or regulations
0
0
0
0
# of FDA recalls
0
0
0
0
Number of substantiated complaints concerning breaches of customer 
privacy and losses of customer data
0
0
0
0
Number of public legal cases regarding corruption brought against the 
organization or its employees during the reporting period 
0
0
0
0
Antitrust Cases
2
0
See notes
See notes
Nature and total number of critical concerns communicated to highest 
governance body regarding CSR topics
0
0
0
0
Total employees covered by collective bargaining agreements
0
0
0
0
Incidents of discrimination and corrective actions taken
See note 3
See note 3
See note 3
See note 3
Transparency Reporting Law Enforcement & National Security Requests
N/A
2020 Privacy
Transparency 
Report
2021 Privacy
Transparency 
Report
2022 Privacy
Transparency 
Report
Security personnel are trained in organization’s policies or procedures 
concerning aspects of human rights that are relevant to operations.
N/A
N/A
N/A
Yes
The organization is unaware of any operations in which there is a 
significant risk for incidents of child labor.
N/A
N/A
N/A
Confirmed
The organization is unaware in which there is a significant risk for 
incidents of forced or compulsory labor.
N/A
N/A
N/A
Confirmed
1. On January 11, 2021, Complete Genomics, Inc., BGI Americas Corp., and MGI Americas, Inc. (collectively BGI) filed a complaint in the 
US District Court for the Northern District of California alleging that Illumina violated federal antitrust and state unfair competition laws, 
based on a patent infringement suit Illumina filed against BGI in the same court. Illumina denies the allegations, which are without merit. 
In July 2022, Illumina and BGI settled all US litigation, and the case was dismissed. 
2. On March 30, 2021, the United States Federal Trade Commission (FTC) filed an administrative complaint alleging that Illumina’s 
acquisition of GRAIL, Inc. violates federal antitrust law. Following a full trial on the merits, in September 2022 the FTC’s Chief 
Administrative Law Judge’s (ALJ) rejected the FTC’s complaint and found in favor of Illumina. On April 3, 2023, the FTC overturned the 
ALJ’s rejection of the FTC complaint, and the FTC issued an opinion and order requiring Illumina to divest GRAIL. Illumina has filed a 
petition for expedited review with a US Court of Appeals, and the FTC’s order to unwind the acquisition will be automatically stayed 
pending appeal.
3. During the past thirteen years, neither the EEOC nor any court or administrative agency has issued a finding against Illumina in a 
claim involving discrimination. There was one claim of discrimination filed during the reporting period. Illumina denies the allegation. 
The matters that were pending during the last reporting period have been resolved. We do not tolerate acts of discrimination, and 
promote an open culture to report concerns (including anonymously). Illumina takes all reports of misconduct seriously and has a strict 
non-retaliation policy. If a report is substantiated, the company would respond as it deems appropriate or necessary, consistent with 
the law, and will act swiftly to correct the problem and deter future occurrences. Depending on the circumstances, this may include 
training and/or disciplinary action up to, and including, termination. Individuals may also be subject to civil or criminal prosecution for 
violating the law.
ESG Governance Topics
Position
Level from CEO
Level from Board
Corporate Social Responsibility / ESG
SVP, Chief Public Affairs Officer
1
2
Environment, Health & Safety, Supply Chain, 
Facilities, Operations
SVP, Chief of Global Operations
1
2
People, Employment, Diversity, Equity, and Inclusion
SVP, Chief People Officer
1
2
Compliance, Ethics, Legal
SVP, General Counsel
1
2
Product
SVP, Chief Technology Officer
1
2
Cybersecurity
SVP, Chief Information Officer
1
2
Finance, Investor Relations, Internal Audit
SVP, Chief Financial Officer
1
2
Board of Directors (BoD)
2022
BoD level oversight for CSR and ESG (including themes of sustainability and climate action; diversity, equity, and 
inclusion; human rights; cybersecurity; data privacy; and ethical and responsible business practices)
Yes
Clawback provision
Yes
Commitment to gender diversity on BoD
Yes
BoD composition by gender (% female)
33%
BoD composition by racial/ethnic minority representation
33%
Number of Directors
9
Number of Indepenent Directors
8
Average Board Tenure
6.6 years
Operate Responsibly
Key Performance Indicators

CY’22 CSR Report
98
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Supply Chain
2019
2020
2021
2022
Quantity of product shipped
3,118,142 units
3,297,561 units
3,862,839 units
3,752,857 units
Spend with direct suppliers
$440 million
$396 million
$585 million 
$694 million
Supplier Code of Conduct in place
Yes
Yes
Geographic location of suppliers
Countries: AE, AM, AR, AT, AU, BE, BS, CA, CH, CL, 
CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, ID, 
IE, IL, IN, IS, IT, JP, KR, LT, LU, MO, MX, MY, NL, NO, 
NZ, PA, PE, PH, PL, PT, RO, RU, SE, SG, SI, TH, TR, 
TW, UA, US, UY, VN, ZA
Countries: AE, AM, AR, AU, AU, BE, BR, BY, 
CA, CH, CL, CN, CR, CZ, DE, DK, EE, ES, FI, FR, 
GB, GH, HK, ID, IE, IL, IND, IS, IT, JP, KR, LT, 
LU, MY, MX, NL, NO, NZ, PE, PH, PL, PT, RU, 
SA, SE, SG, TH, TR, TW, UA, US,
UY, ZA
Countries: AE, AM, AR, AT, AU, BE, BG, BR, CA, 
CH, CN, CO, CZ, DE, DK, ES, FI, FR, GB, GH, 
HK, ID, IE, IL, IN, IT, JP, KR, LK, LT, LU, LV, MY, 
NL, NO, NZ, PL, RO, RU, SA, SE, SG, SI, TH, 
TR, TW, US, ZA
Countries: US, DE, CA, GB, SG, CH, JP, PL, FR, 
AU, ZA, BE, NZ, IT, CN, NL, DK, NO, MY, IN, 
ES, IS, SE, IL, PT, AR, HK, AM, KR, UA, IE, BN, 
ID, BD, EC, AT, FI, TW, MO, LU, VN, TR, LK, AE, 
MX, CZ, RU, RO, TH, BR, LV, CR, PH, BY, UY, 
SA, HU, SI, GR, PK, CY, BG, LT, RS, BO, PY, NG, 
KY, GT, PA, SV, KE, EE, PE, CL, CO
A description of the organization’s supply chain
Illumina’s global supply chain consists of suppliers, sub-contractors, channel partners, manufacturing sites, distribution centers, and customers
Types of suppliers
Direct, indirect, strategic, finished medical device, custom spec, off the shelf, and services
Number of suppliers engaged by organization
3,891
3,704
3,798
3,323
Estimated monetary value of payments made to suppliers
>$1 billion
$935 million
>$1 billion
>$1 billion
Number of active diverse suppliers (US)
>400
334
517
919
Diverse supplier spend
$190 million
$152 million
$209 million
$269 million
Percentage of total PO spend with diverse suppliers (US)
19%
16%
17%
18%
Percentage of strategic suppliers that have committed to minimizing their 
environmental footprint
N/A
75%
84%
89
% of total PO Spend with total diverse suppliers (Global)
N/A
N/A
N/A
13%
Key Performance Indicators
Operate Responsibly continued

CY’22 CSR Report
99
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Political Contributions
2019
2020
2021
2022
Total monetary value of financial and in-kind political contributions 
made directly and indirectly by the organization by country and 
recipient/beneficiary
$50,000 
$0 
$0 
$0
Trade Association & Memberships
2021
2022
Illumina participates in various trade associations and industry memberships for collaboration and exchange of ideas. Some of these organizations may 
utilize a portion of membership fees for non-deductible state and federal lobbying and political expenditures. As part of our transparency practices, we 
disclose trade memberships for which we contribute at least $5,000 annually in fees.
Trade and Industry Group Memberships Above $5,000 Threshold Annually
Global
World Economic Forum
$330,000
$330,000
EMEA Trade Association Memberships
All.Can (ASBL)
$35,000
$32,204
EUCOPE
$27,892
$19,322
US Qatar Business Council
$10,000
$10,000
US Saudi Arabian Business Council
$10,000
$10,000
US UAE Business Council
$10,000
$10,000
International Quality Network for Pathology (IQN Path)
$5,000
$0
APJ and Greater China Trade Association Memberships
US India Business Council
$27,500
$20,000
Pathology Technology Australia
$7,309
$20,868
US Chamber — China 
$25,000
$25,000
US-China Business Council (USCBC)
$15,000
$15,000
US-ASEAN
$11,686
$14,500
AmCham China
$7,413
$4,026
U.S. Trade Association Memberships
World 50, Inc.
$393,766
$240,850
US Chamber of Commerce
$150,000
$160,000
Coalition for Access to Prenatal Screening (CAPS)
$100,000
$100,000
Access to Comprehensive Genomic Profiling Coalition
$80,813
$75,000
Procurement Leaders 
$57,000
$58,710
Biocom
$56,300
$57,500
American Clinical Laboratory Association (ACLA)
$50,000
$50,000
Coalition for 21st Century Medicine
$50,000
$50,000
Personalized Medicine Coalition (PMC)
$32,000
$32,000
California Chamber of Commerce
$25,000
$0
San Diego Economic Development Corp. (SDEDC)
$25,000
$25,000
National Association of Manufacturers (NAM) 
$24,500
$24,500
AdvaMed
$19,950
$19,950
American Cancer Society—Cancer Action Network (ACS-CAN)*
$10,000
$0
San Diego Regional Chamber of Commerce (SD Chamber)
$7,650
$7,650
Industrial Environmental Association (IEA)
$6,000
$6,000
Healthcare Business Women's Association (HBA)
$5,000
$5,000
For the trade associations with membership fees greater than $50,000, the portion of such payments that is non-deductible under Section 162(e)(1)
(B) of the Internal Revenue Code, such as payments to organizations designated as 501(c)(4) and 501(c)(6) associated with state and federal lobbying 
efforts annually.
Organization
Total Annual Membership Fee
% Membership Fees Used for 
State or Federal Lobbying
Dollars Applied to State 
or Federal Lobbying From 
Membership Fees
2021
2022
2021
2022
2021
2022
US Chamber of Commerce
$161,625
$160,000
25%
35%
$40,406 
$56,000
Coalition for Access to 
Prenatal Screening (CAPS)
$100,000
$100,000
25%
$0
$25,000
$0
American Clinical Laboratory 
Association (ACLA)
$50,000
$50,000
33%
30%
$16,500 
$29,500
Biocom
$56,300
$57,500
10%
10%
$5,630 
$5,750 
Coalition for 21st 
Century Medicine
$50,000
$50,000
45%†
30%
$22,500†
$15,000
Operate Responsibly continued
Key Performance Indicators
† Updated data to reflect most current information.

GRI Description
GRI Section
Illumina Report
GRI 1:Foundation 2021
Statement of use
Illumina has reported in accordance with the GRI Standards for 
the period 1st January 2022 to 31st December 2022
GRI 1 reference
GRI 1
GRI 1: Foundation 2021
GRI 2: General Disclosures 2021
Organizational details
GRI 2-1
Pages: 8, 9, 89
Entities included in the organization, sustainability reporting
GRI 2-2
Page: 86
Reporting period, frequency and contact point
GRI 2-3
Page: 86
Restatements of information
GRI 2-4
Page: 86
External assurance
GRI 2-5
Page: 108
Activities, value chain and other business relationships
GRI 2-6
Pages: 8-9, 13-15, 22-22, 27-31, 51-52, 80-83, 
89, 101 
Employees
GRI 2-7
Pages: 57-68, 93-99
Workers who are not employees
GRI 2-8
Page: 93
Governance structure and composition
GRI 2-9
Pages: 12-17, 72, 100
Nomination and selection of the highest governance body
GRI 2-10
Pages: 16, 72, 100
Chair of the highest governance body
GRI 2-11
Pages: 16, 72, 100
Role of the highest governance body in overseeing the management 
of impacts
GRI 2-12
Pages: 16, 72, 100
Delegation of responsibility for managing impacts
GRI 2-13
Page: 16
Role of the highest governance body in sustainability reporting
GRI 2-14
Pages: 16, 72, 100
Conflicts of interest
GRI 2-15
Page: 72-76
Communication of critical concerns
GRI 2-16
Page: 100
Collective knowledge of the highest governance body
GRI 2-17
Page: 16, 72-76, 100
Evaluation of the performance of the highest governance body
GRI 2-18
Page: 72
Remuneration policies
GRI 2-19
Page: 72, Proxy
Process to determine remuneration
GRI 2-20
Page: 72
Annual total compensation ratio
GRI 2-21
Page: 72
Statement on sustainable development strategy
GRI 2-22
Page: 2-3, 12-16
Policy commitments
GRI 2-23
Page: 13-17, 44, 52, 62, 68, 72, 73, 74, 77, 78, 
79-84
Embedding policy commitments
GRI 2-24
Page: 13-17, 44, 52, 62, 68, 72, 73, 74, 77, 78, 
79-84
Processes to remediate negative impacts
GRI 2-25
Page: 71-84, 100, 106
Mechanisms for seeking advice and raising concerns
GRI 2-26
Page: 71-84, 106
Compliance with laws and regulations
GRI 2-27
Page: 68, 71-84, 100
Membership associations
GRI 2-28
Page: 17, 22, 29, 31, 41, 44, 86
Approach to stakeholder engagement
GRI 2-29
Page: 17
Collective bargaining agreements
GRI 2-30
Page: 100
GRI Description
GRI Section
Illumina Report
GRI 3: Material Topics
Process to determine material topics
GRI 3-1
Page: 12-17
List of material topics
GRI 3-2
Page: 14,17
Management of material topics
GRI 3-3
Page: 12-17, 72
GRI 201: Economic Performance 2016
Management of material topics
GRI 3-3
Page: 12-17
Direct economic value generated and distributed
GRI 201-1
Page: Proxy
Financial implications and other risks and opportunities due to 
climate change
GRI 201-2
Page: 44-45, 51, 53-54, 107
Defined benefit plan obligations and other retirement plans
GRI 201-3
Page: 67, 98
GRI 202: Market Presence 2016
Management approach: Market Presence
GRI 3-3
Page: 12-17
Ratios of standard entry level wage by gender compared to local 
minimum wage
GRI 202-1
Page: 62, 98
Proportion of senior management hired from the local community
GRI 202-2
Page: 63
GRI 203: Indirect Economic Impacts
Management approach: Indirect Economic Impacts
GRI 3-3
Page: 12-17, 19, 36, 57, 71
Infrastructure investments and services supported
GRI 203-1
Page: 19, 22-23, 25, 26, 30, 37, 40-41, 54-55
Significant indirect economic impacts
GRI 203-2
Page: 19, 22-23, 25, 26, 30, 37, 40-41, 54-55
GRI 204: Procurement Practices
Management approach: Procurement Practice
GRI 3-3
Page: 12-17, 71, 80-81
Proportion of spending on local suppliers
GRI 204-1
Page: 82, 101
GRI 205: Anti-corruption
Management approach: Anti-corruption
GRI 3-3
Page: 12-17, 71
Operations assessed for risks related to corruption
GRI 205-1
Page: 71-76, 80-81, 100
Communication and training about anti-corruption policies 
and procedures
GRI 205-2
Page: 73-74, 80, 81, 100
Confirmed incidents of corruption and actions taken
GRI 205-3
Page: 100
GRI 206: Anti-competitive Behavior 2016
Management approach: Anti-competitive
GRI 3-3
Page: 12-17
Legal actions for anti-competitive behavior, anti-trust, and 
monopoly practices
GRI 206-1
Page: 100
CY’22 CSR Report
100
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
GRI Index
GRI Description
GRI Section
Illumina Report
GRI 1:Foundation
Statement of use
Illumina has reported in accordance with the GRI Standards for 
the period 1st January 2022 to 31st December 2022
GRI 1 reference
GRI 1
GRI 1: Foundation 2021
GRI 2: General Disclosures
Organizational details
GRI 2-1
Pages: 8, 9, 86
Entities included in the organization, sustainability reporting
GRI 2-2
Page: 83
Reporting period, frequency and contact point
GRI 2-3
Page: 83
Restatements of information
GRI 2-4
Page: 83
External assurance
GRI 2-5
Page: 105
Activities, value chain and other business relationships
GRI 2-6
Pages: 8-9, 12-14, 21-21, 26-30, 48-49, 77-80, 
86, 98 
Employees
GRI 2-7
Pages: 54-65, 90-96
Workers who are not employees
GRI 2-8
Page: 90
Governance structure and composition
GRI 2-9
Pages: 11-16, 69, 97
Nomination and selection of the highest governance body
GRI 2-10
Pages: 15, 69, 97
Chair of the highest governance body
GRI 2-11
Pages: 15, 69, 97
Role of the highest governance body in overseeing the management 
of impacts
GRI 2-12
Pages: 15, 69, 97
Delegation of responsibility for managing impacts
GRI 2-13
Page: 15
Role of the highest governance body in sustainability reporting
GRI 2-14
Pages: 15, 69, 97
Conflicts of interest
GRI 2-15
Pages: 69-73
Communication of critical concerns
GRI 2-16
Page: 97
Collective knowledge of the highest governance body
GRI 2-17
Pages: 15, 69-73, 97
Evaluation of the performance of the highest governance body
GRI 2-18
Page: 69
Remuneration policies
GRI 2-19
Page: 69, Proxy
Process to determine remuneration
GRI 2-20
Page: 69
Annual total compensation ratio
GRI 2-21
Page: 69
Statement on sustainable development strategy
GRI 2-22
Page: 2-3, 11-15
Policy commitments
GRI 2-23
Pages: 12-16, 41, 49, 59, 65, 69, 70, 71, 74, 75, 
76-81
Embedding policy commitments
GRI 2-24
Pages: 12-16, 41, 49, 59, 65, 69, 70, 71, 74, 75, 
76-81
Processes to remediate negative impacts
GRI 2-25
Page: 68-81, 97, 103
Mechanisms for seeking advice and raising concerns
GRI 2-26
Page: 68-81, 103
Compliance with laws and regulations
GRI 2-27
Page: 65, 69-83, 97
Membership associations
GRI 2-28
Page: 16, 21, 28, 30, 38, 41, 83
Approach to stakeholder engagement
GRI 2-29
Page: 16
Collective bargaining agreements
GRI 2-30
Page: 97
GRI Description
GRI Section
Illumina Report
GRI 3: Material Topics
Process to determine material topics
GRI 3-1
Pages: 11-16
List of material topics
GRI 3-2
Pages: 13,16
Management of material topics
GRI 3-3
Pages: 11-16, 69
GRI 201: Economic Performance
Management of material topics
GRI 3-3
Pages: 11-16
Direct economic value generated and distributed
GRI 201-1
Proxy
Financial implications and other risks and opportunities due to 
climate change
GRI 201-2
Pages: 41-42, 48, 50-51, 104
Defined benefit plan obligations and other retirement plans
GRI 201-3
Pages: 64, 95
GRI 202: Market Presence 2016
Management approach: Market Presence
GRI 3-3
Pages: 11-16
Ratios of standard entry level wage by gender compared to local 
minimum wage
GRI 202-1
Pages: 59, 95
Proportion of senior management hired from the local community
GRI 202-2
Page: 60
GRI 203: Indirect Economic Impacts
Management approach: Indirect Economic Impacts
GRI 3-3
Pages: 11-16, 18, 33, 54, 68
Infrastructure investments and services supported
GRI 203-1
Pages: 18, 21-22, 24, 25, 29, 34, 37-38, 51-52
Significant indirect economic impacts
GRI 203-2
Pages: 18, 21-22, 24, 25, 29, 34, 37-38, 51-52
GRI 204: Procurement Practices
Management approach: Procurement Practice
GRI 3-3
Pages: 11-16, 68, 77-78
Proportion of spending on local suppliers
GRI 204-1
Pages: 79, 98
GRI 205: Anti-corruption
Management approach: Anti-corruption
GRI 3-3
Pages: 11-16, 68
Operations assessed for risks related to corruption
GRI 205-1
Pages: 68-73, 77-78, 97
Communication and training about anti-corruption policies 
and procedures
GRI 205-2
Pages: 70-71, 77, 78, 97
Confirmed incidents of corruption and actions taken
GRI 205-3
Pages: 97
GRI 206: Anti-competitive Behavior
Management approach: Anti-competitive
GRI 3-3
Pages: 11-16
Legal actions for anti-competitive behavior, anti-trust, and 
monopoly practices
GRI 206-1
Pages: 97

GRI Description
GRI Section
Illumina Report
GRI 301: Materials
Management approach: Materials
GRI 3-3
Pages: 12-17, 43, 49
Reclaimed products and their packaging materials
GRI 301-3
Page: 49
GRI 302: Energy
Management approach: Energy
GRI 3-3
Pages: 12-17, 43-45, 46
Energy consumption within the organization
GRI 302-1
Pages: 43-44, 46, 51, 90, 91, 107
Energy consumption outside of the organization
GRI 302-2
Pages: 43-44, 49, 51, 52, 91,107
Energy intensity
GRI 302-3
Pages: 46, 91
Reduction of energy consumption
GRI 302-4
Pages: 43-44, 46, 50-51, 55, 90-91
Reductions in energy requirements of products and services
GRI 302-5
Pages: 49-50, 53-55
GRI 303: Water and Effluents
Management approach: Water and Effluents
GRI 3-3
Pages: 12-17, 43, 47
Interactions with water as a shared resource
GRI 303-1
Pages: 47, 92
Management of water discharge-related impacts
GRI 303-2
Pages: 47, 92
Water withdrawal
GRI 303-3
Pages: 47, 92
Water discharge
GRI 303-4
Pages: 47, 92
Water consumption
GRI 303-5
Pages: 47, 92
GRI 304: Biodiversity
Management approach: Biodiversity
GRI 3-3
Page: 12-17, 43-45
Operational sites owned, leased, managed in, or adjacent to, 
protected areas and areas of high biodiversity value outside 
protected areas
GRI 304-1
Page: 45-46
Significant impacts of activities, products and services on biodiversity
GRI 304-2
Page: 45
Habitats protected or restored
GRI 304-3
Page: 45-46, 53-55
IUCN Red List species and national conservation list species with 
habitats in areas affected by operations
GRI 304-4
Page: 45, 46
GRI 305: Emissions
Management approach: Emissions
GRI 3-3
Page: 12-17, 43-45
Direct (Scope 1) GHG emissions
GRI 305-1
Page: 43-44, 46, 90-91
Energy indirect (Scope 2) GHG emissions
GRI 305-2
Page: 43-44, 46, 90-91
Other indirect (Scope 3) GHG emissions
GRI 305-3
Page: 43-44, 51, 91
GHG emissions intensity
GRI 305-4
Page: 46, 91
Reduction of GHG emissions
GRI 305-5
Page: 43-44, 46, 50-51, 55, 90-91
Emissions of ozone-depleting substances (ODS)
GRI 305-6
Page: 91
Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant 
air emissions
GRI 305-7
Page: 91
GRI Description
GRI Section
Illumina Report
GRI 306: Waste
Management approach: Waste
GRI 3-3
Pages: 12-17, 43, 48
Waste generation and significant waste-related impacts
GRI 306-1
Pages: 43, 48-50, 92
Management of significant waste-related impacts
GRI 306-2
Pages: 43, 48-50
Waste generated
GRI 306-3
Pages: 48, 92
Waste diverted from disposal
GRI 306-4
Pages: 48, 92
Waste directed to disposal
GRI 306-5
Pages: 48, 92
GRI 308: Supplier Environmental Assessment
Management approach: Supplier Environmental Assessment
GRI 3-3
Pages: 12-17, 43, 52, 71
New suppliers that were screened using environmental criteria
GRI 308-1
Pages: 81, 89
Negative environmental impacts in the supply chain and actions taken
GRI 308-2
Pages: 50-51
GRI 401: Employment
Management approach: Employment
GRI 3-3
Pages: 12-17, 57
New employee hires and employee turnover
GRI 401-1
Page: 96
Benefits provided to full-time employees that are not provided to 
temporary or part-time employees
GRI 401-2
Pages: 67, 98
Parental leave
GRI 401-3
Page: 98
GRI 403: Occupational Health and Safety
Management approach: Health and Safety
GRI 3-3
Pages: 12-17, 57
Occupational health and safety management system
GRI 403-1
Pages: 68, 99
Hazard identification, risk assessment, and incident investigation
GRI 403-2
Pages: 68, 99
Occupational health services
GRI 403-3
Pages: 67-68, 99
Worker participation, consultation, and communication on 
occupational health and safety
GRI 403-4
Page: 68
Worker training on occupational health and safety
GRI 403-5
Pages: 68, 99
Promotion of worker health
GRI 403-6
Pages: 67-68
Prevention and mitigation of occupational health and safety impacts 
directly linked by business relationships
GRI 403-7
Pages: 68- 69
Workers covered by an occupational health and safety 
management system
GRI 403-8
Pages: 68, 99
Work-related injuries
GRI 403-9
Pages: 68, 99
Work-related ill health
GRI 403-10
Pages: 68, 99
CY’22 CSR Report
101
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
GRI Index continued
GRI Description
GRI Section
Illumina Report
GRI 301: Materials
Management approach: Materials
GRI 3-3
Pages: 11-16, 40, 46
Reclaimed products and their packaging materials
GRI 301-3
Page: 46
GRI 302: Energy
Management approach: Energy
GRI 3-3
Pages: 11-16, 40-42, 43
Energy consumption within the organization
GRI 302-1
Pages: 40-41, 43, 48, 87, 88, 104
Energy consumption outside of the organization
GRI 302-2
Pages: 40-41, 43, 48, 87, 88, 104
Energy intensity
GRI 302-3
Pages: 43, 88
Reduction of energy consumption
GRI 302-4
Pages: 40-41, 43, 47-48, 52, 87-88
Reductions in energy requirements of products and services
GRI 302-5
Pages: 46-47, 50-52
GRI 303: Water and Effluents
Management approach: Water and Effluents
GRI 3-3
Pages: 11-16, 40, 44
Interactions with water as a shared resource
GRI 303-1
Pages: 44, 89
Management of water discharge-related impacts
GRI 303-2
Pages: 44, 89
Water withdrawal
GRI 303-3
Pages: 44, 89
Water discharge
GRI 303-4
Pages: 44, 89
Water consumption
GRI 303-5
Pages: 44, 89
GRI 304: Biodiversity
Management approach: Biodiversity
GRI 3-3
Page: 11-16, 40-42
Operational sites owned, leased, managed in, or adjacent to, 
protected areas and areas of high biodiversity value outside 
protected areas
GRI 304-1
Page: 42-43
Significant impacts of activities, products and services on biodiversity
GRI 304-2
Page: 42
Habitats protected or restored
GRI 304-3
Page: 42-43, 50-52
IUCN Red List species and national conservation list species with 
habitats in areas affected by operations
GRI 304-4
Page: 42-43
GRI 305: Emissions
Management approach: Emissions
GRI 3-3
Page: 11-16, 40-42
Direct (Scope 1) GHG emissions
GRI 305-1
Page: 40-41, 43, 87-88
Energy indirect (Scope 2) GHG emissions
GRI 305-2
Page: 40-41, 43, 87-88
Other indirect (Scope 3) GHG emissions
GRI 305-3
Page: 40-41, 48, 88
GHG emissions intensity
GRI 305-4
Page: 43, 88
Reduction of GHG emissions
GRI 305-5
Page: 40-41, 43, 47-48, 52, 87-88
Emissions of ozone-depleting substances (ODS)
GRI 305-6
Page: 88
Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant 
air emissions
GRI 305-7
Page: 88
GRI Description
GRI Section
Illumina Report
GRI 306: Waste
Management approach: Waste
GRI 3-3
Pages: 11-16, 40, 45
Waste generation and significant waste-related impacts
GRI 306-1
Pages: 40, 45-47, 89
Management of significant waste-related impacts
GRI 306-2
Pages: 40, 45-47
Waste generated
GRI 306-3
Pages: 45, 89
Waste diverted from disposal
GRI 306-4
Pages: 45, 89
Waste directed to disposal
GRI 306-5
Pages: 45, 89
GRI 308: Supplier Environmental Assessment
Management approach: Supplier Environmental Assessment
GRI 3-3
Pages: 11-16, 40, 49, 68
New suppliers that were screened using environmental criteria
GRI 308-1
Pages: 78, 86
Negative environmental impacts in the supply chain and actions taken
GRI 308-2
Pages: 47-48
GRI 401: Employment
Management approach: Employment
GRI 3-3
Pages: 11-16, 54
New employee hires and employee turnover
GRI 401-1
Page: 93
Benefits provided to full-time employees that are not provided to 
temporary or part-time employees
GRI 401-2
Pages: 64, 95
Parental leave
GRI 401-3
Page: 95
GRI 403: Occupational Health and Safety
Management approach: Health and Safety
GRI 3-3
Pages: 11-16, 54
Occupational health and safety management system
GRI 403-1
Pages: 65, 96
Hazard identification, risk assessment, and incident investigation
GRI 403-2
Pages: 65, 96
Occupational health services
GRI 403-3
Pages: 64-65, 96
Worker participation, consultation, and communication on 
occupational health and safety
GRI 403-4
Page: 65
Worker training on occupational health and safety
GRI 403-5
Pages: 65, 96
Promotion of worker health
GRI 403-6
Pages: 64-65
Prevention and mitigation of occupational health and safety impacts 
directly linked by business relationships
GRI 403-7
Pages: 65-66
Workers covered by an occupational health and safety 
management system
GRI 403-8
Pages: 65, 96
Work-related injuries
GRI 403-9
Pages: 65, 96
Work-related ill health
GRI 403-10
Pages: 65, 96

GRI Description
GRI Section
Illumina Report
GRI 404: Training and Education
Management approach: Training and Education
GRI 3-3
Pages: 12-17, 57
Average hours of training per year per employee
GRI 404-1
Pages: 6, 63, 98
Programs for upgrading employee skills and transition 
assistance programs
GRI 404-2
Pages: 61, 63-66
Percentage of employees receiving regular performance and career 
development reviews
GRI 404-3
Pages: 64, 98
GRI 405: Diversity and Equal Opportunity
Management approach: Diversity and Equal Opportunity
GRI 3-3
Pages: 12-17, 57, 60
Diversity of governance bodies and employees
GRI 405-1
Pages: 57-59, 93-97, 72, 100
Ratio of basic salary and remuneration of women to men
GRI 405-2
Pages: 98
GRI 406: Non-discrimination
Management approach:
GRI 3-3
Pages: 12-17, 57, 62
Incidents of discrimination and corrective actions taken
GRI 406-2
Pages: 100
GRI 407: Freedom of Association and Collective Bargaining
Management approach: Freedom of Association and 
Collective Bargaining
GRI 3-3
Pages: 12-17, 57
Operations and suppliers in which the right to freedom of association 
and collective bargaining may be at risk
GRI 407-1
Page: 106
GRI 408: Child Labor
Management approach: Child Labor
GRI 3-3
Pages: 12-17, 71, 77
Operations and suppliers at significant risk for incidents of child labor
GRI 408-1
Page: 77
GRI 409: Forced or Compulsory Labor
Management approach: Forced and Compulsory Labor
GRI 3-3
Pages: 12-17, 71, 77, 80, 81, 100
Operations and suppliers at significant risk for incidents of forced or 
compulsory labor
GRI 409-1
Pages: 77, 81, 100
GRI 410: Security Practices
Management approach: Security Practice
GRI 3-3
Pages: 12-17
Security personnel trained in human rights policies or procedures
GRI 410-1
Page: 100
GRI 413: Local Communities
Management approach: Local Communities
GRI 3-3
Pages: 12-17, 36
Operations with local community engagement, impact assessments, 
and development programs
GRI 412-1
Pages: 36-41
GRI Description
GRI Section
Illumina Report
GRI 414: Supplier Social Assessment
Management approach: Supplier Social Assessment
GRI 3-3
Pages: 12-17, 52, 71, 80
New suppliers that were screened using social criteria
GRI 414-1
Page: 101
GRI 415: Public Policy
Management approach: Public Policy
GRI 3-3
Pages: 12-17, 71, 84
Political contributions
GRI 415-1
Pages: 84, 102
GRI 417: Marketing and Labeling
Management approach: Marketing and Labeling
GRI 3-3
Pages: 12-17, 71, 76
Requirements for product and service information and labeling
GRI 417-1
Pages: 76, 106
Incidents of non-compliance concerning product and service 
information and labeling
GRI 417-2
Page: 106
Incidents of non-compliance concerning marketing communications
GRI 417-3
Page: 106
GRI 418: Customer Privacy
Management approach: Customer Privacy
GRI 3-3
Pages: 12-17, 71, 75, 78-79
Substantiated complaints concerning breaches of customer privacy 
and losses of customer data
GRI 418-1
Page: 100
CY’22 CSR Report
102
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
GRI Index continued
GRI Description
GRI Section
Illumina Report
GRI 404: Training and Education
Management approach: Training and Education
GRI 3-3
Pages: 11-16, 54
Average hours of training per year per employee
GRI 404-1
Pages: 6, 60, 95
Programs for upgrading employee skills and transition 
assistance programs
GRI 404-2
Pages: 58, 60-63
Percentage of employees receiving regular performance and career 
development reviews
GRI 404-3
Pages: 61, 95
GRI 405: Diversity and Equal Opportunity
Management approach: Diversity and Equal Opportunity
GRI 3-3
Pages: 11-16, 54, 57
Diversity of governance bodies and employees
GRI 405-1
Pages: 54-56, 69, 90-94, 97
Ratio of basic salary and remuneration of women to men
GRI 405-2
Page: 95
GRI 406: Non-discrimination
Management approach:
GRI 3-3
Pages: 11-16, 54, 59
Incidents of discrimination and corrective actions taken
GRI 406-2
Page: 97
GRI 407: Freedom of Association and Collective Bargaining
Management approach: Freedom of Association and 
Collective Bargaining
GRI 3-3
Pages: 11-16, 54
Operations and suppliers in which the right to freedom of association 
and collective bargaining may be at risk
GRI 407-1
Page: 103
GRI 408: Child Labor
Management approach: Child Labor
GRI 3-3
Pages: 11-16, 68, 74
Operations and suppliers at significant risk for incidents of child labor
GRI 408-1
Page: 74
GRI 409: Forced or Compulsory Labor
Management approach: Forced and Compulsory Labor
GRI 3-3
Pages: 11-16, 68, 74, 77, 78, 97
Operations and suppliers at significant risk for incidents of forced or 
compulsory labor
GRI 409-1
Pages: 74, 78, 97
GRI 410: Security Practices
Management approach: Security Practice
GRI 3-3
Pages: 11-16
Security personnel trained in human rights policies or procedures
GRI 410-1
Page: 97
GRI 413: Local Communities
Management approach: Local Communities
GRI 3-3
Pages: 11-16, 33
Operations with local community engagement, impact assessments, 
and development programs
GRI 412-1
Pages: 33-38
GRI Description
GRI Section
Illumina Report
GRI 414: Supplier Social Assessment
Management approach: Supplier Social Assessment
GRI 3-3
Pages: 11-16, 49, 68, 77
New suppliers that were screened using social criteria
GRI 414-1
Page: 98
GRI 415: Public Policy
Management approach: Public Policy
GRI 3-3
Pages: 11-16, 68, 81
Political contributions
GRI 415-1
Pages: 81, 99
GRI 417: Marketing and Labeling
Management approach: Marketing and Labeling
GRI 3-3
Pages: 11-16, 68, 73
Requirements for product and service information and labeling
GRI 417-1
Pages: 73, 103
Incidents of non-compliance concerning product and service 
information and labeling
GRI 417-2
Page: 103
Incidents of non-compliance concerning marketing communications
GRI 417-3
Page: 103
GRI 418: Customer Privacy
Management approach: Customer Privacy
GRI 3-3
Pages: 11-16, 68, 72, 75-76
Substantiated complaints concerning breaches of customer privacy 
and losses of customer data
GRI 418-1
Page: 97

CY’22 CSR Report
103
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
The Sustainability Accounting Standards Board (SASB) is an independent standards-setting organization that promotes disclosure of material sustainability information to meet investor needs. Illumina is classified officially in 
the Health Care Sector and Medical Equipment & Supply Industry. We have also chosen to add relevant sections from the industry categories of Biotechnology & Pharmaceuticals as well as Software & IT Services.
Dimension
General Issue Category
Disclosure Topic
Code
Accounting Metric
Response
PRIMARY SICS SECTOR: HEALTHCARE | Primary SICS Industry: Medical Equipment & Supplies
Social 
Capital
Access & Affordability
Affordability and Pricing
HC-MS-240a.1
Ratio of weighted average rate of net price increases to the annual increase in the U.S. Consumer Price Index
76
Affordability and Pricing
HC-MS-240a.2
Description of how price information for each product is disclosed to customers or to their agents
76
Product Quality & Safety
Product Safety
HC-MS-250a.1
Number of FDA recalls issued, total units recalled
0
Product Safety
HC-MS-250a.2
List of products listed in the FDA’s MedWatch safety alerts for human medical products database
0
Product Safety
HC-MS-250a.3
Number of fatalities related to products as reported in FDA Manufacturer and User Facility Device Experience
0
Product Safety
HC-MS-250a.4
Number of FDA enforcement actions taken in response to violations of Current Good Manufacturing Practices (cGMP)
0
Selling Practices & 
Product Labeling
Ethical Marketing
HC-MS-270a.1
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims
0
Ethical Marketing
HC-MS-270a.2
Description of code of ethics governing promotion of off-label use of products
76, Illumina Code of Conduct
Business 
Model & 
Innovation
Product Design & 
Lifecycle Management
Product Design & 
Lifecycle Management
HC-MS-410a.1
Discussion of process to assess and manage environmental and human health considerations associated with chemicals 
in products, and meet demand for sustainable products
43, 49
Product Design & 
Lifecycle Management
HC-MS-410a.2
Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipment 
and (2) supplies
48, 92
Supply Chain Management
Supply Chain Management
HC-MS-430a.1
Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in third-party audit programs for manufacturing 
and product quality
71, 83
Supply Chain Management
HC-MS-430a.2
Description of efforts to maintain traceability within the distribution chain
83
Supply Chain Management
HC-MS-430a.3
Description of the management of risks associated with the use of critical materials
80-81, 83
Leadership & 
Governance
Business Ethics
Business Ethics
HC-MS-510a.1
Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption
0
Business Ethics
HC-MS-510a.2
Description of code of ethics governing interactions with health care professionals
73-74, Interactions with HCP Policy
Other
Activity Metrics
Activity Metrics
HC-MS-000.A
Number of units sold by product category
101
Supplemental SICS Industry: Biotech & Pharma
Human 
Capital
Employee Engagement, 
Diversity & Inclusion
Employee Recruitment, 
Development & Retention
HC-BP-330a.1
Discussion of talent recruitment and retention efforts for scientists and R&D personnel
63-66
Employee Recruitment, 
Development & Retention
HC-BP-330a.2
1) Voluntary and 2) involuntary turnover rate for a) executive/senior managers b) mid-level managers c) professionals d) all others
97
Supplemental SICS Industry: Software & IT Services
Human Capital
Employee Engagement, 
Diversity & Inclusion
Recruiting & Managing 
a Global, Diverse & 
Skilled Workforce
TC-SI-330a.3
Percentage of gender and racial/ethnic group representation for 1) management 2) technical staff 3) all other employees
58-59, 94-95
SASB Index

CY’22 CSR Report
104
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
TCFD voluntary climate-related disclosure recommendations have been used to guide our reporting. We believe addressing climate change is key to achieving a sustainable, just, and resilient future for all. We are committed to 
transparency and will continue to share progress in our annual CSR Report and CDP submissions. 
TCFD Disclosure Element
Topic
Description
Illumina CSR Report Section/CDP Questionnaire Response
Governance
Describe organization’s governance around climate-related 
risks and opportunities.
Board oversight
Describe Board’s oversight of climate-related risks and opportunities.
CSR Report 15-16, 41, 69, 7
CDP C1.1, C1.1a., C1.1b
Management role
Describe management’s role in assessing and managing risks and opportunities.
CSR Report 15-16, 41, 71 
CDP C1.2, C1.2a
Strategy
Describe the actual and potential impacts of climate-
change risks and opportunities on the organization’s 
business, strategy, and financial planning where such 
information is material.
Climate risk and opportunities timeline
Describe the climate-related risks and opportunities the organization has identified 
over the short, medium, and long term. 
CSR Report 40-52
CDP C2.1a, C2.1b, C2.2, C2.2a, C2.3, C2.3b, C2.4, C2.4b
Climate risk and opportunities impact
Describe the impact of climate-related risks and opportunities on the organization’s 
businesses, strategy, and financial planning.
CSR Report 11, 16, 40-52, 71
CDP 2.2, C2.2a, C2.3b, C2.4b, C3.1, C3.2, C3.2a, C3.2b, C3.3, C3.4, C3.5
Targets to manage climate risk 
and opportunities
Describe the resilience of the organization’s strategy, taking into consideration 
different climate-related scenarios, including a 2°C or lower scenario.
CSR Report 40-52, 69, 71, 77-78, 87-89
CDP 2.2, C3.1, C3.2, C3.2a, C3.2b, C3.3
Risk Management
Disclose how the organization identifies, assesses, and 
manages climate-related risks.
Process to identify climate risk
Describe the organization’s processes for identifying and assessing climate-related risks.
CSR Report 12-14, 40-52, 69, 71, 77-78
CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3
Process to manage climate risk
Describe the organization’s processes for managing climate-related risks.
CSR Report 12-14, 33-34, 40-52, 69, 71, 77-78
CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3
Process to integrate climate risk in 
overall risk management
Describe how processes for identifying, assessing, and managing climate-related risks 
are integrated into the organization’s overall risk management.
CSR Report 12-16, 33-34, 40-52, 69, 71, 77-78
CDP 2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.1, C3.2a, C3.3
Metrics & Targets
Disclose the metrics and targets used to assess and 
manage relevant climate-related risks and opportunities 
where such information is material.
Climate-related metrics
Disclose the metrics used by the organization to assess climate-related risks and 
opportunities in line with its strategy and risk management process.
CSR Report 40-41, 43-46, 48-49, 68, 78, 79, 87-89
CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a, 
C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c
GHG emission data
Disclose Scope 1, Scope 2, and, if appropriate, Scope 3 greenhouse gas (GHG) emissions, 
and the related risks.
CSR Report 40-41, 43-46, 48-49, 68, 78, 79, 87-89
CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a, 
C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c
Targets to manage climate risk and 
performance to targets
Describe the targets used by the organization to manage climate-related risks and 
opportunities and performance against targets.
CSR Report 40-41, 43-46, 48-49, 68, 78, 79, 87-89
CDP 4.1, C4.1a, C4.2, C4.2b, C4.2c, C6.1, C6.2, C6.3, C6.5, C6.5a, C6.10, C7.1a, 
C7.2. C7.3b, C7.3c, C7.5, C7.6b, C7.6c
Task Force on Climate-related Financial Disclosures (TCFD) Index

CY’22 CSR Report
105
Message from the CEO
CSR Strategy & Governance 
Access
Community
People
Operate Responsibly 
Appendix
Introduction
Sustainability 
About This Report           2030 Targets           Recognition           Key Performance Indicators           GRI Index           SASB Index           TCFD Index           Assurance Statements           Disclosures
Independent Limited Assurance Report to Illumina, Inc.
We have not performed any procedures with respect to other information included in the Illumina 2022 Corporate Responsibility Report and, therefore, no conclusion on the Report as a whole is expressed. 
Background and Introduction
ISOS Group, Inc. (“ISOS” or “we”) were engaged by Illumina, Inc. (“Illumina” or “Company”) to undertake a limited assurance engagement in 
accordance with ISAE 3000 and ISAE 3410 covering select information reported within Illumina’s 2022 Corporate Social Responsibility Report 
(“2022 CSR Report”) for the period beginning January 1, 2021, and ending December 31, 2021 (“FY21”). 
We have performed our limited assurance engagement in accordance with the International Standard on Assurance Engagements 3000 (ISAE 
3000), Assurance other than Audits or Reviews of Historical Financial Information, as well as the International Standard on Assurance Engagements 
3410 (ISAE 3410) Assurance Engagements on Greenhouse Gas Statements, issued by the International Auditing and Assurance Standards Board. 
The engagement covered all entities and all facilities under the operational control of Illumina. 
Our review was limited to the data reported in the following Key Performance Indicator Summary sections (pages 88–95) and marked with the 
symbol * (“Reported Information”), comprising of: 
Integrating Environmental Sustainability:
Nurturing Our People:
•	 Energy Consumption
•	 Energy Consumption by Activity and Region
•	 Renewable Electricity Consumption
•	 Emissions
•	 Regional Emissions
•	 Greenhouse Gas Breakdown
•	 Country-Specific Scope 1
•	 Country- Specific Scope 2 Market-Based
•	 Facility-Specific Emissions
•	 Emission Intensity Ratios
•	 Scope 3 Emissions
•	 Scope 3 Emissions: % of Total Scope 3 Emissions
•	 Water
•	 Workforce Data
•	 Gender Data
•	 Percentage Female and Male of Each EEOC Category (US)
•	 EEOC Minority Summary (US)
•	 EEOC Minority by Category (US)
•	 EEOC Data by Level (US)
•	 New Hire Data
•	 Percentage New Hire per EEOC (US)
•	 Promotion Data
•	 Promotion Rate by EEOC (US)
•	 Veteran Data (US)
•	 Employee Turnover Data
Reporting Criteria 
The reporting criteria are the standards identified in the 2022 CSR Report – Reporting Overview (“Reporting Criteria”).
Inherent Uncertainty 
The nature of non-financial information and the methods used to determine non-financial information, allow for different, but acceptable 
measurement techniques, which can result in materially different measurements and can impact accuracy and comparability. Furthermore, the 
nature and methods used to determine such information, as well as the measurement criteria and the precision thereof, may change over time. 
The Reported Information has been measured applying the Reporting Criteria, which has been adopted solely for the purpose of providing this 
non-financial information. As such the Reported Information may not be suitable for another purpose. Where significant assumptions or deductions 
are utilized, they are disclosed. Where direct data was unavailable, the company used industry standards as estimates. The assurance provided 
therefore does not guarantee or provide certainty over the completeness of reported data. 
Illumina’s Responsibilities 
The Company’s management are responsible for: 
•	 The accuracy and completeness of the information contained in the Reported Information.
•	 The design, implementation, and maintenance of internal controls relevant to the preparation of the report to provide reasonable assurance that the 
report is free from material misstatement, whether due to fraud or error.
•	 Ensuring the Reported Information is fairly stated in accordance with the applicable criteria (“Reporting Criteria”) and for the content and statements 
contained therein.
Our Responsibilities
Our responsibility is to express a limited assurance conclusion in accordance with ISAE 3000 and ISAE 3410 whether the Reported Information 
has been properly prepared in accordance with the Reporting Criteria and to provide this in a report to Illumina. 
Work Performed 
•	 The procedures we performed were based on our professional judgment. Our work included, but was not limited to: 
•	 Assessing the appropriateness of the Reporting Criteria for the Reported Information
•	 Carrying out interviews with key personnel to understand the systems and controls in place during the reporting period
•	 Assessing the systems, processes, and controls to collate, aggregate, validate, 
and report the data
•	 Reviewing a selection of factors and formulae used and calculations performed over the Reported Information
•	 Considering the appropriateness of the Reported Information provided by Illumina and any third-party data management system service providers
•	 Testing a sample of records against underlying records, which were either individually material or where there was potential for errors to accumulate to 
material amounts included:
•	 Testing of energy consumption, scope 1 and 2 emissions, and water consumption at company facilities across 12 countries in scope of the reporting
•	 Testing of scope 3 emissions across the 11 calculated scope 3 emissions categories
•	 Testing of human capital data aggregated across three regions and 28 countries where company operates, including against EEO-1 reporting for US 
operations
•	 Reperforming a selection of calculations of the Reported Information
The relative effectiveness and significance of specific control procedures at Illumina and their effect on assessment of control risk at a facility 
level are dependent on their interaction with the controls and other factors present at individual facilities. We have not performed any procedures 
to evaluate the effectiveness of controls at individual facilities. We have not conducted any work outside the agreed scope and therefore restrict 
our conclusion to the above-mentioned subject matter. 
Restriction of Use 
This assurance report is made solely to Illumina in accordance with the terms of our engagement, which include agreed arrangements for 
disclosure. Our work has been undertaken so that we might state to Illumina those matters we have been engaged to state in this limited 
assurance report and for no other purpose. Our limited assurance report should not be regarded as suitable to be used or relied on by any party 
wishing to acquire rights against us other than Illumina for any purpose or in any context. Any party other than Illumina who obtains access to our 
limited assurance report or a copy thereof and chooses to rely on our limited assurance report (or any part thereof) will do so at its own risk. To 
the fullest extent permitted by law, we accept or assume no responsibility and deny any liability to any party other than Illumina for our work, for 
this independent limited assurance report, or for the conclusions we have reached. 
Conclusion 
Based on the procedures we have performed and the evidence we have obtained, nothing has come to our attention that causes us to believe 
that the Reported Information, noted in the Key Performance Indicator Summary (pages 88–95) for FY21 ended on December 31, 2021, has not 
been prepared, in all material respects, in accordance with Illumina’s Reporting Criteria.
Brian Noveck
CSAP Practitioner for, and on behalf of, ISOS Group, Inc. 
31 March 2022
Learn More: CY’ 22 Assurance Letter

Disclosures
This release may contain forward-looking statements that involve risks 
and uncertainties. Among the important factors to which our business is 
subject that could cause actual results to differ materially from those in 
any forward-looking statements are: (i) changes in the rate of growth in 
the markets we serve; (ii) the volume, timing and mix of customer orders 
among our products and services; (iii) our ability to adjust our operating 
expenses to align with our revenue expectations; (iv) our ability to 
manufacture robust instrumentation and consumables; (v) the success of 
products and services competitive with our own; (vi) challenges inherent 
in developing, manufacturing, and launching new products and services, 
including expanding or modifying manufacturing operations and reliance 
on third-party suppliers for critical components; (vii) the impact of recently 
launched or pre-announced products and services on existing products 
and services; (viii) our ability to further develop and commercialize our 
instruments, consumables, and products, including Galleri®, the cancer 
screening test developed by GRAIL, to deploy new products, services, and 
applications, and to expand the markets for our technology platforms; (ix) 
the risks and costs associated with the integration of GRAIL’s business if 
we are ultimately able to integrate GRAIL, and our ability to successfully 
realize the related anticipated synergies; (x) the risk of incurring fines 
associated with the consummation of our acquisition of GRAIL and the 
possibility that we may be required to divest all or a portion of the assets 
or equity interests of GRAIL on terms that could be materially worse than 
the terms on which we acquired GRAIL; (xi) the risk that disruptions from 
the consummation of our recent acquisition of GRAIL or any associated 
legal or regulatory proceedings or obligations will harm our business, 
including current plans and operations; (xii) our ability to obtain approval 
by third-party payors to reimburse patients for our products; (xiii) our 
ability to obtain regulatory clearance for our products from government 
agencies; (xiv) our ability to successfully partner with other companies 
and organizations to develop new products, expand markets, and grow our 
business; (xv) the application of generally accepted accounting principles, 
which are highly complex and involve many subjective assumptions, 
estimates, and judgments and (xvi) legislative, regulatory and economic 
developments, together with other factors detailed in our filings with the 
Securities and Exchange Commission, including our most recent filings on 
Forms 10-K and 10-Q, or in information disclosed in public conference calls, 
the date and time of which are released beforehand. We undertake no 
obligation, and do not intend, to update these forward-looking statements, 
to review or confirm analysts’ expectations, or to provide interim reports or 
updates on the progress of the current quarter.
+1.800.809.4566 toll-free (US) +1.858.202.4566 tel
www.illumina.com
©2023 Illumina, Inc. 
All rights reserved. All other names, logos, and other trademarks are the 
property of their respective owners.
Stay up to date on recent news, stories, 
and more by connecting with us.
Photo Credit: Juraj Krivda
Illumina Employee | Distribution Planner
Singapore | Woodlands Facility